Composition useful for therapy of GM1 gangliosidosis

A replication-defective adeno-associated virus vector delivering the GLB1 gene addresses the lack of effective therapies for GM1 gangliosidosis by improving neurological symptoms and life expectancy through targeted enzyme replacement in the central nervous system.

JP2024161415APending Publication Date: 2024-11-19THE TRUSTEES OF THE UNIV OF PENNSYLVANIA
View PDF 3 Cites 0 Cited by

Patent Information

Application Number
JP2024125570
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2019-04-17
Filing Date
2024-08-01
Publication Date
2024-11-19

AI Technical Summary

Technical Problem

Current therapies for GM1 gangliosidosis, a neurodegenerative disease caused by mutations in the GLB1 gene leading to β-galactosidase deficiency, are inadequate, with no disease-modifying treatments available and existing options like substrate reduction therapy and hematopoietic stem cell transplantation showing limited efficacy and side effects.

Method used

Development of a replication-defective adeno-associated virus (rAAV) vector carrying the GLB1 gene encoding human β-galactosidase, administered via intracisternal injection to deliver functional β-galactosidase to the central nervous system, aiming to correct enzyme deficiency and slow disease progression.

Benefits of technology

The rAAV.GLB1 vector improves neurological symptoms and increases life expectancy, reduces the need for feeding tubes, decreases seizure frequency, and delays neurocognitive decline in GM1 gangliosidosis patients, particularly those under 18 months old.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024161415000048
    Figure 2024161415000048
  • Figure 2024161415000049
    Figure 2024161415000049
  • Figure 2024161415000050
    Figure 2024161415000050
Patent Text Reader

Abstract

To provide a recombinant (r) duplicate defect adeno-associated virus (AAV) for therapy, which is useful for treating and / or reducing a symptom related to GM1 gangliosidosis as an alternative therapy for therapy of a state related to an abnormal GLB1 gene.SOLUTION: There is provided a recombinant adeno-associated virus (rAAV) (namely, rAAVhu68.GBL1) including a vector genome which includes: AAVhu68 capsid, and lysosome β-galactosidase gene (for example, galactosidase β1 gene, GBL1). For example, there is also provided a composition including an effective dose of rAAVhu68.GBL1 for increasing an average life, reducing necessity of a nutrient pipe, reducing incidence rate and a frequency of stroke, reducing progress of reduction of nerve cognition, and / or improving development of nerve cognition, and for improving a symptom of GM1 gangliosidosis.SELECTED DRAWING: None
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] Incorporation by Reference of Materials Submitted in Electronic Form Applicants hereby incorporate by reference the Sequence Listing material filed in electronic form herein. The file is labeled "18-8537PCT_SequenceListing_ST25.txt", dated August 29, 2019, and is 144,703 bytes in size. [Background technology]

[0002] GM1 gangliosidosis (hereafter referred to as GM1) is a recessive lysosomal storage disease caused by mutations in the GLB1 gene, which encodes lysosomal acid β-galactosidase (β-gal), an enzyme that catalyzes the first step in the degradation of GM1 ganglioside and keratan sulfate (Brunetti-Pierri and Scaglia, 2008, GM1 gangliosidosis: Review of clinical, molecular, and therapeutic aspects, Molecular Genetics and Metabolism, 94: 391-96). The GLB1 gene is located on chromosome 3 and gives rise to two alternatively spliced ​​mRNAs, a 2.5 kb transcript encoding the β-gal lysosomal enzyme and a 2.0 kb transcript encoding the elastin-binding protein (EBP) (Oshima et al. 1988, Cloning, sequencing, and expression of cDNA for human β-galactosidase, Biochemical and Biophysical Research, 2009). Communications, 157: 238-44; Morreau et al. 1989, Alternative splicing of beta-galactosidase mRNA generates the classic lysosomal enzyme and a beta-galactosidase-related protein, Journal of Biological Chemistry, 264: 20655-63). β-gal is synthesized as an 85 kDa precursor that is posttranslationally glycosylated to an 88 kDa form and processed to the mature 64 kDa lysosomal enzyme (D'Azzo et al. 1982, Molecular defect in combined beta-galactosidase and neuraminidase deficiency in man, Proceedings of the National Academy of Sciences, 79: 4535-39). Within the lysosome, the enzyme is complexed with the protective protein cathepsin A (PPCA) and neuraminidase hydrolase.

[0003] In patients with GLB1 alleles that produce little or no residual β-gal, GM1 ganglioside accumulates in neurons throughout the brain, resulting in a rapidly progressive neurodegenerative disease (Brunetti-Pierri and Scaglia 2008). The molecular mechanisms that cause the pathogenesis of the disease remain poorly understood, but hypotheses include severe neuronal vacuolization, neuronal death and demyelination with astrogliosis and microgliosis in areas of neuronal apoptosis (Tessitore et al. 2004, GM1-Ganglioside-Mediated Activation of the Unfolded Protein Response Causes Neuronal Death in a Neurodegenerative Gangliosidosis, Molecular Cell, 15: 753-66), and abnormal axoplasmic transport leading to myelin deficiency (van der Voorn et al. 2004, The leukoencephaloplasty). athy of infantile GM1 gangliosidosis: oligodendrocytic loss and axonal dysfunction, Acta Neuropathologica, 107: 539-45), impaired neuron-oligodendroglia interactions (Folkerth 1999,Abnormalities of Developing White Matter in Lysosomal Storage Diseases, Journal of Neuropathology and Experimental Neurology, 58: 887-902; Kaye et al. 1992,Dysmyelinogenesis in animal model of GM1 gangliosidosis', Pediatric Neurology, 8: 255-61), and inflammatory responses (Jeyakumar et al. 2003,Central nervous system inflammation is a hallmark of pathogenesis in mouse models of GM1 and GM2 gangliosidosis, Brain, 126: 974-87).

[0004] Currently, there are no disease-modifying therapies for GM1. Supportive and symptomatic treatments, including feeding tube placement, respiratory therapy, and antiepileptic drugs, are the current treatment modalities (Jarnes Utz et al. 2017, Infantile gangliosidoses: Mapping a timeline of clinical changes, Molecular Genetics and Metabolism, 121: 170-79). Substrate reduction therapy (SRT) with the glucosylceramide synthase inhibitor miglustat has been evaluated in GM1 and GM2 patients. Miglustat is generally well tolerated but has not provided significant improvements in symptom control or disease progression, and some patients experience dose-limiting gastrointestinal side effects (Shapiro et al., 2009, Regier et al., 2016b). When used in combination with a ketogenic diet, miglustat has been shown to be well tolerated and to increase survival in some patients (Jarnes Utz et al., 2017). However, it should be noted that no randomized controlled studies have been performed with miglustat, and miglustat is not approved for the treatment of GM1 gangliosidosis. There is limited experience with hematopoietic stem cell transplantation (HSCT) using bone marrow or umbilical cord blood in this disease. Bone marrow transplantation performed in patients with type 2 GM1 resulted in normalization of leukocyte β-galactosidase levels in patients with presymptomatic early-onset GM1-gangliosidosis, but did not improve long-term clinical outcomes (Shield et al., 2005, Bone marrow transplantation correcting β-galactosidase activity does not influence neurological outcome in juvenile GM1-gangliosidosis. Journal of Inherited Metabolic Disease. 28(5):797-798.) Because the effect of HSCT is slow, it is not suitable for the rapidly progressive type 1 GM1 disease (Peters and Steward, 2003, Hematopoietic cell transplantation for inherited metabolic diseases: an overview of outcomes and practice guidelines.Bone Marrow Transplantation.31:229.).

[0005] Adeno-associated viruses (AAVs), members of the parvovirus family, are small, nonenveloped, icosahedral viruses with a single-stranded linear DNA (ssDNA) genome approximately 4.7 kilobases (kb) long. The wild-type genome contains inverted terminal repeats (ITRs) at both ends of the DNA strand, as well as two The AAV contains the open reading frames (ORFs) rep and cap. Rep is composed of four overlapping genes encoding the rep proteins required for the AAV life cycle, and cap contains overlapping nucleotide sequences of the capsid proteins VP1, VP2, and VP3, which self-assemble to form a capsid with icosahedral symmetry.

[0006] AAV is assigned to the Dependovirus genus because the virus was found as a contaminant in purified adenovirus stocks. The life cycle of AAV includes a latent phase in which the AAV genome is specifically integrated into the host chromosome after infection, and an infectious phase in which the integrated genome is subsequently rescued, replicated, and packaged into an infectious virus after infection with either adenovirus or herpes simplex virus. The properties of non-pathogenicity, broad host range infectivity including non-dividing cells, and potential site-specific chromosomal integration make AAV an attractive tool for gene transfer.

[0007] What is desired are alternative therapies for the treatment of conditions associated with abnormal GLB1 genes. Summary of the Invention

[0008] Therapeutic recombinant (r) replication-defective adeno-associated virus (AAV) is provided, which is useful for treating and / or alleviating symptoms associated with GM1 gangliosidosis in human patients in need of such treatment and / or alleviation. The rAAV is desirably replication-defective and has a vector genome comprising a GLB1 gene encoding human (h) β-galactosidase under the control of regulatory sequences directing the expression of human (h) β-galactosidase in target human cells, and as used herein, may be referred to as rAAV.GLB1. In certain embodiments, the rAAV comprises an AAVhu68 capsid. This rAAV is referred to herein as rAAVhu68.GLB1, although in certain instances the terms rAAVhu68.GLB1 vector, rAAVhu68.hGLB1, rAAVhu68.hGLB1 vector, AAVhu68.GLB1, or AAVhu68.GLB1 vector are used interchangeably to refer to the same construct. In certain embodiments, the vector genome does not contain AAVhu68 genome sequences and is entirely exogenous to the AAVhu68 capsid. In certain embodiments, capsids other than AAVhu68 capsids may be utilized. In further embodiments, the AAV capsid is suitable for delivering the vector genome to the central nervous system (CNS, e.g., neurons, glial cells, epithelial cells, or other cells in the CNS). Additionally, methods, vectors (viral or non-viral vectors such as plasmids), and cells for use in producing (e.g., generating and / or purifying) rAAV are provided.

[0009] In certain embodiments, the GLB1 gene encodes a signal peptide and a mature GLB1 amino acid sequence of amino acids 24 to 677 of SEQ ID NO: 4, or a functional fragment thereof. In certain embodiments, a native human GLB1 signal peptide is used, e.g., the amino acid sequence of amino acids 1 to 23 of SEQ ID NO: 4.

[0010] In certain embodiments, the GLB1 gene has a nucleic acid sequence selected from SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, or SEQ ID NO:8, or a sequence at least 95%-99.9% identical to SEQ ID NO:6, SEQ ID NO:7, or SEQ ID NO:8. In further embodiments, the GLB1 nucleic acid sequence encodes amino acids 24-677 of SEQ ID NO:4, or a functional fragment thereof. In another embodiment, the GLB1 nucleic acid sequence encodes the amino acid sequence of SEQ ID NO:4, or a functional fragment thereof.

[0011] In certain embodiments, the regulatory sequence comprises a human ubiquitin C (UbC) promoter.

[0012] In certain embodiments, the vector genome has a sequence selected from SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, or SEQ ID NO:15.

[0013] In certain embodiments, an aqueous pharmaceutical composition is provided that includes a formulation buffer and rAAV.GLB1 (e.g., rAAVhu68.GLB1). In certain embodiments, the formulation buffer includes a buffered saline solution, an artificial cerebrospinal fluid including one or more of sodium, calcium, magnesium, potassium, or mixtures thereof, and a surfactant. In certain embodiments, the surfactant comprises about 0.0005% to about 0.001% of the suspension. In further embodiments, the percentages (%) are calculated based on a weight (w) ratio (i.e., w / w). In certain embodiments, the composition has a pH of 7.2 to 7.8. In certain embodiments, the composition has a pH of 6.2 to 7.7. In certain embodiments, the composition has a pH of 6.0 to 7.5. In one embodiment, the pH is about 7.

[0014] In certain embodiments, a method of treating a patient having GM1 gangliosidosis comprises administering rAAV.GLB1 as described herein (e.g., rAAVhu68.GLB1), or a composition comprising the same as provided. The method involves delivering rAAV.GLB1 to a human patient having GM1 gangliosidosis. In certain embodiments, the rAAV.GLB1 or composition is administered via CT-guided suboccipital injection into the cisterna magna. In certain embodiments, the method comprises delivering rAAV.GLB1 or the composition to the human patient in a single dose.

[0015] In certain embodiments, rAAV.GLB1 (such as rAAVhu68.GLB1) or a composition comprising same can be administered to a patient via intracisternal injection (ICM). In certain embodiments, rAAV.GLB1 (e.g., rAAVhu68.GLB1) or a composition comprising same is provided and can be administered to a patient with infantile gangliosidosis 18 months of age or younger. rAAV.GLB1 (e.g., rAAVhu68.GLB1) or a composition comprising same is provided and can be administered to a patient in need thereof to improve symptoms of GM1 gangliosidosis, e.g., neurological symptoms of GM1. In certain embodiments, improvement of GM1 gangliosidosis includes increased life expectancy, reduced need for feeding tubes, reduced incidence and frequency of seizures, reduced progression to neurocognitive decline, and / or improved neurocognitive development.

[0016] These and other aspects of the invention will become apparent from the following detailed description of the invention. [Brief description of the drawings]

[0017] [Figure 1A] A schematic diagram of the AAV vector genome is provided showing the 5'ITR, human ubiquitin C (UbC) promoter, chimeric intron, the GLB1 gene encoding human β-galactosidase (β-gal), the SV40 late polyA signal, and the 3'ITR (i.e., "AAVhu68.Ubc.hGLB1co.SV40"). [Figure 1B] 1 provides a schematic diagram of the cis-plasmid containing the AAV vector genome harbored by cis-plasmid pAAV.UbC.hGLB1co.SV40.KanR. GLB1: β-galactosidase, ITR: inverted terminal repeats, KanR: kanamycin resistance, Ori: origin of replication, PolyA: polyadenylation, and UbC: ubiquitin C. [Figure 1C] A schematic diagram of the trans plasmid containing the coding sequence of the full-length AAV2 replicase (AAV2 Rep), which encodes four proteins, and the AAVhu68 vp1 capsid gene (encoding VP1, VP2, and VP3 proteins): AAV2: adeno-associated virus serotype 2, AAVhu68: adeno-associated virus serotype hu68, Cap: capsid, KanR: kanamycin resistance, Ori: origin of replication, and Rep: replicase. [Figure 2A-2B] Figure 1 illustrates β-gal activity in the brain and cerebrospinal fluid (CSF) of wild-type mice treated with rAAVhu68.GLB1 expressing human β-gal using different promoters, respectively. Wild-type mice were treated with a single ICV injection of rAAVhu68.GLB1 expressing human GLB1 from the CB7, EF1a, or UbC promoter (n=10 per group). Untreated wild-type mice (n=5) served as controls. 14 days after administration of rAAVhu68.GLB1, brains (frontal cortex) and CSF were collected and β-gal activity was measured using a fluorogenic substrate. *p<0.05, **p<0.01, ***p<0.001, Kruskal-Wallis test followed by Dunn's test. [Figure 3A-3E] Illustrating β-gal activity in serum and peripheral organs. β-gal activity was measured in serum (Figure 3A), as well as lung (Figure 3B), liver (Figure 3C), heart (Figure 3D) and spleen (Figure 3E) samples, respectively, using a fluorogenic substrate. PBS: phosphate-buffered saline (vehicle), AAV: adeno-associated virus (AAVhu68.UbC.hGLB1). *p<0.05, **p<0.01, Kruskal-Wallis test followed by Dunn's test. NS: not significant difference. [Figure 4A-4B]Illustrates β-gal activity in brain and CSF. Brains (frontal cortex) and CSF were collected at autopsy and β-gal activity was measured using a fluorogenic substrate. PBS: phosphate buffered saline (vehicle), AAV: adeno-associated virus (AAVhu68.UbC.hGLB1). *p<0.05, **p<0.01, Kruskal-Wallis test followed by Dunn's test. NS: not significant. [Diagram 5] Figure 1 shows decreased hexosaminidase (HEX) activity in the brains of rAAVhu68.GLB1-treated GLB1- / - mice. Brains (frontal cortex) were harvested at necropsy and HEX activity was measured using a fluorogenic substrate. PBS: phosphate-buffered saline (vehicle); AAV: adeno-associated virus (AAVhu68.UbC.hGLB1). *p<0.05, **p<0.01, Kruskal-Wallis test followed by Dunn's test. NS: not significant. [Figure 6] Correlation between β-gal activity and anti-β-gal antibodies. β-gal activity and serum anti-β-gal antibodies were measured in serum samples taken from AAV-treated mice at necropsy. Each point represents an individual animal. [Figure 7A-7G]Correction of gait abnormalities in AAV-treated GLB1- / - mice. Figures 7A and 7B show that untreated GLB1- / - mice (n=12) and GLB1+ / - control mice (n=22) of average 5 months of age were assessed using the CatWalk system on two consecutive days. Mean walking speed (Figure 7A) and hindlimb footprint length (Figure 7B) were quantified for each animal across at least three trials. **p<0.01 Mann-Whitney test. Figures 7C and 7D show that 4-month-old GLB1+ / - (n=15) or GLB1- / - (n=15) mice treated with vehicle, and GLB1- / - mice (n=14) treated with AAV were assessed using the CatWalk system. Mean walking speed (Figure 7C) and hindlimb footprint length (Figure 7D) were quantified across at least three trials for each animal on the second day of testing. *p<0.05, **p<0.01, Kruskal-Wallis test followed by Dunn's test. NS: not significant. Figures 7E-G show representative hind paw footprints for AAV-treated GLB1- / - mice (Figure 7G), and vehicle-treated GLB1+ / - (Figure 7E) and GLB1- / - (Figure 7F) control mice. [Figure 8A-8B] Correlation between walking speed and gait parameters. GLB1+ / - controls (n=22) were assessed on two consecutive days using the CatWalk system. Locomotor parameters measured in at least three trials on the second day of testing were recorded. Correlation analysis demonstrated a strong correlation between walking speed and gait parameters, such as stride length (Spearman r=0.7432, p<0.001, Figure 8A). In contrast, hindlimb footprint length was independent of speed (Spearman r=-0.1239, p=0.423, Figure 8B). [Figure 9A-9F]β-gal activity (FIG. 9A), body weight (FIG. 9B), neurological examination score (neurological score, FIG. 9C), hind paw print length (FIG. 9D), and swing time (FIG. 9E) as well as hind paw stride length (FIG. 9F) of GLB1− / − mice receiving one of four doses of rAAVhu68.UbC.GLB1 (1.3×1011 GC, 4.4×1010 GC, 1.3×1010 GC, or 4.4×109 GC) or vehicle by ICV injection are provided. GLB1+ / − mice receiving vehicle (Het+vehicle) serve as controls. More details are provided in Example 4, section A. [Figure 10A-10B] An alignment is provided showing the amino acid sequence of the vp1 capsid protein of AAVhu68 (SEQ ID NO:2) (denoted as hu68.vp1 in the alignment) along with AAV9 (SEQ ID NO:20), AAVhu31 (denoted as hu.31 in the alignment, SEQ ID NO:21), and AAVhu32 (denoted as hu.32 in the alignment, SEQ ID NO:22). Two mutations (A67E and A157V) were found to be important in AAVhu68 (circled in the figure) compared to AAV9, AAVhu31, and AAVhu32. [Figures 11A-11E] An alignment of nucleic acid sequences encoding the vp1 capsid protein of AAVhu68 (SEQ ID NO:1), along with AAV9 (SEQ ID NO:23), AAVhu31 (SEQ ID NO:24), and AAVhu32 (SEQ ID NO:25), is provided. [Figure 12A] 1 provides an exemplary flow chart of a manufacturing process for producing rAAVhu68.GLB1 drug substance. AEX: anion exchange, CRL: Charles River Laboratories, ddPCR: droplet digital polymerase chain reaction, DMEM: Dulbecco's modified Eagle's medium, DNA: deoxyribonucleic acid, FFB: final formulation buffer, GC: genome copy, HEK293: human embryonic kidney 293 cells, ITFFB: intrathecal final formulation buffer, PEI: polyethylenemine, Ph.Eur.: European Pharmacopoeia, SDS-PAGE: sodium dodecyl sulfate-polyacrylamide gel electrophoresis, TFF: tangential flow filtration, USP: United States Pharmacopoeia, WCB: working cell bank. [Figure 12B]1 provides an exemplary flow chart of a manufacturing process for producing the rAAVhu68.GLB1 formulation. Ad5: adenovirus serotype 5, AUC: analytical ultracentrifugation, BDS: bulk drug substance, BSA: bovine serum albumin, CZ: Crystal Zenith, ddPCR: droplet digital polymerase chain reaction, E1A: early region 1A (gene), ELISA: enzyme-linked immunosorbent assay, FDP: final drug product, GC: genome copies, HEK293: human embryonic kidney 293 cells, ITFFB: intrathecal final formulation buffer, KanR: kanamycin resistance (gene), MS: mass spectrometry, NGS: next generation sequencing, Ph.Eur.: European Pharmacopoeia, qPCR: quantitative polymerase chain reaction, SDS-PAGE: sodium dodecyl sulfate-polyacrylamide gel electrophoresis, TCID50: 50% tissue culture infectious dose, UPLC: ultra performance liquid chromatography, USP: United States Pharmacopoeia. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0018] Provided herein are compositions and methods based on adeno-associated virus (AAV) for treating GM1 gangliosidosis (GM1). An effective amount of genome copies (GC) of recombinant AAV (rAAV) (rAAVhu68.GLB1) carrying a vector genome with AAVhu68 capsid and encoding normal human β-galactosidase (GLB1) enzyme is delivered to a patient. Desirably, the rAAVhu68.GLB1 is formulated with an aqueous buffer. In certain embodiments, the suspension is suitable for intrathecal injection. In certain embodiments, rAAVhu68.GLB1 is AAVhu68.UbC.GLB1 (also referred to as AAVhu68.UbC.hGLB1), wherein the GLB1 gene (i.e., the β-galactosidase (as used herein, also referred to as the GLB1 enzyme, β-gal, or galactosidase) coding sequence) is under the control of regulatory sequences comprising a promoter derived from human ubiquitin C (UbC). In certain embodiments, the composition is delivered via intracisternal injection (ICM).

[0019] Nucleic acid sequences encoding the capsid of an adeno-associated virus of phylogenetic group F, referred to herein as AAVhu68, are utilized to produce AAVhu68 capsids and recombinant AAV (rAAV) carrying vector genomes. As used herein, the term "vector genome" refers to a vector that is packaged into a viral capsid, e.g., an AAV capsid, and is capable of infecting a host cell or refers to a nucleic acid molecule that can be delivered to a patient's cells. In certain embodiments, the vector genome is an expression cassette, with inverted terminal repeat (ITR) sequences at the extreme 5' and 3' ends necessary for packaging the vector genome into an AAV capsid, and between them, the GLB1 gene described herein operably linked to a sequence that directs expression. Additional details related to AAVhu68 are provided in WO2018 / 160582 (incorporated herein by reference in its entirety) and in this detailed description. The rAAVhu68.GLB1 described herein is highly suitable for delivering vector genomes containing the GLB1 gene to cells in the central nervous system (CNS), including the brain, hippocampus, motor cortex, cerebellum, and motor neurons. These rAAVhu68.GLB1 can be used to target other cells in the CNS, as well as certain other tissues and cells outside the CNS. Alternatively, the AAVhu68 capsid can be replaced by another capsid that is also suitable for delivering the vector genome to the CNS, such as AAVcy02, AAV8, AAVrh43, AAV9, AAVrh08, AAVrh10, AAVbb01, AAVhu37, AAVrh20, AAVrh39, AAV1, AAVhu48, AAVcy05, AAVhu11, AAVhu32, or AAVpi02.

[0020] I. GM1 and Therapeutic GLB1 Genes GM1 gangliosidosis (i.e., GM1) can be classified into three types based on clinical phenotype: (1) type 1 or infantile type with onset from birth to 6 months of age: rapidly progressing with hypotonia, severe central nervous system (CNS) degeneration, and death by 1-2 years of age, (2) type 2 late infantile or juvenile type with onset from 7 months to 3 years of age: delayed motor and cognitive development, and slower progression, and (3) type 3 adult or chronic variant with late onset (3-30 years of age): progressive extrapyramidal disorders due to focal deposition of glycosphingolipids in the caudate nucleus (Brunetti-Pierri and Scaglia, 2008. GM1 gangliosidosis: Review of clinical, molecular, and therapeutic aspects, Molecular Genetics and Metabolism, 94: 391-96). Infant GM1 subjects with onset of symptoms before 6 months of age uniformly show rapid and predictable progression of both motor and cognitive disorders. The majority of patients die within the first few years of life (median survival 46 months; Jarnes Utz et al., 2017). Despite a common underlying pathophysiology, the adult (type 3) GM1 phenotype is variable and the disease course is notably milder. Most patients with type 3 GM1 first develop neurological symptoms in late childhood with little subsequent progression into adulthood.

[0021] The severity of each type is inversely related to the residual activity of mutant β-gal (Brunetti-Pierri and Scaglia, 2008), encoded by the GLB1 gene. More than 130 disease-causing GLB1 mutations have been identified in humans (Hofer et al., 2010, Phenotype determining alleles in GM1 gangliosidosis patients bearing novel GLB1 mutations. Clinical Genetics. 78(3):236-246, and Caciotti et al., 2011, M1 gangliosidosis and Morquio B disease: An update on genetic alterations and clinical findings.Biochimica et Biophysica Acta(BBA)-Molecular Basis of Disease.1812(7):782-790.) Several GLB1 mutations have been genetically and biochemically analyzed and correlated with clinical phenotypes (Gururaj et al.,2005,Magnetic Resonance Imaging Findings and Novel Mutations in GM1 Gangliosidosis.Journal of Child Neurology.20(1):57-60;C (Aciotti et al., 2011, and Sperb et al., 2013, Genotypic and phenotypic characterization of Brazilian patients with GM1 gangliosidosis. Gene. 512(1):113-116), many GLB1 mutations remain uncharacterized. In broad terms, the genotype of the patients results in different amounts of residual enzyme activity, but generally, the higher the residual enzyme activity, the milder the phenotype (Ou (Hofer et al., 2018, SAAMP 2.0: An algorithm to predict genotype-phenotype correlation of lysosomal storage diseases. Clinical Genetics. 93(5):1008-1014.). The diagnosis of GM1 is confirmed by either biochemical assays of β-gal and neuraminidase and / or GLB1 molecular analysis. However, the use of genotype-phenotype correlations in predicting clinical manifestations in affected individuals is limited because residual enzyme activity by itself cannot predict the disease subtype caused by mutations in the GLB1 gene (Hofer et al., 2018, SAAMP 2.0: An algorithm to predict genotype-phenotype correlation of lysosomal storage diseases. Clinical Genetics. 93(5):1008-1014.). (Escobar et al., 2010; Caciotti et al., 2011; Ou et al., 2018). Predictive values ​​are best for individuals with two severe mutations (i.e., mutations that abrogate GLB1 enzyme activity) that are generally associated with a severe, early-onset phenotype (Caciotti et al., 2011; Sperb et al., 2013). Although data on concordance rates in siblings are rare, evidence indicates that the clinical course of siblings with infantile GM1 is similar in terms of time to onset and general disease manifestations (Gururaj et al., 2005).

[0022] The gene therapy vectors provided herein, i.e., rAAV.GLB1 (e.g., rAAVhu68.GLB1, rAAVhu68.UbC.GLB1), or compositions comprising them, are useful for treating conditions associated with a lack of normal levels of functional β-galactosidase. As used herein, gene therapy vector refers to rAAV as described herein, suitable for use in treating patients. In certain embodiments, the gene therapy vectors or compositions provided herein are useful for treating type 1 of GM1. In certain embodiments, the gene therapy vectors or compositions provided herein are useful for treating type 2 of GM1. In certain embodiments, the gene therapy vectors or compositions provided herein are useful for treating type 3 of GM1. In certain embodiments, the gene therapy vectors or compositions provided herein are useful for treating types 1 and 2 of GM1. In certain embodiments, the gene therapy vectors or compositions provided herein are useful for treating GM1 patients aged 18 months or younger. In certain embodiments, the gene therapy vectors or compositions provided herein are for treating GM1 excluding type 3. In certain embodiments, the gene therapy vectors or compositions provided herein are useful for treating neurological conditions associated with a lack of normal levels of functional β-galactosidase. In certain embodiments, the gene therapy vectors or compositions provided herein are useful for improving symptoms associated with GM1 gangliosidosis. In certain embodiments, the gene therapy vectors or compositions provided herein are useful for improving neurological symptoms associated with GM1 gangliosidosis.

[0023] In certain embodiments, the patient has infantile gangliosidosis and is 18 months of age or younger. In certain embodiments, the patient receiving rAAV.GLB1 is between 1 month and 18 months of age. In certain embodiments, the patient receiving rAAV.GLB1 is between 4 months and 18 months of age. In certain embodiments, the infant is less than 4 months of age. In certain embodiments, the patient receiving rAAV.GLB1 is about 1, about 2, about 3, about 4, about 5, about 6, about 7, about 8, about 9, about 10, about 11, about 12, about 13, about 14, about 15, about 16, about 17, or about 18 months of age. In certain embodiments, the patient is a toddler, e.g., between 18 months and 3 years of age. In certain embodiments, the patient receiving rAAV.GLB1 is between 3 years and 6 years of age, between 3 years and 12 years of age, ... between 18 years and 3 years, between 3 years and 30 years. In certain embodiments, the patient is 18 years or older.

[0024] In certain embodiments, improvement in symptoms associated with GM1 gangliosidosis is observed following treatment, such as increased life span (length of life), reduced need for feeding tubes, reduced incidence, frequency, and length of seizures, delayed onset of seizures, improved quality of life (e.g., as measured by PedsQL), reduced progression of neurocognitive decline, and / or improved neurocognitive development (e.g., improved adaptive behavior, cognition, language (receptive and expressive communication), and motor function (gross motor, fine motor) as measured by the Bayley Scales of Infant Development (BSID-III) and the Vineland Scales of Adaptive Behavior (Vineland-II), earlier age-at-achievement and later age-at-loss for motor milestones). milestones), delayed increase in brain tissue volume (cerebral cortex and other smaller structures) and ventricular volumes, delayed decrease in size of brain substructures including the corpus callosum, caudate nucleus, putamen, cerebellar cortex and stabilization of brain atrophy and brain volume changes, delayed progression of abnormal T1 / T2 signal intensity in the thalamus and basal ganglia, increased beta-gal enzyme (GLB1) activity in CSF and serum, decreased CSF GM1 concentrations, decreased serum and / or urinary keratan sulfate levels, decreased hexosaminidase activity, decreased inflammatory response in the brain, delayed increase in abnormal liver and spleen volumes, delayed increase in abnormal electroencephalogram (EEG) and visual evoked potentials (VEP), and / or improvement in swallowing disorders, gait function, motor skills, speech and / or respiratory function.

[0025] In certain embodiments, after infusion of rAAV.GLB1 for patients who would not otherwise qualify for AAV therapy as described herein, the patient receives a combination therapy, which may include enzyme replacement therapy, substrate suppression therapy (e.g., with miglustat (OGT918, N-butyl-deoxynojirimycin)), tanganil (acetyl-DL-leucine) treatment, respiratory therapy, feeding tube use, anti-epileptic drugs), or hematopoietic stem cell transplant (HSCT) from bone marrow or umbilical cord blood.

[0026] Optionally, immunosuppressive combination therapy may be used in the subject in need. Immunosuppressants for such combination therapy include, but are not limited to, glucocorticoids, steroids, antimetabolites, T-cell inhibitors, macrolides (e.g., rapamycin or rapalogs), and cytostatic agents (including alkylating agents, antimetabolites, cytotoxic antibiotics, antibodies, or agents active against immunophilins). Immunosuppressants may include nitrogen mustards, nitrosoureas, platinum compounds, methotrexate, azathioprine, mercaptopurine, fluorouracil, dactinomycin, anthracyclines, mitomycin C, bleomycin, mithramycin, IL-2 receptor (CD25)-specific antibodies or CD3-specific antibodies, anti-IL-2 antibodies, cyclosporine, tacrolimus, sirolimus, IFN-β, IFN-γ, opioids, or TNF-α (tumor necrosis factor-α) binding agents. In certain embodiments, immunosuppressive therapy may be initiated 0, 1, 2, 3, 4, 5, 6, 7, or more days prior to or after administration of rAAV.GLB1. Such immunosuppressive therapy may involve administration of one, two, or more drugs (e.g., glucocorticoids, prenelisone, mycophenolate mofetil (MMF) and / or sirolimus (i.e., rapamycin)). Such immunosuppressive drugs may be administered to a patient / subject in need once, twice, or more times at the same dose or adjusted doses. Such therapy may involve simultaneous administration of two or more drugs on the same day (e.g., prenelisone, mycophenolate mofetil (MMF) and / or sirolimus (i.e., rapamycin)). One or more of these drugs may be continued at the same dose or adjusted doses after administration of rAAV.GLB1. Such therapy may be for about one week (7 days), about 60 days, or more, as needed. In certain embodiments, a tacrolimus-free regimen is selected.

[0027] In certain embodiments, an "effective amount" of rAAV.GLB1 (e.g., rAAV.GLB1, rAAV.UbC.GLB1) provided herein is an amount that achieves an improvement in symptoms associated with GM1 gangliosidosis. In certain embodiments, an "effective amount" of rAAV.GLB1 provided herein is an amount that achieves one or more of the following endpoints: an increase in GLB1 pharmacodynamic and biological activity in cerebrospinal fluid (CSF), an increase in GLB1 pharmacodynamic and biological activity in serum, an increase in patient life expectancy (survival time), a delay in disease progression of GM1 gangliosidosis (as assessed by one or more of age at achievement, age at loss, and the proportion of patients who maintain or acquire age-appropriate developmental and motor milestones), and an improvement in neurocognitive development based on a change in one or more of the age-equivalent cognitive, gross motor, fine motor, receptive, and expressive communication scores of the Bayley Scales of Infant Development (BSID, e.g., BSID Third Edition (BSID-III)), a change in standard scores for each domain of the Vineland Adaptive Behavior Scale. For older children and adults, an "effective amount" of rAAV.GLB1 provided herein, in some embodiments, can be an amount that improves dysphagia, ambulatory function, motor skills, language and / or respiratory function, change in standard scores for each domain of the Vineland Adaptive Behavior Scales, Second Edition (Vineland-II), reduction in seizure frequency and age at seizure onset, and improved odds of tube feeding independence at 24 months of age. Examples of age-appropriate developmental and motor milestones are provided by the World Health Organization (WHO). See, e.g., Wijnhoven See TM, et al. (2004). Assessment of gross motor development in the WHO Multicentre Growth Reference Study. Food Nutr Bull. 25(1 Suppl):S37-45, and the following table. In certain embodiments, an "effective amount" of rAAV.GLB1 (such as rAAVhu68, GLB1) provided herein is an amount that achieves a pharmacodynamic effect of rAAV.GLB1 on CSF and serum GLB1 activity, CSF GM1 concentration, and serum and urinary keratan sulfate, changes in brain MRI, liver and spleen volume monitoring, electroencephalogram (EEG) and visual evoked potential (VEP) monitoring. [Table 1] Adapted from Wijnhoven et al., 2004, Assessment of gross motor development in the WHO Multicentre Growth Reference Study. Food Nutr Bull. 25(1 Suppl):S37-45. Abbreviations: WHO, World Health Organization.

[0028] The rAAV.GLB1 described herein, and compositions comprising them, contain a GLB1 gene (i.e., β-Gal coding sequence) that encodes and expresses human β-galactosidase (which may also be referred to as normal GLB1 enzyme) or a functional fragment thereof. The GLB1 enzyme catalyzes the hydrolysis of β-galactosides to monosaccharides. The amino acid sequence of human β-galactosidase (2034 bp, 677 aa, Genbank#AAA51819.1, EC3.2.1.23) is reproduced herein as SEQ ID NO:4 and is also recognized as β-galactosidase, isoform 1. See, e.g., UniProtKB-P16278 (BGAL_HUMAN). In certain embodiments, the GLB1 enzyme can have the sequence of amino acid 24 to amino acid 677 of SEQ ID NO:4 (i.e., the mature GLB1 enzyme without the signal peptide). In certain embodiments, the GLB1 enzyme may have the sequence of amino acids 31 to 677 of SEQ ID NO: 4 (i.e., β-galactosidase, isoform 3). In certain embodiments, the GLB1 enzyme is isoform 2 having the amino acid sequence of SEQ ID NO: 26. Any fragment that retains the function of full-length β-galactosidase may be encoded by the GLB1 gene described herein and is referred to as a "functional fragment." For example, a functional fragment of β-galactosidase may have at least about 25%, 50%, 60%, 70%, 80%, 90%, 100%, or more of the activity of full-length β-galactosidase (i.e., normal GLB1 enzyme, which may be β-galactosidase having the sequence of amino acids 24 to 677 of SEQ ID NO: 4, or any one of the three isoforms). Methods for assessing the activity of β-galactosidase can be found in the Examples as well as in publications. For example, Radoslaw Kwapiszewski, Determination of Acid β-Galactosidase Acti vity: Methodology and Perspectives. Indian J Clin Biochem. 2014 Jan;29(1): 57-62. In certain embodiments, the functional fragment is a truncated β-galactosidase lacking about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 30, or more amino acids at the N-terminus and / or C-terminus of full-length β-galactosidase. In certain embodiments, a functional fragment contains about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 30, or more conservative amino acid substitution(s) compared to full-length β-galactosidase. As used herein, a conservative amino acid substitution is an amino acid substitution in a protein that changes a given amino acid to a different amino acid that has similar biochemical properties (e.g., charge, hydrophobicity, and size).

[0029] In one embodiment, the GLB1 gene has a sequence of SEQ ID NO:5. In certain embodiments, the GLB1 gene is engineered to have a sequence of SEQ ID NO:6. In certain embodiments, the GLB1 gene is engineered to have a sequence of SEQ ID NO:7. In certain embodiments, the GLB1 gene is engineered to have a sequence of SEQ ID NO:8. In certain embodiments, the GLB1 gene is engineered to have a sequence at least 95% to 99.9% identical to SEQ ID NO:6. In certain embodiments, the GLB1 gene is engineered to have a sequence at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or at least about 99.9% identical to SEQ ID NO:6. In certain embodiments, the GLB1 gene is engineered to have a sequence at least 95% to 99.9% identical to SEQ ID NO:7. In certain embodiments, the GLB1 gene is engineered to have a sequence at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or at least about 99.9% identical to SEQ ID NO:7. In certain embodiments, the GLB1 gene is engineered to have a sequence at least about 95% to 99.9% identical to SEQ ID NO:8. In certain embodiments, the GLB1 gene is engineered to have a sequence at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or at least about 99.9% identical to SEQ ID NO:8. In further embodiments, the engineered sequence encodes a full-length β-galactosidase or a functional fragment thereof. In yet further embodiments, the engineered sequence encodes amino acid 24 to amino acid 677 of SEQ ID NO:4 or a functional fragment thereof. In another embodiment, the engineered sequence encodes the amino acid sequence of SEQ ID NO:4 or a functional fragment thereof.

[0030] In certain embodiments, the GLB1 gene encodes the GLB1 enzyme, which comprises a signal (leader) peptide and the GLB1 mature protein, amino acids 24-677 of SEQ ID NO:4. The leader sequence is preferably of human origin or a derivative of a human leader sequence and is about 15 to about 28 amino acids, preferably about 20-25 amino acids, or about 23 amino acids in length. In certain embodiments, the signal peptide is the native signal peptide (amino acids 1-23 of SEQ ID NO:4). In certain embodiments, the GLB1 enzyme comprises an exogenous leader sequence instead of the native leader sequence (amino acids 1-23 of SEQ ID NO:4). In another embodiment, the leader may be derived from human IL2 or a mutated leader. In another embodiment, the human serpin F1 secretion signal may be used as the leader peptide.

[0031] II.AAVhu68 Based on the numbering of SEQ ID NO:2, AAVhu68 (previously referred to as AAV3G2) differs from another phylogenetic group F virus, AAV9, by two encoded amino acids at positions 67 and 157 in vp1. In contrast, other phylogenetic group F AAVs (AAV9, hu31, hu31) have an Ala at position 67 and an Ala at position 157. Novel AAVhu68 capsids and / or engineered AAV capsids are provided and include the following numbering schemes: It has a valine (Val or V) at position 157 based on the numbering and, optionally, a glutamic acid (Glu or E) at position 67 based on the numbering of SEQ ID NO:2.

[0032] As used herein, the term "clade" in relation to a group of AAVs refers to a group of AAVs that are phylogenetically related to each other, as determined using a Neighbor-Joining algorithm based on an alignment of AAV vp1 amino acid sequences with a bootstrap value of at least 75% (out of at least 1000 replicates) and a Poisson-corrected distance measure of 0.05 or less. Neighbor-joining algorithms are described in the literature. See, for example, Nei and S. Kumar, Molecular Evolution and Phylogenetics (Oxford University Press, New York (2000). Computer programs are available that can be used to implement this algorithm. For example, the MEGA v2.1 program implements a modified Nei-Gojobori method. Using these techniques and computer programs, as well as the sequence of the AAV vp1 capsid protein, one of skill in the art can readily determine whether a selected AAV is in one clade identified herein, in another clade, or outside these clades. See, for example, G Gao, et al., "Clade-Based Genetics: A Novel Genetic Approach to Genetic Analysis of AAV vp1 Capsid Proteins," in "Clade-Based Genetics ... See, al, J Virol, 2004 Jun;78(10):6381-6388, which identifies Clades A,B,C,D,E and F, and provides nucleic acid sequences of novel AAV, GenBank Accession Numbers AY530553 to AY530629. See also, WO2005 / 033321.

[0033] In certain embodiments, the AAVhu68 capsid is further characterized by one or more of the following: The AAVhu68 capsid protein is selected from the group consisting of AAVhu68 vp1 protein produced by expression from a nucleic acid sequence encoding the predicted amino acid sequence of 1-736 of SEQ ID NO:2, vp1 protein produced from SEQ ID NO:1, or vp1 protein produced from a nucleic acid sequence that is at least 70% identical to SEQ ID NO:1 encoding the predicted amino acid sequence of 1-736 of SEQ ID NO:2, AAVhu68 vp2 protein produced by expression from a nucleic acid sequence that encodes the predicted amino acid sequence of at least about amino acids 138-736 of SEQ ID NO:2, vp2 protein produced from a sequence that includes at least nucleotides 412-2211 of SEQ ID NO:1, or vp2 protein produced from a nucleic acid sequence that encodes the predicted amino acid sequence of at least about amino acids 138-736 of SEQ ID NO:2 that is at least 70% identical to at least nucleotides 412-2211 of SEQ ID NO:1 that encodes the predicted amino acid sequence of at least about amino acids 138-736 of SEQ ID NO:2, and / or AAVhu68 vp2 protein produced by expression from a nucleic acid sequence that encodes the predicted amino acid sequence of at least about amino acids 203-736 of SEQ ID NO:2. vp3 protein, a vp3 protein produced from a sequence including at least nucleotides 607-2211 of SEQ ID NO:1, or a vp3 protein produced from a nucleic acid sequence that is at least 70% identical to at least nucleotides 607-2211 of SEQ ID NO:1, which encodes the predicted amino acid sequence of at least about amino acids 203-736 of SEQ ID NO:2.

[0034] AAVhu68 vp1, vp2, and vp3 proteins are typically expressed as alternative splice variants encoded by the same nucleic acid sequence that encodes the full-length vp1 amino acid sequence (amino acids (aa) 1-736). Optionally, the vp1 coding sequence is used alone to express the vp1, vp2, and vp3 proteins. Alternatively, the sequence may be expressed as a nucleic acid sequence or a complementary strand thereof that encodes the AAVhu68 vp3 amino acid sequence (about aa203-736) without the vp1 unique region (about aa1 to about aa137) and / or the vp2 unique region (about aa1 to about aa202), the corresponding mRNA or tRNA (e.g., about nucleotides (nt) 607 to about n of SEQ ID NO:1). t2211), or a sequence that is at least 70% to at least 99% (e.g., at least 85%, at least 90%, at least 95%, at least 97%, at least 98%, or at least 99%) identical to SEQ ID NO:1 encoding aa 203 to 736 of SEQ ID NO:2. Additionally or alternatively, the vp1 and / or vp2 coding sequences may be co-expressed with a nucleic acid sequence encoding the AAVhu68 vp2 amino acid sequence of SEQ ID NO:2 (about aa 1 to about 137) or a complementary strand thereto, the corresponding mRNA or tRNA (e.g., an mRNA transcribed from nt 412 to 2211 of SEQ ID NO:1), or a sequence that is at least 70% to at least 99% (e.g., at least 85%, at least 90%, at least 95%, at least 97%, at least 98%, or at least 99%) identical to SEQ ID NO:1 encoding about aa 138 to 736 of SEQ ID NO:2.

[0035] As described herein, rAAVhu68 has rAAVhu68 capsids produced in a production system that expresses capsids from an AAVhu68 nucleic acid sequence encoding the vp1 amino acid sequence of SEQ ID NO:2, and, optionally, additional nucleic acid sequences (e.g., sequences encoding vp3 proteins without the vp1 and / or vp2 unique regions). rAAVhu68 resulting from production using a single nucleic acid sequence vp1 produces a heterogeneous population of vp1, vp2, and vp3 proteins. More specifically, AAVhu68 capsids contain subpopulations within the vp1, vp2, and vp3 proteins that have modifications from the predicted amino acid residues of SEQ ID NO:2. These subpopulations include at least deamidated asparagine (N or Asn) residues. For example, the asparagine in an asparagine-glycine pair is highly deamidated.

[0036] In one embodiment, the AAVhu68 vp1 nucleic acid sequence has the sequence of SEQ ID NO: 1, or a complementary strand thereto, e.g., a corresponding mRNA or tRNA. In certain embodiments, vp2 and / or vp3 proteins may additionally or alternatively be expressed from a nucleic acid sequence different from vp1, e.g., to alter the ratio of vp proteins in a selected expression system. In certain embodiments, a nucleic acid sequence encoding the AAVhu68 vp3 amino acid sequence of SEQ ID NO: 2 (about aa203-736) or a complementary strand thereto, a corresponding mRNA or tRNA (about nt607 to about nt2211 of SEQ ID NO: 1), without the vp1 unique region (about aa1 to about aa137) and / or the vp2 unique region (about aa1 to about aa202), is also provided. In certain embodiments, a nucleic acid sequence encoding the AAVhu68 vp2 amino acid sequence of SEQ ID NO:2 (about aa 138-736) without the vp1 unique region (about aa 1 to about 137), or a complementary strand thereto, the corresponding mRNA or tRNA (nt 412-2211 of SEQ ID NO:1) is also provided.

[0037] However, other nucleic acid sequences encoding the amino acid sequence of SEQ ID NO:2 may be selected for use in producing rAAVhu68 capsids. In certain embodiments, the nucleic acid sequence has a nucleic acid sequence of SEQ ID NO:1, or a sequence at least 70%-99% identical, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 97%, at least 99% identical to SEQ ID NO:1, and encodes SEQ ID NO:2. In certain embodiments, the nucleic acid sequence has a nucleic acid sequence of SEQ ID NO:1, or a sequence at least 70%-99%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 97%, at least 99% identical to SEQ ID NO:1 from about nt 412 to about nt 2211 of SEQ ID NO:1, and encodes the vp2 capsid protein (about aa 138-736) of SEQ ID NO:2. In certain embodiments, the nucleic acid sequence is a nucleic acid sequence from about nt 607 to about nt 2211 of SEQ ID NO:1, or a nucleic acid sequence that is at least 70% to 99%, at least 75%, at least 80%, at least 85%, at least It has a sequence identical to that of SEQ ID NO:2, such as 90%, at least 95%, at least 97%, or at least 99%, and encodes the vp3 capsid protein (approximately aa 203-736) of SEQ ID NO:2.

[0038] It is within the skill of the art to design a nucleic acid sequence encoding this AAVhu68 capsid, including DNA (genomic or cDNA), or RNA (e.g., mRNA). In certain embodiments, a nucleic acid sequence encoding the AAVhu68 vp1 capsid protein is provided in SEQ ID NO:1. See also, Figures 11A-11E. In other embodiments, a nucleic acid sequence that is 70%-99.9% identical to SEQ ID NO:1 may be selected to express the AAVhu68 capsid protein. In certain other embodiments, the nucleic acid sequence is at least about 75% identical, at least 80% identical, at least 85%, at least 90%, at least 95%, at least 97% identical, or at least 99%-99.9% identical to SEQ ID NO:1. Such nucleic acid sequences may be codon optimized for expression in a selected system (i.e., cell type) and can be designed by a variety of methods. This optimization can be performed using methods available online (e.g., GeneArt), published methods, or companies that provide codon optimization services, e.g., DNA2.0 (Menlo Park, Calif.). One codon optimization method is described, for example, in U.S. International Patent Publication No. WO 2005 / 023363. No. 2015 / 012924, incorporated herein by reference in its entirety. See also, for example, U.S. Patent Publication No. 2014 / 0032186 and U.S. Patent Publication No. 2006 / 0136184. Preferably, the entire length of the open reading frame (ORF) of the product is modified. However, in some embodiments, only a fragment of the ORF may be modified. By using one of these methods, a frequency can be applied to any given polypeptide sequence to produce a nucleic acid fragment of a codon-optimized coding region that encodes a polypeptide. Several options are available for performing the actual changes to the codons or for synthesizing the codon-optimized coding region designed as described herein. Such modification or synthesis can be performed using standard and routine molecular biology operations well known to those skilled in the art. In one approach, a series of complementary oligonucleotide pairs, each 80-90 nucleotides in length and spanning the length of the desired sequence, are synthesized by standard methods. These oligonucleotide pairs are synthesized such that when annealed, they form 80-90 base pair double stranded fragments with cohesive ends, e.g., each oligonucleotide in the pair is synthesized to extend 3, 4, 5, 6, 7, 8, 9, 10 or more bases beyond the region that is complementary to the other oligonucleotide in the pair. The single stranded end of each pair of oligonucleotides is designed to anneal with the single stranded end of another pair of oligonucleotides. The oligonucleotide pairs are annealed, and then approximately 5-6 of these double stranded fragments are annealed together via the cohesive single stranded ends, which are then ligated together and cloned into a standard bacterial cloning vector, e.g., a TOPO® vector available from Invitrogen Corporation, Carlsbad, Calif. The constructs are then sequenced by standard methods. Several of these constructs are prepared, consisting of 5-6 fragments of the 80-90 base pair fragments ligated together, i.e., approximately 500 base pair fragments, so that the entire desired sequence is represented in a series of plasmid constructs.The inserts of these plasmids are then cut with appropriate restriction enzymes and ligated together to form the final construct. The final construct is then cloned into a standard bacterial cloning vector and sequenced. Additional methods will be readily apparent to those of skill in the art. Additionally, gene synthesis is readily available commercially.

[0039] In certain embodiments, AAVhu68 capsids are produced using a nucleic acid sequence of SEQ ID NO:1, or a sequence that encodes at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 97%, at least 99% of the vp1 amino acid sequence of SEQ ID NO:2 that includes a modification described herein (e.g., a deamidated amino acid). It is reproduced.

[0040] As used herein, when used to refer to vp capsid proteins, the term "heterologous" or any grammatical variation thereof refers to a population of non-identical members, e.g., having vp1, vp2, or vp3 monomers (proteins) with different modified amino acid sequences. SEQ ID NO:2 provides the encoded amino acid sequence of the AAVhu68 vp1 protein. The term "heterologous" used in relation to vp1, vp2, and vp3 proteins (alternatively referred to as isoforms) refers to differences in the amino acid sequences of vp1, vp2, and vp3 proteins within a capsid. AAV capsids contain subpopulations within the vp1, vp2, and vp3 proteins, with modifications from predicted amino acid residues. These subpopulations include at least certain deamidated asparagine (N or Asn) residues. For example, a particular subpopulation contains at least one, two, three, or four highly deamidated asparagine (N) positions in asparagine-glycine pairs, and optionally further contains other deamidated amino acids, where the deamidation results in an amino acid change and any other modifications.

[0041] As used herein, a "subpopulation" of vp proteins, unless otherwise specified, refers to a group of vp proteins that have at least one defined common characteristic and that consists of at least one group member and fewer than all members of a reference group. For example, a "subpopulation" of vp1 proteins is at least one (1) vp1 protein in an assembled AAV capsid, but less than all vp1 proteins, unless otherwise specified. A "subpopulation" of vp3 proteins can be one (1) vp3 protein less than all vp3 proteins in an assembled AAV capsid, unless otherwise specified. For example, vp1 proteins can be a subpopulation of vp proteins, vp2 proteins can be a separate subpopulation of vp proteins, and vp3 can be a further subpopulation of vp proteins in an assembled AAV capsid. In another example, vp1, vp2, and vp3 proteins can include subpopulations with, for example, at least one, two, three, or four highly deamidated asparagines, e.g., different modifications at asparagine-glycine pairs.

[0042] Unless otherwise specified, extensive deamidation refers to at least 45% deamidation, at least 50% deamidation, at least 60% deamidation, at least 65% deamidation, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 97%, at least 99%, or up to about 100% deamidation at a reference amino acid position compared to the predicted amino acid sequence at the reference amino acid position (e.g., at least 80% of the asparagine at amino acid 57 based on the numbering of SEQ ID NO:2 (AAVhu68) may be deamidated based on the total vp1 protein and may be deamidated based on the total vp1, vp2, and vp3 proteins). Such percentages may be determined using 2D gels, mass spectrometry techniques, or other suitable techniques.

[0043] Without intending to be bound by theory, deamidation of at least the highly deamidated residues in the vp protein in the AAV capsid is thought to be nonenzymatic in nature and is caused by functional groups within the capsid protein that deamidate selected asparagine, and to a lesser extent glutamine, residues. Efficient capsid assembly of the majority of deamidated vp1 proteins indicates that these events occur after capsid assembly or that deamidation in individual monomers (vp1, vp2, or vp3) is structurally well tolerated and largely does not affect assembly kinetics. In general, extensive deamidation in the VP1-unique (VP1-u) region (approximately aa1-137), which is thought to be internally located prior to cell entry, suggests that VP deamidation may occur prior to capsid assembly. It suggests that deamidation of N may occur by nucleophilic attack on the side chain amide carbon atom of Asn through the backbone nitrogen atom of its C-terminal residue. It is believed that an intermediate ring-closed succinimide residue is formed. The succinimide residue then undergoes rapid hydrolysis to give the end product aspartic acid (Asp) or isoaspartic acid (IsoAsp). Thus, in certain embodiments, deamidation of asparagine (N or Asn) gives Asp or IsoAsp, which can be interconverted, for example, via a succinimide intermediate, as exemplified below. [ka]

[0044] As provided herein, each deamidated N in VP1, VP2, or VP3 can independently be aspartic acid (Asp), isoaspartic acid (isoAsp), aspartate, and / or an interconverted blend of Asp and isoAsp, or a combination thereof. Any suitable ratio of α- and isoaspartic acid can be present. For example, in certain embodiments, the ratio can be 10:1 to 1:10 aspartic acid to isoaspartic acid, about 50:50 aspartic acid:isoaspartic acid, or about 1:3 aspartic acid:isoaspartic acid, or another selected ratio.

[0045] In certain embodiments, one or more glutamines (Q) can be deamidated to glutamic acid (Glu), i.e., α-glutamic acid, γ-glutamic acid (Glu), or a blend of α- and γ-glutamic acid, which can be interconverted via a common glutarimide intermediate. Any suitable ratio of α- and γ-glutamic acid can be present. For example, in certain embodiments, the ratio can be 10:1 to 1:10 α to γ, about 50:50 α:γ, or about 1: It may be an α:γ ratio of 3, or another selected ratio. [ka]

[0046] Thus, the rAAV contains subpopulations in the rAAV capsid of vp1, vp2, and / or vp3 proteins that have deamidated amino acids, including at least one subpopulation that contains at least one highly deamidated asparagine. Additionally, other modifications may include isomerization at specifically selected aspartic acid (D or Asp) residue positions. In yet other embodiments, modifications may include amidation at Asp positions.

[0047] In certain embodiments, the AAV capsid comprises a subpopulation of vp1, vp2, and vp3 having at least 4 to at least about 25 deamidated amino acid residue positions, of which at least 1-10% are deamidated relative to the encoded amino acid sequence of the vp protein. The majority of these may be N residues. However, Q residues may be deamidated.

[0048] In certain embodiments, the rAAV has an AAV capsid with vp1, vp2 and vp3 proteins with subpopulations containing combinations of two, three, four or more deamidated residues at the positions shown in the table provided in Example 1 and incorporated herein by reference. The deamidation of rAAV can be determined using 2D gel electrophoresis, and / or mass spectrometry (MS), and / or protein modeling techniques. Online chromatography can be performed on an Acclaim PepMap column and Thermo UltiMate 3000 RSLC system (Thermo Fisher Scientific) coupled to a Q Exactive HF with a NanoFlex source (Thermo Fisher Scientific). MS data can be analyzed by Q-PCR. The data-dependent Top-20 method of Exactive HF was used to dynamically select the most abundant yet unsequenced precursor ions from the survey scan (200-2000 m / z). Sequencing was performed via higher energy collisional dissociation fragmentation with a target value of 1e5 ions determined with predictive auto-increment control, and precursor isolation in a window of 4 m / z. Survey scans were acquired with a resolution of 120,000 at m / z 200. The resolution of the HCD spectrum may be set to 30,000 at m / z 200 with a maximum ion injection time of 50 ms and a normalized collision energy of 30. The S-lens RF level may be set to 50 to optimize the transmission of the m / z region occupied by peptides from the digest. Precursor ions may be excluded from the fragmentation selection as single, unassigned, or with more than six charge states. BioPharma Finder 1.0 software (Thermo Fischer Scientific) may be used to analyze the acquired data. For peptide mapping, searches are performed using a single-entry protein FASTA database with carbamidomethylation set as a fixed modification, oxidation, deamidation, and phosphorylation set as variable modifications, 10 ppm mass accuracy, high protease specificity, and a confidence level of 0.8 for MS / MS spectra. Examples of suitable proteases may include, for example, trypsin or chymotrypsin. Mass spectrometric identification of deamidated peptides is relatively straightforward, since deamidation adds the mass of the intact molecule + 0.984 Da (the mass difference of the -OH and -NH2 groups). The deamidation rate of a particular peptide is determined by dividing the mass area of ​​the deamidated peptide by the sum of the areas of the deamidated and native peptides. Considering the number of possible deamidation sites, isotonic species that are deamidated at different sites may co-migrate in a single peak. Thus, fragment ions derived from peptides with multiple potential deamidation sites can be used to identify or distinguish between multiple deamidation sites. In these cases, the relative intensities within the observed isotopic patterns can be used to specifically determine the relative abundances of different deamidated peptide isomers.This method assumes that the fragmentation efficiency for all isomeric species is the same and is independent at the deamidation site.It will be understood by those skilled in the art that some variations of these exemplary methods can be used.For example, suitable mass analyzers include, for example, quadruple flight mass analyzers (QTOF), such as Waters Xevo or Agilent 6530, or Orbitrap Fusion or Orbitra. The liquid chromatography system may include, for example, an Orbitrap device such as p Velos (Thermo Fisher). Suitable liquid chromatography systems include, for example, Acquity UPLC systems from Waters or Agilent systems (1100 or 1200 series). Suitable data analysis software may include, for example, MassLynx (Waters), Pinpoint and Pepfinder (Thermo Fischer Scientific), Mascot (Matrix Science), Peaks DB (Bioinformatics Solutions). Still other techniques may be described, for example, in X. Jin et al, Hu Gene Therapy Methods, Vol. 28, No. 5, pp. 255-267, published online on June 16, 2017.

[0049] In addition to deamidation, other modifications may occur that do not convert one amino acid into a different amino acid residue, such modifications may include acetylated residues, isomerization, phosphorylation, or oxidation.

[0050] Modulation of deamidation: In certain embodiments, AAV is modified to change the glycine of asparagine-glycine pairs to reduce deamidation. In other embodiments, asparagine is changed to a different amino acid, for example, glutamine, which deamidates at a slower rate, or an amino acid lacking an amide group (e.g., glutamine and asparagine contain an amide group), and / or an amino acid lacking an amine group (e.g., lysine, arginine, and histidine contain an amine group). As used herein, an amino acid lacking an amide or amine side group refers to, for example, glycine, alanine, valine, leucine, isoleucine, serine, threonine, cystine, phenylalanine, tyrosine, or tryptophan, and / or proline. The modification as described may be in one, two, or three of the asparagine-glycine pairs found in the encoded AAV amino acid sequence. In certain embodiments, such modification is not made in all four of the asparagine-glycine pairs. Thus, the method for reducing deamidation of AAV and / or engineered AAV variants has a lower deamidation rate. In addition, or alternatively, one or more other amide amino acids may be changed to non-amide amino acids to reduce deamidation of AAV. In certain embodiments, the mutant AAV capsid described herein comprises a mutation in an asparagine-glycine pair, such that glycine is changed to an alanine or serine. The mutant AAV capsid may comprise one, two, or three mutations where the reference AAV naturally comprises four NG pairs. In certain embodiments, the AAV capsid may comprise one, two, three, or four such mutations where the reference AAV naturally comprises five NG pairs. In certain embodiments, the mutant AAV capsid comprises only a single mutation in an NG pair. In certain embodiments, the mutant AAV capsid comprises a mutation in two different NG pairs. In certain embodiments, the mutant AAV capsid comprises two different NG pairs that comprise mutations, located at structurally distinct positions in the AAV capsid. In certain embodiments, the mutation is not in the VP1 unique region. In certain embodiments, one of the mutations is in the VP1 unique region.Optionally, the mutant AAV capsid does not contain a modification in the NG pair, but does contain a mutation to minimize or eliminate deamidation in one or more asparagines or glutamines located outside the NG pair.

[0051] In certain embodiments, a method for increasing the potency of rAAV is provided, comprising engineering an AAV capsid to eliminate one or more of the NGs in wild-type AAV capsid. In certain embodiments, the coding sequence of "G" of "NG" is engineered to code for another amino acid. In the specific example below, "S" or "A" is substituted. However, other suitable amino acid coding sequences may be selected. See the table in Example 1 (incorporated herein by reference).

[0052] In the AAVhu68 capsid protein, four residues (N57, N329, N45 2, N512) routinely show deamidation levels of over 70% across various lots, and in most cases over 90%. Additional asparagine residues (N94, N253, N270, N304, N409, N477, and Q599) also show deamidation levels of up to about 20% across various lots. Deamidation levels were initially identified using trypsin digestion and verified with chymotrypsin digestion.

[0053] AAVhu68 capsids include subpopulations within the vp1, vp2, and vp3 proteins that have modifications from the predicted amino acid residues of SEQ ID NO:2. These subpopulations include at least certain deamidated asparagine (N or Asn) residues. For example, certain subpopulations include at least one, two, three, or four highly deamidated asparagine (N) positions in the asparagine-glycine pairs of SEQ ID NO:2, and optionally further include other deamidated amino acids, where deamidation results in amino acid changes and other optional modifications. SEQ ID NO:3 provides the amino acid sequence of a modified AAVhu68 capsid and illustrates positions that may have a percentage of deamidated or otherwise modified amino acids. Various combinations of these and other modifications are described herein.

[0054] In other embodiments, the method involves increasing the yield of rAAV and thus increasing the amount of rAAV present in the supernatant without the need for cell lysis or prior to cell lysis. The method involves engineering the AAV VP1 capsid gene to express a capsid protein with Glu at position 67, Val at position 157, or both, based on an alignment with amino acid numbering of the AAVhu68 vp1 capsid protein. In other embodiments, the method involves engineering the VP2 capsid gene to express a capsid protein with Val at position 157. In yet other embodiments, the rAAV has a modified capsid that includes both vp1 and vp2 capsid proteins with Glu at position 67 and Val at position 157.

[0055] As used herein, "AAV9 capsid" refers to a self-assembled AAV capsid consisting of multiple AAV9 vp proteins. AAV9 vp proteins are typically expressed as alternative splice variants encoded by the nucleic acid sequence of SEQ ID NO:23, or at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 97%, at least 99% thereof, and encode the vp1 amino acid sequence of GenBank Accession No. AAS99264. In certain embodiments, "AAV9 capsid" includes AAV having an amino acid sequence 99% identical to AAS99264 or 99% identical to SEQ ID NO:20. See also US7906111 and WO2005 / 033321. As used herein, "AAV9 variants" include, for example, variants described in WO2016 / 049230, US8,927,514, US2015 / 0344911, and US8,734,809.

[0056] Methods for generating the capsid and thus the coding sequence, and for producing rAAV have been described, see, e.g., Gao, et al, Proc. Natl. Acad. Sci. USA100 (10), 6081-6086 (2003) and US 2013 / 0045186A1.

[0057] The terms "substantial homology" or "substantial similarity," when referring to a nucleic acid or a fragment thereof, when optimally aligned with another nucleic acid (or its complementary strand), with appropriate nucleotide insertions or deletions, have nucleotide sequence identity over at least about 95-99% of the aligned sequence. Preferably, the homology is over the full length sequence, or its open reading frame, or another suitable fragment that is at least 15 nucleotides in length. Examples of fragments are described herein.

[0058] The terms "sequence identity," "percent sequence identity," or "percent identical" in the context of nucleic acid sequences refer to residues in two sequences that are the same when aligned for maximum correspondence. The length of sequence identity comparison can be over the entire length of a genome, the entire length of a gene coding sequence, or a fragment of at least about 500-5000 nucleotides, desirably. However, identity between smaller fragments, e.g., of at least about 9 nucleotides, usually at least about 20-24 nucleotides, at least about 28-32 nucleotides, at least about 36 nucleotides or more, may also be desired. Similarly, "percent sequence identity" can be readily determined for amino acid sequences over the entire length of a protein or fragments thereof. Preferably, the fragments are at least about 8 amino acids in length and can be up to about 700 amino acids in length. Examples of suitable fragments are described herein.

[0059] The term "substantial homology" or "substantial similarity", when referring to an amino acid or a fragment thereof, indicates that when optimally aligned with another amino acid (or its complementary strand) with appropriate amino acid insertions or deletions, there is amino acid sequence identity in at least about 95-99% of the aligned sequence. Preferably, the homology is over the full length sequence, or a protein thereof, e.g., cap protein, rep protein, or a fragment thereof that is at least 8 amino acids in length, or more preferably, at least 15 amino acids in length. Examples of suitable fragments are described herein.

[0060] The term "highly conserved" means at least 80% identity, preferably at least 90% identity, more preferably greater than 97% identity. Identity is readily determined by those of skill in the art using algorithms and computer programs known to those of skill in the art.

[0061] Generally, when referring to "identity", "homology", or "similarity" between two different adeno-associated viruses, the "identity", "homology", or "similarity" is determined with reference to "aligned" sequences. An "aligned" sequence or "alignment" refers to multiple nucleic acid or protein (amino acid) sequences, often including corrections for missing or additional bases or amino acids, as compared to a reference sequence. In the examples, the AAV alignment is performed using the published AAV9 sequence as a reference point. The alignment is performed using a variety of multiple sequence alignment programs, either public or commercially available. Examples of such programs include "Clustal Omega", "Clustal W", "CAP Sequence Assembly", "MAP", and "MEME", which are accessible through web servers on the Internet. Other sources of such programs are known to those of skill in the art. Alternatively, the Vector NTI utility is also used. There are also several algorithms known in the art that can be used to measure nucleotide sequence identity, including those included in the programs described above. As another example, polynucleotide sequences can be compared using Fasta™, a program in GCG version 6.1. Fasta™ provides alignment and percent sequence identity of the best overlapping regions between the query sequence and the search sequence. For example, percent sequence identity between nucleic acid sequences can be determined using Fasta™ with its default parameters (word size 6 and NOPAM factor for the scoring matrix) as provided in GCG version 6.1 (hereby incorporated by reference). Multiple sequence alignment programs such as "Clustal Omega", "Clustal X", "MAP", "PIMA", "MSA", "BLOCKMAKER", "MEME" and "Match-Box" programs are also available for amino acid sequences. Generally, any of these programs are used with default settings, but if necessary, Those skilled in the art can change these settings. Alternatively, those skilled in the art can utilize other algorithms or computer programs that provide at least the level of identity or alignment as provided by the referenced algorithms and programs. See, e.g., JD Thomson et al, Nucl. Acids. Res., "A See, “Comprehensive comparison of multiple sequence alignments”, 27(13):2682-2690 (1999).

[0062] III. rAAV Recombinant adeno-associated virus (rAAV) has been described as a suitable vehicle for gene delivery. Typically, an exogenous expression cassette containing a transgene (e.g., GLB1 gene) for delivery by rAAV replaces the functional rep and cap genes from the natural AAV source, resulting in a replication-incompetent vector. These rep and cap functions are provided in trans in the vector production system, but are not present in the final rAAV.

[0063] As shown above, rAAV is provided having an AAV capsid and a vector genome, and includes at least the AAV inverted terminal repeats (ITRs) necessary for packaging the vector genome into the capsid, the GLB1 gene, and the regulatory sequence that directs the expression thereof. In certain embodiments, the AAV capsid is derived from AAVhu68. Although the examples herein utilize a single-stranded AAV vector genome, in certain embodiments, rAAVs that include a self-complementary (sc) AAV vector genome can be utilized in the present invention.

[0064] The necessary regulatory control elements are operably linked to the gene (e.g., GLB1) in a manner that allows its transcription, translation, and / or expression in cells that take up the rAAV. As used herein, "operably linked" sequences include both expression control sequences adjacent to the gene of interest and expression control sequences that act in trans or at a distance to control the gene of interest. Such regulatory sequences typically include, for example, one or more of the following: promoter, enhancer, intron, polyA, self-cleaving linker (e.g., furin, furin-F2A, IRES). The following examples utilize the CB7 promoter (e.g., SEQ ID NO: 10), EF1a promoter (e.g., SEQ ID NO: 11), or human ubiquitin C (UbC) promoter (e.g., SEQ ID NO: 9) for the expression of the GLB1 gene. However, in certain embodiments, other promoters, or additional promoters, may be selected.

[0065] In certain embodiments, in addition to the GLB1 gene, a non-AAV sequence may be included that encodes one or more additional gene products. Such gene products may be peptides, polypeptides, proteins, functional RNA molecules (e.g., miRNAs, miRNA inhibitors), or other gene products of interest. Useful gene products also include miRNAs. miRNAs and other small interfering nucleic acids control gene expression through cleavage / degradation of target RNA transcripts or translational repression of target messenger RNAs (mRNAs). miRNAs are typically naturally expressed as final 19-25 untranslated RNA products. miRNAs exhibit their activity through sequence-specific interactions with the 3′ untranslated regions (UTRs) of target mRNAs. These endogenously expressed miRNAs form hairpin precursors that are then processed into miRNA duplexes and further into “mature” single-stranded miRNA molecules. This mature miRNA induces the multiprotein complex miRISC, which identifies target sites of target mRNAs, for example, within the 3′UTR region, based on complementarity with the mature miRNA.

[0066] AAV vector genomes typically contain cis-acting 5' and 3' inverted terminal repeat (ITR) sequences (see, e.g., B. J. Carter, in "Handbook of Parvoviruses", ed., P. Tijsser, CRC Press, pp. 155 168 (1990)). The ITR sequences are approximately 145 base pairs (bp) in length. Preferably, substantially the entire sequences encoding the ITRs are used in the molecule, although some minor modification of these sequences is tolerated. The ability to modify these ITR sequences is within the skill of the art. (See, e.g., Sambrook et al, "Molecular Cloning. A Laboratory Manual", 2d ed., Cold Spring Harbor Laboratory, New York (1989); and K. Fisher et al., J. Virol., 70:520 532 (1996)). One example of such a molecule utilized in the present invention is a "cis-acting" plasmid that contains a transgene flanked by 5' and 3' AAV ITR sequences with selected transgene sequences and associated regulatory elements. In one embodiment, the ITRs are from a different AAV than the one supplying the capsid. In one embodiment, the ITR sequences are from AAV2. A shortened version of the 5'ITR, called ΔITR, has been described, in which the D sequence and terminal separation site (trs) are deleted. In other embodiments, full-length AAV5' and 3'ITRs are used. However, ITRs from other AAV sources may be selected. If the source of the ITR is from AAV2 and the AAV capsid is from another AAV source, the resulting rAAV may be referred to as pseudotyped. However, other configurations of these elements may also be suitable.

[0067] In certain embodiments, as part of the expression control sequence (regulatory sequence), additional or alternative promoter sequences may be included, for example, located between the selected 5'ITR sequence and the coding sequence. Constitutive promoters, regulatable promoters (see, for example, WO2011 / 126808 and WO2013 / 04943), tissue-specific promoters (e.g., neuron-specific or glial cell-specific promoters, or CNS-specific promoters), or promoters that respond to physiological cues may be utilized in the rAAVs described herein. The promoter(s) may be selected from different sources, such as human cytomegalovirus (CMV) immediate early enhancer / promoter, SV40 immediate early enhancer / promoter, JC polymomavirus promoter, myelin basic protein (MBP) or glial fibrillary acidic protein (GFAP) promoter, herpes simplex virus (HSV-1) latency-associated promoter (LAP), Rous sarcoma virus (RSV) long terminal repeat (LTR) promoter, neuron-specific promoter (NSE), platelet-derived growth factor (PDGF) promoter, hSYN, melanin-concentrating hormone (MCH) promoter, CBA, matrix metalloprotein promoter (MPP), and chicken β-actin promoter. Other suitable promoters may include the CB7 promoter. In addition to the promoter, the vector genome may include one or more other suitable transcription initiation sequences, transcription termination sequences, enhancer sequences, efficient RNA processing signals such as splicing and polyadenylation (polyA) signals, sequences that stabilize cytoplasmic mRNA (e.g., WPRE), sequences that enhance translation efficiency (i.e., Kozak consensus sequences), sequences that enhance protein stability, and, if necessary, sequences that enhance secretion of the encoded product. An example of a suitable enhancer is the CMV enhancer. Other suitable enhancers include those appropriate for the desired target tissue indication. In one embodiment, the regulatory sequence includes one or more expression enhancers. In one embodiment, the regulatory sequence contains two or more expression enhancers. These enhancers may be the same or different from each other.For example, the enhancer may comprise a CMV immediate early enhancer. This enhancer may be present in two copies located adjacent to each other. Alternatively, the double copies of the enhancer are separated by one or more sequences. In yet another embodiment, the expression cassette further comprises an intron, for example, a chicken β-actin intron. In a particular embodiment, the intron is a chimeric intron (CI), a hybrid intron consisting of a human β-globin splice donor and an immunoglobulin G (IgG) splice acceptor element. Other suitable introns are described in the art, for example, those described in WO2011 / 126808. The polyA sequence may include introns known in the art. Examples of suitable polyA sequences include, for example, SV40, SV50, bovine growth hormone (bGH), human growth hormone, and synthetic polyA. Optionally, one or more sequences may be selected to stabilize the mRNA. One example of such a sequence is a modified WPRE sequence, which may be engineered upstream of the polyA sequence and downstream of the coding sequence (e.g., MA Zanta-Boussif, et al, Gene Therapy (2009) 16: 605-619). In certain embodiments, the WPRE sequence is absent.

[0068] In certain embodiments, a vector genome is constructed that includes 5'AAV ITR-promoter-optional enhancer-optional intron-GLB1 gene-polyA-3'ITR. In certain embodiments, the ITR is not from AAV2. In certain embodiments, two or more promoters are present. In certain embodiments, an enhancer is present in the vector genome. In certain embodiments, two or more enhancers are present. In certain embodiments, an intron is present in the vector genome. In certain embodiments, an enhancer and an intron are present. In certain embodiments, the intron is a chimeric intron (CI), a hybrid intron consisting of a human β-globin splice donor and an immunoglobulin G (IgG) splice acceptor element. In certain embodiments, the polyA is an SV40 polyA (i.e., a polyadenylation (PolyA) signal derived from a simian virus 40 (SV40) late gene). In certain embodiments, the polyA is a rabbit beta globin (RBG) polyA. In certain embodiments, the vector genome comprises 5'AAV ITR-CB7 promoter-GLB1 gene-RBG polyA-3'ITR. In certain embodiments, the vector genome comprises 5'AAV ITR-EF1a promoter-GLB1 gene-SV40 polyA-3'ITR. In certain embodiments, the vector genome comprises 5'AAV ITR-UbC promoter-GLB1 gene-SV40 polyA-3'ITR. In certain embodiments, the GLB1 gene has SEQ ID NO:5. In certain embodiments, the GLB1 gene has SEQ ID NO:6. In certain embodiments, the GLB1 gene has SEQ ID NO:7. In certain embodiments, the GLB1 gene has SEQ ID NO:8. In certain embodiments, the vector genome has a sequence of SEQ ID NO:12, or a sequence at least about 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% to about 99.9% identical thereto. In certain embodiments, the vector genome has a sequence of SEQ ID NO:13, or a sequence at least about 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% to about 99.9% identical thereto.In certain embodiments, the vector genome has a sequence of SEQ ID NO: 14 or a sequence at least about 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% to about 99.9% identical thereto. In certain embodiments, the vector genome has a sequence of SEQ ID NO: 15 or a sequence at least about 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% to about 99.9% identical thereto. In certain embodiments, the vector genome has a sequence of SEQ ID NO: 16 or a sequence at least about 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% to about 99.9% identical thereto.

[0069] IV. rAAV Vector Production For use in the production of AAV viral vectors (e.g., recombinant (r)AAV), the vector genome can be carried on any suitable vector, e.g., a plasmid, that is delivered to a packaging host cell. Plasmids useful in the present invention can be engineered to be suitable for in vitro replication and packaging in prokaryotic, insect, mammalian cells, among others. Suitable transfection techniques and packaging host cells are known and / or can be readily designed by one of skill in the art. An exemplary production process is provided in Figures 12A-12B.

[0070] Methods for generating and isolating AAV suitable for use as vector are known in the art.See generally, for example, Grieger & Samulski, 2005, Adeno-associated virus as a gene therapy vector: Vector development, production and clinical applications, Adv.Biochem.Engin / Biotechnol.99:119-145; Buning et al., 2008, Recent developments in adeno-associated virus vector technology, J.Gene Med.10:717-733, and the references cited below (each of which is incorporated herein by reference in its entirety).In order to package genes into virions, ITRs are the only AAV components that are required in cis in the same construct as the nucleic acid molecule that contains the genes.Cap and rep genes can be supplied in trans.

[0071] In one embodiment, the selected genetic element can be delivered to the AAV packaging cell by any suitable method, including transfection, electroporation, liposome delivery, membrane fusion techniques, high-speed DNA-coated pellets, viral infection, and protoplast fusion. Stable AAV packaging cells can also be produced. Methods used to produce such constructs are known to those skilled in nucleic acid manipulation and include genetic engineering, recombinant engineering, and synthetic techniques. For example, see Molecular Cloning: A See Laboratory Manual, ed. Green and Sambrook, Cold Spring Harbor Press, Cold Spring Harbor, NY (2012).

[0072] The term "AAV intermediate" or "AAV vector intermediate" refers to an assembled rAAV capsid that lacks the desired genomic sequence packaged therein. These may be referred to as "empty" capsids. Such capsids may contain no detectable genomic sequence of an expression cassette or may contain only partially packaged genomic sequence that is insufficient to achieve expression of a gene product (e.g., β-gal). These empty capsids are non-functional for introducing a gene of interest into a host cell. In certain embodiments, rAAV.GLB1 or compositions described herein may be at least about 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 99.9% free of AAV intermediates, i.e., less than 20%, 15%, 10%, 5%, 4%, 3%, 2%, 1%, or 0.1% AAV intermediates.

[0073] The recombinant adeno-associated virus (AAV) described herein can be produced using known techniques.See, for example, WO2003 / 042397;WO2005 / 033321, WO2006 / 110689;US7588772 B2. Such methods include culturing a host cell that contains an expression cassette consisting of a nucleic acid sequence encoding an AAV capsid protein, a functional rep gene, at a minimum an AAV inverted terminal repeat (ITR) and a transgene, and sufficient helper functions to allow the expression cassette to be packaged into an AAV capsid protein.Methods for producing capsids, coding sequences therefor, and methods for producing rAAV viral vectors have been described.See, for example, Gao, et al, Proc.Natl.Acad.Sci.USA100(10),6081-6086(2003) and US 2013 / 0045186A1.

[0074] In one embodiment, a producer cell culture is provided that is useful for producing recombinant AAV (such as rAAVhu68). Such a cell culture is capable of expressing AAV capsid proteins in a host cell. The nucleic acid to be expressed comprises a nucleic acid molecule suitable for packaging into AAV capsid, such as a vector genome comprising AAV ITRs and a GLB1 gene operably linked with a regulatory sequence that directs the expression of the gene in a cell (e.g., the cell of a patient in need), and sufficient AAV rep function and adenovirus helper function to allow packaging of the vector genome into recombinant AAV capsid. In one embodiment, the cell culture is composed of mammalian cells (e.g., human embryonic kidney 293 cells, among others) or insect cells (e.g., Spodoptera frugiperda (Sf9) cells). In a particular embodiment, the baculovirus provides the helper function required to package the vector genome into recombinant AAVhu68 capsid.

[0075] Optionally, the rep function is provided by an AAV other than the capsid source AAV AAVhu68. In certain embodiments, at least a portion of the rep function is from AAVhu68. In another embodiment, the rep protein is a heterologous rep protein other than AAVhu68, such as, but not limited to, AAV1 rep protein, AAV2 rep protein, AAV3 rep protein, AAV4 rep protein, AAV5 rep protein, AAV6 rep protein, AAV7 rep protein, AAV8 rep protein, AAV9 rep protein, AAV10 rep protein, AAV11 rep protein, AAV12 rep protein, AAV13 rep protein, AAV14 rep protein, AAV15 rep protein, AAV16 rep protein, AAV17 rep protein, AAV18 rep protein, AAV19 rep protein, AAV20 rep protein, AAV21 rep protein, AAV22 rep protein, AAV23 rep protein, AAV24 rep protein, AAV25 rep protein, AAV26 rep protein, AAV27 rep protein, AAV28 rep protein, AAV29 rep protein, AAV30 rep protein, AAV31 rep protein, AAV32 rep protein, AAV33 rep protein, AAV34 rep protein, AAV35 rep protein, AAV36 rep protein, AAV37 rep protein, AAV38 rep protein, AAV39 rep protein, AAV310 rep protein, AAV32 rep protein, AAV33 rep protein, AAV34 rep protein, AAV35 rep protein, AAV36 rep protein, AAV37 rep protein, AAV38 rep protein, AAV39 rep protein, AAV39 rep protein, AAV39 rep protein, AAV310 rep protein, AAV311 rep protein, AAV312 rep protein, AAV313 rep protein, A The capsid may be the rep protein, the AAV6 rep protein, the AAV7 rep protein, the AAV8 rep protein, or rep78, rep68, rep52, rep40, rep68 / 78, and rep40 / 52, or fragments thereof, or another source. Any of these AAVhu68 or mutant AAV capsid sequences may be under the control of exogenous regulatory control sequences that direct their expression in the host cell.

[0076] In one embodiment, the cells are produced in a suitable cell culture (e.g., HEK293 or Sf9) or suspension. The methods for producing gene therapy vectors described herein include methods well known in the art, such as production of plasmid DNA used for the production of gene therapy vectors, production of vectors, and purification of vectors. In some embodiments, the gene therapy vector is rAAV, and the produced plasmids are cis-plasmids encoding the AAV vector genome containing the gene of interest, AAV trans-plasmids containing AAV rep and cap genes, and adenovirus helper plasmids. The vector production process can include method steps such as initiation of cell culture, passaging of cells, seeding of cells, transfection of cells with plasmid DNA, medium exchange with serum-free medium after transfection, and harvesting of vector-containing cells and culture medium. The harvested vector-containing cells and culture medium are referred to herein as crude cell harvest. In yet another system, the gene therapy vector is introduced into insect cells by infection with a baculovirus-based vector. For reviews of these production systems, see, in general, e.g., Zhang et al., 2009, Adenovirus-adeno-associated virus hybrid for large-scale recombinant adeno-associated virus production, Human Gene Therapy. 20:922-929, the contents of each of which are incorporated herein by reference in their entireties. Methods of making and using these and other AAV production systems are also described in the following U.S. patents, the contents of which are incorporated herein by reference in their entireties: 5,139,941, 5,741,683, 6,057,152, 6,204,059, 6,268,213, 6,491,907, 6,660,514, 6,951,753, 7,094,604, 7,172,893, 7,201,898, 7,229,823, and 7,439,065.

[0077] The crude cell harvest may then be subjected to various purification procedures, such as concentration of the rAAV harvest, diafiltration of the rAAV harvest, microfluidization of the rAAV harvest, nuclease digestion of the rAAV harvest, filtration of the microfluidized intermediate, crude purification by chromatography, crude purification by ultracentrifugation, buffer exchange by tangential flow filtration, and / or formulation and filtration to prepare bulk rAAV. is subjected to a method step.

[0078] A two-step high salt affinity chromatography purification, followed by anion exchange resin chromatography, is used to purify rAAV preparations and remove empty capsids. These methods are described in WO2017 / 160360, filed December 9, 2016, International Patent Application No. PCT / US2016 / 065970, and its priority documents, U.S. Patent Application No. 62 / 322,071, filed April 13, 2016, and "Scalable Purification Methods," filed December 11, 2015. No. 62 / 226,357, entitled "In Vivo Immunodeficiency Virus Type 1 (AV1) Inhibition of AAV9 Infections," which are incorporated herein by reference.

[0079] To calculate empty and full particle content, the VP3 band volume for a selected sample (e.g., in the examples herein, an iodixanol gradient-purified preparation, where (GC) = number of particles) is plotted against the GC particles loaded. The resulting linear equation (y = mx + c) is used to calculate the number of particles in the band volume of the test material peak. The number of particles (pt) per 20 μL loaded is then multiplied by 50 to obtain particles (pt) / mL. Pt / mL is divided by GC / mL to obtain the ratio of particles to genome copies (pt / GC). Pt / mL - GC / mL gives empty pt / mL. Empty pt / mL is divided by pt / mL and then x100 to obtain the percentage of empty particles.

[0080] In general, assay methods for rAAV particles containing empty capsids and packaged genomes are known in the art.See, for example, Grimm et al., Gene Therapy (1999) 6:1322-1330; Sommer et al., Molec. Ther. (2003) 7:122-128.To test for denatured capsids, the method includes subjecting the processed AAV stock to SDS-polyacrylamide gel electrophoresis, consisting of any gel capable of separating the three capsid proteins, such as a gradient gel containing 3-8% Tris-acetate in buffer, then running the gel until the sample material is separated, blotting the gel onto a nylon or nitrocellulose membrane, preferably nylon. The anti-AAV capsid antibody is then used as a primary antibody that binds to the denatured capsid protein, preferably an anti-AAV capsid monoclonal antibody, most preferably a B1 anti-AAV-2 monoclonal antibody (Wobus et al., J. Virol. (2000) 74:9281-9293). A secondary antibody is then used that binds to the primary antibody and includes a means for detecting binding with the primary antibody, more preferably an anti-IgG antibody containing a detection molecule covalently bound to the antibody, most preferably a sheep anti-mouse IgG antibody covalently bound to horseradish peroxidase. To semi-quantitatively measure the binding between the primary and secondary antibodies, a method for detecting binding is used, preferably a detection method capable of detecting radioisotope radiation, electromagnetic radiation, or color change, most preferably a chemiluminescence detection kit. For example, for SDS-PAGE, samples from column fractions are collected and heated in SDS-PAGE loading buffer containing a reducing agent (e.g., DTT), and capsid proteins are resolved on precast gradient polyacrylamide gels (e.g., Novex). Silver staining may be performed using SilverXpress (Invitrogen, CA) according to the manufacturer's instructions, or other suitable staining methods, i.e., SYPRO Ruby or Coomassie staining.In one embodiment, the concentration of AAV vector genomes (vg) in the column fractions can be measured by quantitative real-time PCR (Q-PCR). The samples are diluted and digested with DNase I (or another suitable nuclease) to remove exogenous DNA. After inactivation of the nuclease, the samples are further diluted and amplified using primers and TaqMan™ fluorogenic probes specific for the DNA sequence between the primers. A defined level of fluorescence (threshold value) is measured. The number of cycles required to reach a threshold cycle (Ct) is measured for each sample on an Applied Biosystems Prism 7700 sequence detection system. Plasmid DNA containing the same sequence as contained in the rAAV is used to generate a standard curve in a Q-PCR reaction. The cycle threshold (Ct) value obtained from the sample was used to determine the vector genome titer by normalizing it to the Ct value of the plasmid standard curve. An endpoint assay based on digital PCR can also be used.

[0081] In one embodiment, an optimized q-PCR method is used that utilizes a broad-spectrum serum protease, such as Protease K (e.g., commercially available from Qiagen). More specifically, the optimized qPCR genomic titer assay is similar to the standard assay, except that after DNase I digestion, the sample is diluted with Protease K buffer and treated with Protease K, followed by heat inactivation. Suitably, the sample is diluted with an amount of Protease K buffer equal to the sample size. The Protease K buffer may be concentrated 2-fold or more. Typically, the Protease K treatment is about 0.2 mg / mL, but can vary from 0.1 mg / mL to about 1 mg / mL. The treatment step is generally carried out at about 55° C. for about 15 minutes, but may be carried out at lower temperatures (e.g., about 37° C. to about 50° C.) for longer periods (e.g., about 20 minutes to about 30 minutes), or at higher temperatures (e.g., up to about 60° C.) for shorter periods (e.g., about 5 to 10 minutes). Similarly, heat inactivation is generally at about 95° C. for about 15 minutes, but may be performed at lower temperatures (e.g., about 70 to about 90° C.) and for longer periods (e.g., about 20 minutes to about 30 minutes). The sample is then diluted (e.g., 1000-fold) and subjected to TaqMan analysis as described for standard assays.

[0082] Additionally or alternatively, droplet digital PCR (ddPCR) can be used.For example, a method for measuring single-stranded and self-complementary AAV vector genome titer by ddPCR is described.See, for example, M. Lock et al, Hu Gene Therapy Methods, Hum Gene Ther Methods.2014 Apr;25(2):115-25.doi:10.1089 / hgtb.2013.131.Epub 2014 Feb 14.

[0083] Briefly, the method for separating rAAVhu68 particles with packaged genome sequences from genome-defective AAVhu68 intermediates involves subjecting a suspension containing recombinant AAVhu68 viral particles and AAVhu68 capsid intermediates to high performance liquid chromatography, where the AAVhu68 viral particles and AAVhu68 intermediates are bound to a strong anion exchange resin equilibrated at a pH of about 10.2 and subjected to a salt gradient while monitoring the eluate for ultraviolet absorbance at about 260 nanometers (nm) and about 280 nm. The pH can range from about 10.0 to 10.4, although less optimal for rAAVhu68. In this method, AAVhu68 complete capsids are recovered from fractions that elute when the ratio of A260 / A280 reaches an inflection point. In one example, for an affinity chromatography step, the diafiltered product may be applied to Capture Select™ Poros-AAV2 / 9 affinity resin (Life Technologies), which efficiently captures the AAV2 / hu68 serotype. Under these ionic conditions, a significant percentage of residual cellular DNA and proteins flows through the column, while the AAV particles are efficiently captured.

[0084] Also provided herein are production vectors (such as plasmids) or host cells for producing the vector genomes and / or rAAV.GLB1 described herein. As used herein, a production vector that delivers a vector genome to a host cell for generating and / or packaging a gene therapy vector described herein.

[0085] rAAV.GLB1 (e.g., rAAVhu68.GLB1) is suspended in a suitable physiologically compatible composition (e.g., buffered saline). This composition can be frozen for storage, later thawed, and optionally diluted with a suitable diluent. Alternatively, rAAV.GLB1 can be prepared as a composition suitable for delivery to a patient without undergoing a freezing and thawing step.

[0086] V. Compositions and Uses Provided herein are compositions that include at least one rAAV stock (e.g., an rAAVhu68 stock or a mutant rAAVhu68 stock) and optional carriers, excipients and / or preservatives. An rAAV stock refers to multiple rAAVs that are the same, e.g., in the amounts described below in the discussion of concentrations and dosage units.

[0087] In particular, the composition is for the treatment of GM1 gangliosidosis. In one embodiment, the composition is suitable for administration to patients with GM1 gangliosidosis or patients with infantile gangliosidosis aged 18 months or less. In one embodiment, the composition is suitable for administration to patients in need thereof to improve symptoms of GM1 gangliosidosis or to improve neurological symptoms of GM1 gangliosidosis. In some embodiments, the composition is for use in the manufacture of a medicament for the treatment of GM1 gangliosidosis.

[0088] As used herein, "carrier" includes any and all solvents, dispersion media, vehicles, coatings, diluents, antibacterial and antifungal agents, isotonic and absorption delaying agents, buffers, carrier solutions, suspensions, colloids, etc. The use of such media and agents for pharmaceutical active substances is well known in the art. Supplementary active ingredients can also be incorporated into the composition.

[0089] In certain embodiments, provided herein are compositions comprising an rAAV.GLB1 as described herein and a pharma- ceutically acceptable carrier. The phrase "pharmaceutically acceptable" refers to molecular entities and compositions that do not produce allergic or similar adverse reactions when administered to a host.

[0090] In certain embodiments, compositions are provided herein that comprise the rAAV.GLB1 described herein and a delivery vehicle.Delivery vehicles such as liposomes, nanocapsules, microparticles, microspheres, lipid particles, vesicles, etc. can be used to introduce the compositions of the present invention into suitable host cells.In particular, rAAV delivery vector genomes can be formulated for delivery either encapsulated in lipid particles, liposomes, vesicles, nanospheres, or nanoparticles, etc.

[0091] In one embodiment, the composition comprises a final formulation suitable for delivery to a subject / patient, for example, an aqueous liquid suspension buffered to a physiologically compatible pH and salt concentration.Optionally, one or more surfactants are present in the formulation.In another embodiment, the composition can be shipped as a concentrate that is diluted for administration to a subject.In other embodiments, the composition can be lyophilized and reconstituted at the time of administration.

[0092] A suitable surfactant, or combination of surfactants, may be selected from among non-toxic non-ionic surfactants. In one embodiment, a bifunctional block copolymer surfactant terminated in a primary hydroxyl group is selected, such as Pluronic® F68 [BASF], also known as Poloxamer 188, having a neutral pH and an average molecular weight of 8400. Other surfactants and other poloxamers, i.e., polyoxypropylene (PO) flanked by two hydrophilic chains of polyoxyethylene (poly(ethylene oxide)), may also be used. Nonionic triblock copolymers consisting of a central hydrophobic chain of poly(propylene oxide), SOLUTOL HS 15 (macrogol-15 hydroxystearate), LABRASOL (polyoxycapric acid glyceride), polyoxy 10 oleyl ether, TWEEN (polyoxyethylene sorbitan fatty acid ester), ethanol, and polyethylene glycol may be selected. In one embodiment, the formulation contains a poloxamer. These copolymers are generally named using the letter "P" (for poloxamer) followed by three digits, the first two digits x 100 giving the approximate molecular mass of the polyoxypropylene core, and the last digit x 10 giving the percentage of polyoxyethylene content. In one embodiment, poloxamer 188 is selected. In one embodiment, the surfactant may be present in an amount of up to about 0.0005% to about 0.001% (w / w%, weight to weight basis) of the suspension. In another embodiment, the surfactant may be present in an amount of up to about 0.0005% to about 0.001% (v / v%, volume by volume) of the suspension. In yet another embodiment, the surfactant is present in an amount of up to about 0.0005% to about 0.001% of the suspension, where n% represents n grams per 100 mL of suspension.

[0093] rAAV.GLB1 is administered in an amount sufficient to transfect cells and provide sufficient levels of gene transfer and expression to provide a therapeutic effect without undue adverse effects or with a medically acceptable physiological effect, which can be determined by one skilled in the medical arts. Conventional and pharmacologic acceptable routes of administration include, but are not limited to, direct delivery to the desired organ (e.g., brain, CSF, liver (optionally via the hepatic artery), lungs, heart, eyes, kidneys), oral, inhalation, intranasal, intrathecal, intratracheal, intraarterial, intraocular, intravenous, intramuscular, subcutaneous, intradermal, intraparenchymal, intrathecal, ICM, lumbar puncture, and other parenteral routes of administration. Routes of administration may be combined, if desired.

[0094] The dose of rAAV.GLB1 will depend primarily on factors such as the condition being treated, the age, weight, and health of the patient, and therefore may vary between patients. For example, a therapeutically effective human dose of rAAV.GLB1 is generally about 1×10 9 ~1×10 16 The concentration of vector genome copies ranges from about 25 to about 1000 microliters to about 100 mL of solution. In certain embodiments, a suspension volume of about 1 mL to about 15 mL, or about 2.5 mL to about 10 mL, or about 5 mL is delivered. In certain embodiments, a suspension volume of about 1, about 2, about 3, about 4, about 5, about 6, about 7, about 8, about 9, about 10, about 11, about 12, about 13, about 14, or about 15 mL is delivered.

[0095] In some embodiments, the compositions are for administration in a single dose. In some embodiments, the compositions are for administration in multiple doses.

[0096] In certain embodiments, about 8x10 per patient 12 Genome copies (GC) of rAAV.GLB1 ~ approximately 3x10 per patient 14 The dose of rAAV.GLB1 for GC is administered in a volume described herein. In certain embodiments, the dose is about 2x10 per patient. 12 rAAV.GLB1 for GC ~ 3x10 per patient 14 rAAV.GLB1 for GC, or approximately 2x10 per patient 13 rAAV.GLB1 for GC ~ 3x10 per patient 14 rAAV.GLB1 for GC, or approximately 8x10 per patient 13 rAAV.GLB1 for GC ~ 3x10 per patient 14 rAAV.GLB1 for GC, or approximately 9x10 per patient 13 rAAV.GLB1 in GC, or a total of approximately 8.9x10 12 ~2.7x10 14 Administered in GC dose volumes.

[0097] In a specific embodiment, 1x10 per gram of brain mass 10 GCs of rAAV.GLB1 (GCs / g brain mass) ~3.4x1011 The dose of GC / g brain mass is administered in the volumes described herein. In certain embodiments, the dose is 3.4x10 10 GC / g brain mass ~3.4x10 11 GC / g brain mass, or 1.0x10 11 GC / g brain mass ~3.4x10 11 GC / g brain mass, or approximately 1.1x10 11 GC / g brain mass, or approximately 1.1x10 10 GC / g brain mass ~ approx. 3.3x10 11 The dose of GC / g brain mass is administered by volume. In certain embodiments, the dose is about 3.0x10 GC / g brain mass. 9 , about 4.0x10 9 , about 5.0x10 9 , about 6.0x10 9 , about 7.0x10 9 , about 8.0x10 9 , about 9.0x10 9 , about 1.0x10 10 , about 1.1x10 10 , about 1.5x10 10 , about 2.0x10 10 , about 2.5x10 10 , about 3.0x10 10 , about 3.3x10 10 , about 3.5x10 10 , about 4.0x10 10 , about 4.5x10 10 , about 5.0x10 10 , about 5.5x10 10 , about 6.0x10 10 , about 6.5x10 10 , about 7.0x10 10 , about 7.5x10 10 , about 8.0x10 10 , about 8.5x10 10 , about 9.0x10 10 , about 9.5x10 10 , about 1.0x10 11 , about 1.1x10 11 , about 1.5x10 11 , about 2.0x10 11 , about 2.5x10 11 , about 3.0x10 11 , about 3.3x1011 , about 3.5x10 11 , about 4.0x10 11 , about 4.5x10 11 , about 5.0x10 11 , about 5.5x10 11 , about 6.0x10 11 , about 6.5x10 11 , about 7.0x10 11 , about 7.5x10 11 , about 8.0x10 11 , about 8.5x10 11 , about 9.0x10 11 The dose of GC is administered by volume.In certain embodiments, the dose reflects the minimum effective dose shown in GM1 animal model and is adjusted for use in human patients based on genome copies per gram of brain mass.In one embodiment, the dose for use in human patients is calculated using the assumed brain mass listed in the following table. [Table 2]

[0098] Such dosages may be adjusted to balance the therapeutic effect against any side effects, and may vary depending on the therapeutic application for which rAAV.GLB1 is utilized. The level of expression of the transgene product (e.g., β-gal) can be monitored to determine the dosing frequency that results in rAAV.GLB1, preferably a rAAV containing a minigene (e.g., GLB1 gene). Optionally, dosing regimens similar to those described for therapeutic purposes may be utilized for immunization using the compositions of the present invention.

[0099] The replication-defective virus composition is formulated in a dosage unit, which for a human patient is approximately 1.0×10 9 GC~approx. 1.0×10 16 GC, including an amount of replication defective virus (e.g., rAAV.GLB1, rAAVhu68.GLB1 or rAAVhu68.UbC.GLB1) in the range of all integers or subquantities therein, preferably 1.0 x 10 12 GC~1.0×10 14In one embodiment, the composition comprises at least 1x10 per dose, including all integer or fractional amounts within the range. 9 , 2x10 9 , 3x10 9 , 4x10 9 , 5x10 9 , 6x10 9 , 7x10 9 , 8x10 9 , or 9x10 9 In another embodiment, the composition is formulated to contain at least 1x10 GC per dose, including all integers or fractions within the range. 10 , 2x10 10 , 3x10 10 , 4x10 10 , 5x10 10 , 6x10 10 , 7x10 10 , 8x10 10 , or 9x10 10 In another embodiment, the composition is formulated to contain at least 1x10 GC per dose, including all integers or fractions within the range. 11 , 2x10 11 , 3x10 11 , 4x10 11 , 5x10 11 , 6x10 11 , 7x10 11 , 8x10 11 , or 9x10 11 In another embodiment, the composition is formulated to contain at least 1x10 GC per dose, including all integers or fractions within the range. 12 , 2x10 12 , 3x10 12 , 4x10 12 , 5x10 12 , 6x10 12 , 7x10 12 , 8x10 12 , or 9x10 12 In another embodiment, the composition is formulated to contain GC. is at least 1x10 per dose, including all integers or fractions within the range. 13 , 2x10 13 , 3x1013 , 4x10 13 , 5x10 13 , 6x10 13 , 7x10 13 , 8x10 13 , or 9x10 13 In another embodiment, the composition is formulated to contain at least 1x10 GC per dose, including all integers or fractions within the range. 14 , 2x10 14 , 3x10 14 , 4x10 14 , 5x10 14 , 6x10 14 , 7x10 14 , 8x10 14 , or 9x10 14 In another embodiment, the composition is formulated to contain at least 1x10 GC per dose, including all integers or fractions within the range. 15 , 2x10 15 , 3x10 15 , 4x10 15 , 5x10 15 , 6x10 15 , 7x10 15 , 8x10 15 , or 9x10 15 In one embodiment, for human applications, the dose is formulated to contain 1×10 per dose, including all integers or fractions within the range. 10 ~Approx. 1×10 12 It may be in the GC range.

[0100] These above doses may be administered in various volumes of the carrier, excipient, or buffer formulation ranging from about 25 to about 1000 microliters, or higher volumes including all numbers within that range, depending on the size of the area to be treated, the viral titer used, the route of administration, and the desired effect of the method. In one embodiment, the volume of the carrier, excipient, or buffer is at least about 25 μL. In one embodiment, the volume is about 50 μL. In another embodiment, the volume is about 75 μL. In another embodiment, the volume is about 100 μL. In another embodiment, the volume is about 125 μL. In another embodiment, the volume is about 150 μL. In another embodiment, the volume is about 175 μL. In yet another embodiment, the volume is about 200 μL. In another embodiment, the volume is about 225 μL. In yet another embodiment, the volume is about 250 μL. In yet another embodiment, the volume is about 275 μL. In yet another embodiment, the volume is about 300 μL. In yet another embodiment, the volume is about 325 μL. In another embodiment, the capacity is about 350 μL. In another embodiment, the capacity is about 375 μL. In another embodiment, the capacity is about 400 μL. In another embodiment, the capacity is about 450 μL. In another embodiment, the capacity is about 500 μL. In another embodiment, the capacity is about 550 μL. In another embodiment, the capacity is about 600 μL. In another embodiment, the capacity is about 650 μL. In another embodiment, the capacity is about 700 μL. In another embodiment, the capacity is about 700 μL to 1000 μL.

[0101] In certain embodiments, the dose is about 1x10 9 GC / g brain mass ~ approx. 1x10 12 GC / g brain mass. In certain embodiments, the dose is about 3x10 10 GC / g brain mass ~ approx. 3x10 11 GC / g brain mass. In certain embodiments, the dose is about 5x10 10 GC / g brain mass ~ approx. 1.85x10 11 The range may be in the range of GC / g brain mass.

[0102] In one embodiment, the viral construct comprises at least about 1×10 9 GC~approx. 1×10 15 , or approximately 1 × 10 11 ~5×10 13 The GC may be delivered in doses of 1000 mg / kg / day. Appropriate volumes and concentrations for delivery of these doses may be determined by one of skill in the art. For example, a volume of about 1 μL to 150 mL may be selected, although higher volumes may be selected for adults. Typically, for newborn infants, an appropriate volume may be selected from about 0.5 mL to about 10 mL, and for older infants, from about 0.5 mL to about 15 mL. For infants, a volume of about 0.5 mL to about 20 mL may be selected. For children, a volume of up to about 30 mL may be selected. For preteens and teens, a volume of up to about 50 mL may be selected. In yet other embodiments, patients may receive intrathecal administration in a selected volume of about 5 mL to about 15 mL, or about 7.5 mL to about 10 mL. Other appropriate volumes and dosages may be determined. Dosage may be adjusted to balance therapeutic benefit against any side effects, and such dosages may vary depending on the therapeutic application for which rAAV.GLB1 is utilized.

[0103] The rAAV.GLB1 described above can be delivered to a host cell according to published methods. The rAAV, preferably suspended in a physiologically compatible carrier, can be administered to a human or non-human mammalian patient. In certain embodiments, for administration to a human patient, the rAAV is suitably suspended in an aqueous solution containing saline, a surfactant, and a physiologically compatible salt, or mixture of salts. Suitably, the formulation is adjusted to a physiologically acceptable pH, for example, in the range of pH 6-9, or pH 6.0-7.5, or pH 6.2-7.7, or pH 6.5-7.5, pH 7.0-7.7, or pH 7.2-7.8, or about pH 7.0. In certain embodiments, the formulation is adjusted to a pH of about 6.0, about 6.1, about 6.2, about 6.3, about 6.4, about 6.5, about 6.6, about 6.7, about 6.8, about 6.9, about 7.0, about 7.1, about 7.2, about 7.3, about 7.4, about 7.5, about 7.6, about 7.7, or about 7.8. In certain embodiments, for intrathecal delivery, a pH of about 7.28 to about 7.32, about 6.0 to about 7.5, about 6.2 to about 7.7, about 7.5 to about 7.8, about 6.0, about 6.1, about 6.2, about 6.3, about 6.4, about 6.5, about 6.6, about 6.7, about 6.8, about 6.9, about 7.0, about 7.1, about 7.2, about 7.3, about 7.4, about 7.5, about 7.6, about 7.7, or about 7.8 may be desirable, while for intravenous delivery, a pH of about 6.8 to about 7.2 may be desirable. However, other pHs in the broader range, and subranges of these, may be selected for other delivery routes.

[0104] In another embodiment, the composition comprises a carrier, diluent, excipient and / or adjuvant. A suitable carrier can be easily selected by those skilled in the art, taking into consideration the indication for which the introduced virus is intended. For example, one suitable carrier comprises saline, and can be formulated with various buffer solutions (e.g., phosphate buffered saline). Other exemplary carriers include sterile saline, lactose, sucrose, calcium phosphate, gelatin, dextran, agar, pectin, peanut oil, sesame oil, and water. The buffer / carrier should contain a component that prevents rAAV from adhering to the injection tube, but does not interfere with rAAV binding activity in vivo. A suitable surfactant, or combination of surfactants, can be selected from among non-toxic non-ionic surfactants. In one embodiment, a bifunctional block copolymer surfactant terminated in a primary hydroxyl group is selected, such as Poloxamer 188 (also known under the trade names Pluronic® F68 [BASF], Lutrol® F68, Synperonic® F68, Kolliphor® P188), having a neutral pH and an average molecular weight of 8400. Other surfactants and other poloxamers may be selected, i.e., non-ionic triblock copolymers consisting of a central hydrophobic chain of polyoxypropylene (poly(propylene oxide)) flanked by two hydrophilic chains of polyoxyethylene (poly(ethylene oxide)), SOLUTOL HS 15 (macrogol-15 hydroxystearate), LABRASOL (polyoxycapric acid glyceride), polyoxy-oleyl ether, TWEEN (polyoxyethylene sorbitan fatty acid ester), ethanol, and polyethylene glycol. In one embodiment, the formulation contains a poloxamer. These copolymers are generally named using the letter "P" (for poloxamer) followed by three digits, the first two digits x 100 giving the approximate molecular mass of the polyoxypropylene core, and the last digit x 10 giving the percentage of polyoxyethylene content. In one embodiment, poloxamer 188 is selected. The surfactant may be present in an amount up to about 0.0005% to about 0.001% of the suspension.

[0105] In one example, the formulation can contain a buffered saline solution, for example, including one or more of sodium chloride, sodium bicarbonate, dextrose, magnesium sulfate (e.g., magnesium sulfate·7H2O), potassium chloride, calcium chloride (e.g., calcium chloride·2H2O), dibasic sodium phosphate, and mixtures thereof, in water. Preferably, for intrathecal delivery, the osmolality is within a range compatible with cerebrospinal fluid (e.g., about 275 to about 290 milliosmoles per liter (mOsm / L)). For example, , see emedicine.medscape.com / -article / 2093316-overview. Optionally, for intrathecal delivery, a commercially available diluent may be used as the suspending agent or in combination with another suspending agent and any other excipients. See, for example, Elliotts B® solution [Lukare Medical]. Each 10 mL of Elliotts B solution contains: Sodium Chloride, USP 73mg Sodium Bicarbonate, USP 19mg Dextrose, USP 8mg Magnesium sulfate 7H2O, USP 3mg Potassium Chloride, USP 3mg Calcium chloride 2H2O, USP 2mg Sodium Phosphate, Dibasic·7H2O, USP 2mg Water (for injection), USP 10mL appropriate amount Electrolyte Concentration: Sodium 149 mEq / L Bicarbonate 22.6mEq / L Potassium 4.0mEq / L Chlorine 132mEq / L Calcium 2.7mEq / L Sulfuric acid 2.4mEq / L Magnesium 2.4mEq / L Phosphate 1.5mEq / L

[0106] The formula and molecular weight of the component are: [Table 3]

[0107] Elliotts B solution has a pH of 6-7.5 and a calculated osmolality of 288 mOsmol per liter.

[0108] In certain embodiments, the intrathecal final formulation buffer (ITFFB) formulation buffer comprises a buffered saline solution, an artificial cerebrospinal fluid containing one or more of sodium, calcium, magnesium, potassium, or mixtures thereof, and a surfactant. In certain embodiments, the surfactant comprises about 0.0005% to about 0.001% of the suspension. In further embodiments, the percentages (%) are calculated based on a weight (w) ratio (i.e., w / w).

[0109] In certain embodiments, a composition containing rAAVhu68.GLB1 (e.g., an ITFFB formulation) has a pH in the range of 6.0-7.5, or 6.2-7.7, or 6.8-8, or 7.2-7.8, or 7.5-8. In certain embodiments, the final formulation has a pH of about 7, or 7-7.4, or 7.2. In certain embodiments, intrathecal For delivery, a pH above 7.5, for example between 7.5 and 8, or 7.8, may be desirable.

[0110] In certain embodiments, a pH of about 7 is desirable for intrathecal delivery, as well as other delivery routes.

[0111] In certain embodiments, the formulation may contain a buffered saline solution that does not contain sodium bicarbonate. Such formulations may contain a buffered saline solution, such as Harvard buffer, which contains one or more of sodium phosphate, sodium chloride, potassium chloride, calcium chloride, magnesium chloride, and mixtures thereof in water. The aqueous solution may further contain Kolliphor® P188, a poloxamer available from BASF, formerly sold under the trade name Lutrol® F68. In certain embodiments, the aqueous solution may have a pH of 7.2. In certain embodiments, the aqueous solution may have a pH of about 7.

[0112] In another embodiment, the formulation may contain a buffered saline solution comprising 1 mM sodium phosphate (Na3PO4), 150 mM sodium chloride (NaCl), 3 mM potassium chloride (KCl), 1.4 mM calcium chloride (CaCl2), 0.8 mM magnesium chloride (MgCl2), and 0.001% poloxamer (e.g., Kolliphor®) 188. In certain embodiments, the formulation has a pH of about 7.2. In certain embodiments, the formulation has a pH of about 7. See, e.g., harvardapparatus.com / harvard-apparatus-perfusion-fluid.html. In certain embodiments, Harvard buffers are preferred because better pH stability is observed with Harvard buffers. The following table provides a comparison of Harvard buffers and Elliot B buffers. [Table 4]

[0113] In certain embodiments, the formulation buffer is artificial CSF with Pluronic F68. In other embodiments, the formulation may contain one or more penetration enhancers. Examples of suitable penetration enhancers include, for example, mannitol, sodium glycocholate, sodium taurocholate. , sodium deoxycholate, sodium salicylate, sodium caprate, sodium caprate, sodium lauryl sulfate, polyoxyethylene-9-lauryl ether, or EDTA.

[0114] Optionally, the compositions of the present invention may contain other conventional pharmaceutical ingredients, such as preservatives or chemical stabilizers, in addition to the rAAV and carrier(s).Suitable exemplary preservatives include chlorobutanol, potassium sorbate, sorbic acid, sulfur dioxide, propyl gallate, parabens, ethyl vanillin, glycerin, phenol, and parachlorophenol.Suitable chemical stabilizers include gelatin and albumin.

[0115] The composition according to the invention may comprise a pharma- ceutically acceptable carrier as defined above. Suitably, the composition described herein comprises one or more AAV suspended in an effective amount of a pharma- ceutically suitable carrier and / or mixed with a suitable excipient designed for delivery to a subject via injection, osmotic pump, intrathecal catheter, or for delivery by another device or route. In one example, the composition is formulated for intrathecal delivery. In one embodiment, the composition is formulated for administration via intracisternal injection (ICM). In one embodiment, the composition is formulated for administration via CT-guided suboccipital injection into the cisterna magna.

[0116] As used herein, the term "intrathecal delivery" or "intrathecal administration" refers to the route of administration of a drug by injection into the spinal canal, more specifically, into the subarachnoid space to reach the cerebrospinal fluid (CSF). Intrathecal delivery may include lumbar puncture, intraventricular (including intraventricular ventricle (ICV)), suboccipital / intracisternal, and / or C1-2 puncture. For example, material may be introduced by lumbar puncture for diffusion throughout the subarachnoid space. In another example, injection may be into the cisterna magna.

[0117] As used herein, the term "intracisternal delivery" or "intracisternal administration" refers to the route of administration of a drug directly into the cisternal-cerebellar-medullary cerebrospinal fluid, more specifically, by a permanently placed tube, via suboccipital puncture or by direct injection into the cisterna magna.

[0118] In certain embodiments, an aqueous composition comprising a formulation buffer and a rAAV.GLB1 (e.g., rAAVhu68.GLB1) provided herein is delivered to a patient in need thereof. In certain embodiments, the rAAV.GLB1 has an AAV capsid (e.g., AAVhu68 capsid) and a vector genome comprising 5'AAV ITR-promoter-optional enhancer-optional intron-GLB1 gene-polyA-3'ITR. In certain embodiments, the ITR is not from AAV2. In certain embodiments, two or more promoters are present. In certain embodiments, an enhancer is present in the vector genome. In certain embodiments, two or more enhancers are present. In certain embodiments, an intron is present in the vector genome. In certain embodiments, an enhancer and an intron are present. In certain embodiments, the polyA is SV40 polyA. In certain embodiments, the polyA is rabbit β-globin (RBG) polyA. In certain embodiments, the vector genome comprises 5'AAV ITR-CB7 promoter-GLB1 gene-RBG polyA-3'ITR. In certain embodiments, the vector genome comprises 5'AAV ITR-EF1a promoter-GLB1 gene-SV40 polyA-3'ITR. In certain embodiments, the vector genome comprises 5'AAV ITR-UbC promoter-GLB1 gene-SV40 polyA-3'ITR. In certain embodiments, the GLB1 gene has SEQ ID NO:5. In certain embodiments, the GLB1 gene has SEQ ID NO:6. In certain embodiments, the GLB1 gene has SEQ ID NO:7. In certain embodiments, the GLB1 gene has SEQ ID NO:8. In certain embodiments, the vector genome has the sequence of SEQ ID NO:12. In certain embodiments, the vector genome comprises the sequence In certain embodiments, the vector genome has the sequence of SEQ ID NO: 13. In certain embodiments, the vector genome has the sequence of SEQ ID NO: 14. In certain embodiments, the vector genome has the sequence of SEQ ID NO: 15. In certain embodiments, the vector genome has the sequence of SEQ ID NO: 16.

[0119] In certain embodiments, the final formulation buffer comprises an artificial cerebrospinal fluid, including buffered saline and one or more of sodium, calcium, magnesium, potassium, or mixtures thereof, and a surfactant. In certain embodiments, the surfactant is about 0.0005% to about 0.001% of the suspension. In certain embodiments, the surfactant is Pluronic F68. In certain embodiments, the Pluronic F68 is present in an amount of about 0.0001% of the suspension. In certain embodiments, the composition has a pH in the range of 7.5 to 7.8 for intrathecal delivery. In certain embodiments, the composition has a pH in the range of 6.2 to 7.7, or 6.9 to 7.5, or about 7 for intrathecal delivery. In one embodiment, the percentage (%) is calculated based on weight or volume ratio. In another embodiment, the percentage represents "grams per 100 ml of final volume."

[0120] In certain embodiments, treatment with the compositions described herein is well tolerated with respect to sensory neurotoxicity and subclinical sensory neuron pathology, with minimal to mild subclinical degeneration of DRG sensory neurons in animals and / or human patients.

[0121] In certain embodiments, the compositions described herein are useful for improving the functional and clinical outcomes of the treated subjects / patients. Such outcomes may be measured at about 30 days, about 60 days, about 90 days, about 4 months, about 5 months, about 6 months, about 7 months, about 8 months, about 9 months, about 10 months, about 11 months, about 12 months, about 13 months, about 14 months, about 15 months, about 16 months, about 17 months, about 18 months, about 19 months, about 20 months, about 21 months, about 22 months, about 23 months, about 24 months, about 2.5 years, about 3 years, about 3.5 years, about 4 years, about 4.5 years, and then annually for up to about 5 years after administration of the compositions. The measurement frequency can be about every month, about every 2 months, about every 3 months, about every 4 months, about every 5 months, about every 6 months, about every 7 months, about every 8 months, about every 9 months, about every 10 months, about every 11 months, or about every 12 months.

[0122] In certain embodiments, the compositions described herein exhibit pharmacokinetic and clinical efficacy as measured in treated subjects compared to untreated controls.

[0123] In certain embodiments, pharmacokinetic efficacy, clinical efficacy, functional outcome, or clinical outcome may be measured via one or more of the following: (1) survival, (2) tube independence, (3) seizure diary, e.g., seizure incidence, onset, frequency, length, and seizure type, (4) quality of life, e.g., as measured by PedsQL, (5) neurocognitive and behavioral development, (6) β-gal enzyme expression or activity, e.g., in serum or CSF, and (7) other parameters described herein. The Bayley Scales of Infant Development and Vineland Scales may be used to quantify the effect of a composition on development and / or changes in adaptive behavior, cognition, language, motor function, and health-related quality of life.

[0124] In certain embodiments, neurocognitive development is based on one or more of the following: change in age-equivalent cognition, gross motor, fine motor, receptive and expressive communication scores on the Bayley Scales of Infant and Toddler Development, change in standard scores for each domain of the Vineland Adaptive Behavior Scales, and change in standard scores for the Pediatric Quality of Life Inventory (PedsQL) and the Pediatric Quality of Life Inventory Infant Scale (PedsQL). Pediatric quality of life as measured by change in total score of the Pediatric Quality of Life Inventory Infant Scale (PedsQL-IS).

[0125] BSID (Bayley Scale of Infant Development): Used primarily to assess the development of infants aged 1 to 42 months (Albers and Grieve, 2007, Test Review: Bayley, N. (2006). Bayley Scales of Infant. and Toddler Development- Third Edition. San Antonio,TX: Harcourt Assessment. Journal of Psychoeducational Assessment.25(2):180-190). It consists of a set of standardized developmental play tasks, converting raw scores of successfully completed items into scores and composite scores, and deriving developmental indices by comparing scores to norms obtained from typically developing children of the same age. The Bayley-III has three main subtests: the cognitive scale includes items such as attention to familiar and unfamiliar objects, searching for dropped objects, and pretend play; the language scale assesses language comprehension and expression (e.g., ability to follow directions and name objects); and the motor scale measures gross and fine motor skills (e.g., grasping, sitting, stacking blocks, climbing stairs). The latest version is the BSID-III.

[0126] Vineland: Assess adaptive behavior from birth to adulthood (ages 0-90) across five domains: communication, daily living skills, socialization, motor skills, and maladaptive behaviors. The latest version is the Vineland III. Improvements from the Vineland-II to the Vineland-III incorporate questions to better understand developmental disorders.

[0127] The BSID and Vineland are chosen based on data from prospective studies only of infantile GM1 gangliosidosis patients (Brunetti-Pierri and Scaglia, 2008, GM1 gangliosidosis: Review of clinical, molecular, and therapeutic aspects. Molecular Genetics and Metabolism. 94(4):391-396.). BSID-III age-equivalent scores showed a decline to the floor of the test scale by 28 months of age for both cognitive and gross motor domains, while Vineland-II adaptive behavior scale scores remained measurable, although well below normal, by 28 months of age. Although these tools show floor effects, they have been shown to be appropriate measures for measuring developmental change in this severely impaired population, and the cross-cultural validity of the scales makes them suitable for international studies.

[0128] PedsQOL and PedsQL-IS: As with any severe childhood illness, the burden of illness on families is significant. The PedsQL in pediatric patients with Spinal Muscular Atrophy: feasibility, reliability, and validity of the Pediatric Life Inventory™ is a validated tool for assessing the quality of life of children and their parents (by parent proxy report). It has been validated in healthy children and adolescents and has been used in a variety of pediatric disorders (Iannaccone et al., 2009, The PedsQL in pediatric patients with Spinal Muscular Atrophy: feasibility, reliability, and validity of the Pediatric Life Inventory™). Quality of Life Inventory Generic Core Scales and Neuromuscular Module.Neuromuscular disorders: NMD.19(12):805-812, Abs oud et al., 2011, Paediatric UK demyelinating disease longitudinal study (PUDDLS).” BMC Pediatrics. 11(1):68, and Consolaro and Ravelli, 2016, hapter 5-Assessment Tools in Juvenile Idiopathic Arthritis. Handbook of Systemic Autoimmune Diseases. R. Cimaz and T. Lehman, Elsevier. 11:107-127). The PedsQL is therefore included to assess the impact of rAAV.GLB1 on the quality of life of patients and their families. It can be applied to parents of children aged 2 years and older and therefore may be informative as the child ages over the 5-year follow-up period. The Pediatric Quality of Life Survey Infant Scale (Pediatric Quality of Life Survey Infant Scale) The PedsQL™ Infant Scale Inventory (Varni et al., 2011, “The PedsQL™ Infant Scales: feasibility, internal consistency reliability, and validity in healthy and ill infants.” Quality of Life Research. 20(1):45-55.) is a validated modular instrument completed by parents and designed specifically to measure health-related quality of life measures for healthy and ill infants aged 1 to 24 months.

[0129] Given the severity of the disease in the target population, subjects may have achieved motor skills by enrollment, developed other motor milestones and subsequently lost, or may not yet show signs of motor milestone development. Assessment tracks ages achieved and lost for all milestones. Motor milestone achievement is defined for six gross milestones based on the WHO criteria outlined in the table provided herein under Section I GM1 and therapeutic GLB1 genes. Given that subjects with infantile GM1 gangliosidosis may develop symptoms within the first few months of life and acquisition of the first WHO motor milestone (sitting unsupported) typically does not occur before 4 months of age (median age: 5.9 months), this endpoint may lack sensitivity for assessing the extent of therapeutic benefit, especially in subjects who had more obvious symptoms at the time of treatment. For this reason, assessment of age-appropriate developmental milestones that may be applicable to infants is also included (Scharf et al., 2016, Developmental Milestones. Pediatr Rev. 37(1):25-37; quiz 38,47.). One drawback is that the published tools are intended for use by clinicians and parents and organize skills around typical ages of milestone acquisition without reference to normal ranges. However, data can be informative to summarize retention, gain, or loss of developmental milestones over time compared to typical acquisition times in untreated children with infant GM1 disease or neurotypical children.

[0130] As the disease progresses, children may develop seizures. The onset of seizure activity will allow for the determination of whether treatment with rAAV.GLB1 will prevent or delay the onset of seizures or reduce the frequency of seizure events in this population. Parents will be asked to keep a seizure diary, tracking the onset, frequency, duration, and type of seizures.

[0131] In certain embodiments, the pharmacokinetic efficacy, clinical efficacy, functional outcome, or clinical outcome may also include CNS symptoms of the disease, such as volume changes measured by MRI over time. All gangliosidosis infant phenotypes have been shown to have a consistent pattern of macrocephaly and rapid increases in intracranial MRI volumes, both in brain tissue volume (cerebral cortex and other smaller structures) and ventricular volume. In addition, the corpus callosum, caudate, and putamen, as well as the cerebellum, have been shown to have increased cerebral MRI volumes. Various small brain substructures, including the cortex, commonly decrease in size as disease progresses (Regier et al., 2016s, and Nestrasil et al., 2018, cited herein). Treatment with rAAV.GLB1 can slow or halt the progression of CNS disease symptoms, with evidence of stabilization in atrophy and volumetric changes. T1 / T2 signal intensity changes (normal / abnormal) in the thalamus and basal ganglia may also be included based on reported evidence of altered thalamic structures in patients with GM1 and GM2 gangliosidosis (Kobayashi and Takashima, 1994, Thalamic hyperdensity on CT in infantile GM1-gangliosidosis." Brain and Development. 16(6):472-474). In certain embodiments, pharmacokinetic efficacy, clinical efficacy, functional outcome, or clinical outcome may include changes in total brain volume, brain substructure volume, and lateral ventricular volume as measured by MRI, and / or T1 / T2 signal intensity changes in thalamus and basal ganglia activity.

[0132] Alternatively, or additionally, pharmacodynamic efficacy, clinical efficacy, functional outcome, or clinical outcome may include biomarkers, e.g., pharmacodynamics and biological activity of rAAV.GLB1, β-gal enzyme (GLB1) activity that can be measured in CSF and serum, CSF GM1 concentration, serum and urinary keratan sulfate levels, reduced hexosaminidase activity, and brain MRI, which shows consistent rapid atrophy in infantile GM1 gangliosidosis (Regier et al., 2016b, cited herein).

[0133] In certain embodiments, the compositions described herein are useful in slowing disease progression, e.g., as assessed by age at achievement, age at loss, and the percentage of children who maintain or attain age-appropriate developmental and motor milestones (as defined by World Health Organization (WHO) standards).

[0134] In certain embodiments, pharmacokinetic efficacy, clinical efficacy, functional outcomes, or clinical outcomes may include liver and spleen volumes, and / or electroencephalogram (EEG) and visual evoked potentials (VEP).

[0135] VI. DEVICES AND METHODS FOR DELIVERY OF PHARMACEUTICAL COMPOSITIONS INTO THE CEREBROSPINAL FLUID In one aspect, the rAAV or compositions provided herein can be administered intrathecally via the methods and / or devices provided in this section and described in WO2018 / 160582, which is incorporated herein by reference. Alternatively, other devices and methods can be selected.

[0136] In certain embodiments, the method includes a step of CT-guided suboccipital injection via a spinal needle into the patient's cisterna magna. As used herein, the term computed tomography (CT) refers to radiography in which a three-dimensional image of a body structure is constructed from a series of planar cross-sectional images generated along an axis by a computer.

[0137] On the day of the procedure, prepare rAAV.GLB1 at the appropriate concentration. A syringe containing 5.6 mL of rAAV.GLB1 at the appropriate concentration is delivered to the procedure room. The following personnel will be present for the study drug administration: the interventionalist performing the procedure, the anesthesiologist and respiratory technician(s), nurses and physician assistants, the CT (or operating room) technician, and the site research coordinator. Prior to drug administration, a lumbar puncture is performed to remove a predetermined volume of CSF, and then iodinated contrast is injected intrathecally (IT) to aid in visualization of the relevant anatomical structures of the cisterna magna. Intravenous (IV) contrast may be administered prior to or during the needle puncture as an alternative to intrathecal contrast. The use of IV or IT contrast is at the discretion of the interventionalist. The subject is anesthetized, intubated, and positioned on the procedure table. Using sterile technique, the injection site is prepared and covered. The spinal needle (22-25G) is advanced into the cisterna magna under fluoroscopic guidance. A larger introducer needle may be used to aid in needle placement. After needle placement is confirmed, an extension set is attached to the spinal needle and filled with CSF. At the interventionalist's discretion, a syringe containing contrast may be connected to the extension set, and a small volume may be injected to confirm needle placement in the cisterna magna. After needle placement is confirmed with CT guidance + / - contrast injection, a syringe containing 5.6 mL of rAAV.GLB1 is connected to the extension set. The contents of the syringe are slowly injected over 1-2 minutes to deliver a volume of 5.0 mL. The needle is slowly removed from the subject.

[0138] Additional or alternative routes of administration to the intrathecal methods described herein include, for example, systemic, oral, intravenous, intraperitoneal, subcutaneous, or intramuscular administration.

[0139] In one embodiment, doses are scaled by brain mass to provide an approximation of the size of the CSF compartment. In further embodiments, dose conversions are based on brain masses of 0.4 g for adult mice, 90 g for juvenile rhesus macaques, and 800 g for 4-18 month old children. The following table provides exemplary doses for mouse MED studies, NHP toxicity studies, and equivalent human doses. [Table 5]

[0140] In certain embodiments, rAAV.GLB1 is administered to the subject in a single dose.In certain embodiments, multiple doses (e.g., two doses) may be desired.For example, for infants under 6 months of age, multiple doses may be desired at intervals of several days, weeks, or months.

[0141] In certain embodiments, a single dose of rAAV.GLB1 is about 1x10 9 GC / g brain mass ~ approx. 5x10 11 GC / g brain mass. In certain embodiments, a single dose of rAAV.GLB1 can be about 1x10 9 GC / g brain mass ~ approx. 3x10 11 GC brain mass. In certain embodiments, a single dose of rAAV.GLB1 is about 1x10 10 GC / g brain mass ~ approx. 3x10 11 GC / g brain mass. In certain embodiments, the dose of rAAV.GLB1 is about 1x10 10 GC / brain mass ~ approx. 3.33x10 11 GC / brain mass. In certain embodiments, the dose of rAAV.GLB1 is about 1x10 11 GC / brain mass ~ approx. 3.33x10 11 GC / brain mass. In certain embodiments, a single dose of rAAV.GLB1 is about 1.11x10 10 GC / g brain mass ~ approx. 3.33x10 11 GC / g brain mass.

[0142] In certain embodiments, a single dose of rAAV.GLB1 is about 1x10 10 GC / g brain mass ~ approx. 3.4x10 11 GC / g brain mass. In certain embodiments, a single dose of rAAV.GLB1 is about 3.4x10 10 GC / g brain mass ~ approx. 3.4x10 11 GC / g brain mass. In certain embodiments, a single dose of rAAV.GLB1 is about 1.0x10 11 GC / g brain mass ~ approx. 3.4x10 11 GC / g brain mass. In certain embodiments, a single dose of rAAV.GLB1 is about 1.1x10 11 GC / g brain mass. In certain embodiments, a single dose of rAAV.GLB1 is about 1.11x10 10 GC / g brain mass. In other embodiments, different doses may be selected.

[0143] In a preferred embodiment, the subject is a human patient. In this case, a single dose of rAAV.GLB1 is about 1x10 12 GC~approx.3x10 14 In certain embodiments, rA A single dose of AV.GLB1 is approximately 9x10 12 GC~approx.3x10 14 In certain embodiments, the dose of rAAV.GLB1 is about 5x10 13 GC~approx.3x10 14 In certain embodiments, a single dose of rAAV.GLB1 is about 8.90x10 13 GC~approx.2.70x10 14 In certain embodiments, a single dose of rAAV.GLB1 is 8x10 per patient. 12 Genome copies (GC) ~ 3x10 per patient 14 In certain embodiments, a single dose of rAAV.GLB1 is 2x10 per patient. 13 GC ~ 3x10 per patient 14 In certain embodiments, a single dose of rAAV.GLB1 is 8x10 per patient. 13 GC ~ 3x10 per patient 14In certain embodiments, a single dose of rAAV.GLB1 is about 9x10 per patient. 13 In certain embodiments, a single dose of rAAV.GLB1 is at least 8.90 x 10 13 GC. In other embodiments, different doses may be selected.

[0144] The composition is formulated in a dosage unit of about 1×10 9 Genome copies (GC) ~ approx. 5 × 10 14 The composition may contain an amount of AAV in the range of GC (to treat an average subject weighing 70 kg). In some embodiments, the composition is formulated in a dosage unit and contains 1×10 9 Genome copies (GC) ~5×10 13 GC, 1×10 10 Genome copies (GC) ~5×10 14 GC, 1×10 11 GC~5×10 14 GC, 1×10 12 GC~5×10 14 GC, 1×10 13 GC~5×10 14 GC, 8.9×10 13 GC~5×10 14 GC, or 8.9 × 10 13 GC~2.7×10 14 In certain embodiments, the composition is formulated in a dosage unit and contains an amount of AAV in the range of GC to GC. 13 GC, 2.7x10 13 GC, or 8.9x10 13 Contains GC amounts of AAV.

[0145] In one embodiment, a spinal tap is performed and about 15 mL (or less) to about 40 mL of CSF is removed, and rAAV.GLB1 is mixed with the CSF and / or suspended in a compatible carrier and delivered to the subject. In one example, the rAAV.GLB1 concentration is about 1×10 10 Genome copies (GC) ~5×10 14 GC, 1×10 11 GC~5×10 14 GC, 1×10 12 GC~5×1014 GC, 1×10 13 GC~5×10 14 GC, 8.9×10 13 GC~5×10 14 GC, or 8.9 × 10 13 GC~2.7×10 14 GC, but other amounts, e.g., about 1×10 9 GC, approx. 5×10 9 GC, approx. 1×10 10 GC, approx. 5×10 10 GC, approx. 1×10 11 GC, approx. 5×10 11 GC, approx. 1×10 12 GC, approx. 5×10 12 GC, approx. 1.0×10 13 GC, approx. 5×10 13 GC, approx. 1×10 14 GC, or approximately 5 × 10 14 In certain embodiments, the concentration in GC is expressed as GC per spinal tap. In certain embodiments, the concentration in CG is expressed as GC per mL.

[0146] Combination therapies may be delivered with the rAAV.GLB1 compositions provided herein. Combination therapies as described above in this application are incorporated herein by reference.

[0147] One of such combination therapies may be an immunomodulator. Immunosuppressants for such combination therapy include, but are not limited to, glucocorticoids, steroids, antimetabolites, T-cell inhibitors, macrolides (e.g., rapamycin or rapalogs), and cytostatic agents (including alkylating agents, antimetabolites, cytotoxic antibiotics, antibodies, or agents active against immunophilins). Immunosuppressants may include nitrogen mustards, nitrosoureas, platinum compounds, methotrexate, azathioprine, mercaptopurine, fluorouracil, dactinomycin, anthracyclines, mitomycin C, bleomycin, mithramycin, IL-2 receptor (CD25)-specific or CD3-specific antibodies, anti-IL-2 antibodies, cyclosporine, tacrolimus, sirolimus, IFN-β, IFN-γ, opioids, or TNF-α (tumor necrosis factor-α) binding agents. In certain embodiments, immunosuppressive therapy may be initiated prior to gene therapy administration. Such therapy may involve the administration of two or more drugs on the same day, such as prenelisone, mycophenolate mofetil (MMF) and and / or sirolimus (i.e., rapamycin). One or more of these drugs may be continued at the same dose or at adjusted doses following administration of the gene therapy agent. Such therapy may be for about a week, about 15 days, about 30 days, about 45 days, 60 days, or longer, as needed.

[0148] For example, if nutrition is a concern in GM1, placement of a gastrostomy tube is appropriate. If respiratory function deteriorates, a tracheotomy or non-invasive respiratory support is provided. Power chairs and other equipment can improve quality of life.

[0149] The terms "comprise," "comprises," and "comprising" are to be interpreted inclusively rather than exclusively. The words "consist," "consisting," and variations thereof are to be interpreted exclusively rather than inclusively. Although various embodiments herein are set forth using the word "comprising," it is also intended that in other circumstances the relevant embodiment should be construed and described using the word "consisting of" or "consisting essentially of."

[0150] The term "expression" is used herein in the broadest sense and includes the production of RNA or RNA and protein. With respect to RNA, the terms "expression" or "translation" particularly relate to the production of peptides or proteins. Expression can be transient or stable.

[0151] As used herein, the term "NAb titer" is a measure of how many neutralizing antibodies (e.g., anti-AAV Nabs) are produced that neutralize the physiological effects of the targeted epitope (e.g., AAV). Anti-AAV NAb titers can be measured, for example, as described in Calcedo, R., et al., Worldwide Epidemiology of Neutralizing Antibodies to Adeno-Associated Viruses. Journal of Infectious Diseases, 2009.199(3): p.381-390 (herein incorporated by reference).

[0152] In some embodiments, administration of the AAV or composition improves the symptoms of GM1 gangliosidosis or the neurological symptoms of GM1 gangliosidosis. In some embodiments, after treatment, the patient has one or more of an increased life expectancy, a reduced need for feeding tubes, a reduced incidence and frequency of seizures, a reduced progression to neurocognitive decline, and / or improved neurocognitive development.

[0153] As used herein, "expression cassette" refers to a nucleic acid molecule that includes a coding sequence, a promoter, and may include other regulatory sequences therefor. In certain embodiments, a vector genome may include two or more expression cassettes. In other embodiments, the term "transgene" may be used interchangeably with "expression cassette." Typically, such expression cassettes for producing viral vectors include coding sequences for gene products described herein adjacent to the packaging signal of the viral genome, and other expression control sequences such as those described herein.

[0154] The term "heterologous," when used with reference to a protein or nucleic acid, indicates that the protein or nucleic acid contains two or more sequences or subsequences that are not found in the same relationship to each other in nature. For example, nucleic acids having two or more sequences from unrelated genes arranged to create a new functional nucleic acid are typically produced recombinantly. For example, in one embodiment, a nucleic acid directs expression of coding sequences from different genes. In a gene encoding a nucleotide sequence, the promoter is heterologous, with the promoter from one gene positioned so that it is closely spaced from the other gene.

[0155] "Replication-defective virus" or "viral vector" refers to a synthetic or artificial viral particle, in which a vector genome, including an expression cassette containing a gene of interest (e.g., GLB1), is packaged in a viral capsid or envelope, and any viral genomic sequences packaged in the viral capsid or envelope (e.g., AAV or bocavirus) are replication-defective, i.e., they cannot produce progeny virions, but can retain the ability to infect target cells. In one embodiment, the genome of the viral vector does not contain genes encoding enzymes required for replication (the genome can be engineered to be "gutless," containing only the gene of interest flanked by signals required for amplification and packaging of the artificial genome), but these genes can be supplied during production. It is therefore considered safe for use in gene therapy, since replication and infection by progeny virions cannot occur except in the presence of viral enzymes required for replication.

[0156] As used herein, "effective amount" refers to the amount of rAAV composition that delivers and expresses the amount of gene product from vector genome in target cells.Effective amount can be determined based on animal models, not human patients.Examples of suitable mouse or NHP models are described herein.

[0157] The terms "a" or "an" refer to one or more, e.g., "enhancer" refers to one or more. It should be noted that "a" (or "an"), "one or more," and "at least one" are used interchangeably herein.

[0158] As used above, the term "about," when used to modify a numerical value, means a variance of ±10%, unless otherwise specified.

[0159] As described above, "increase," "decrease," "decrease," "improvement," "enhancement," "delay," "early," "slow," "stop" or any grammatical variation thereof, or any similar term, unless otherwise specified, means about a 5-fold, about 2-fold, about 1-fold, about 90%, about 80%, about 70%, about 60%, about 50%, about 40%, about 30%, about 20%, about 10%, about 5% variation compared to a corresponding reference (e.g., an untreated control, a GM1 patient with a corresponding level or a GM1 patient at a certain stage, or a healthy subject or healthy human not having GM1).

[0160] As used herein, "patient" or "subject" refers to a mammal, including humans, veterinary or agricultural animals, domestic or pet animals, and animals that are typically used in clinical research. In one embodiment, the subject of these methods and compositions is a human. In certain embodiments, the patient has GM1.

[0161] Unless otherwise defined herein, technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art and by reference to published documents which provide general guidance to those of ordinary skill in the art for many of the terms used herein. EXAMPLES

[0162] The following examples are illustrative only and are not intended to limit the invention.

[0163] Example 1: AAVhu68+ Deamidation AAVhu68 was analyzed for modifications. Briefly, AAVhu68 was produced using vector genomes not related to this study, each produced using conventional triple transfection methods in 293 cells. For a general description of these techniques, see, e.g., ell CL, et al., The AAV9 receptor and its modification to improve in vivo lung gene transfer in mice. J Clin Invest. 2011;121:2427-2435. Briefly, for example, a plasmid encoding the packaged sequence flanked by AAV2 inverted terminal repeats (transgene expressed from chicken β-actin promoter, intron, and polyA derived from simian virus 40 (SV40) late gene) was packaged by triple transfection of HEK293 cells with a plasmid encoding the AAV2 rep gene and AAVhu68 cap gene, and an adenovirus helper plasmid (pAdΔF6). The resulting AAV viral particles can be purified and concentrated using CsCl gradient centrifugation and frozen for later use.

[0164] Denaturation and alkylation: To 100 μg of thawed virus preparation (protein solution), 2 μl of 1 M dithiothreitol (DTT) and 2 μl of 8 M guanidine hydrochloride (GndHCl) are added and incubated at 90° C. for 10 min. The solution is cooled to room temperature, then 5 μl of freshly prepared 1 M iodoacetamide (IAM) is added and incubated in the dark at room temperature for 30 min. After 30 min, the alkylation reaction is quenched by adding 1 μl of 1 M DTT.

[0165] Digestion: Add 20 mM ammonium bicarbonate, pH 7.5-8, to the denatured protein solution in an amount that dilutes the final GndHCl concentration to 800 mM. Add trypsin solution to achieve a trypsin to protein ratio of 1:20 and incubate overnight at 37 °C. After digestion, add TFA to a final concentration of 0.5% to quench the digestion reaction.

[0166] Mass spectrometry: Approximately 1 microgram of the combined digestion mixture is analyzed by UHPLC-MS / Ms. LC is performed on an UltiMate 3000 RSLCnano System (Thermo Scientific). Mobile phase A is MilliQ water with 0.1% formic acid. Mobile phase B is acetonitrile with 0.1% formic acid. A gradient was run from 4% B to 6% B over 15 min, then 10% B in 25 min (40 min total), then 30% B in 46 min (86 min total). Samples are loaded directly onto the column. The column size is 75 cm x 15 μm inner diameter and is packed with 2 micron C18 media (Acclaim PepMap). The LC is interfaced to a quadrupole-orbitrap mass analyzer (Q-Exactive HF, Thermo Scientific) via Nanoflex electrospray ionization using a source. The column is heated to 35°C and an electrospray voltage of 2.2 kV is applied. The mass analyzer was programmed to acquire tandem mass spectra from the top 20 ions with a maximum MS resolution of 120,000 and an MS / MS resolution of 30,000. The normalized collision energy was set to 30, automatic gain control to 1e5, max fill MS to 100 ms, and max fill MS / MS to 50 ms.

[0167] Data processing: Mass spectrometer raw data files were analyzed by BioPharma Finder 1.0 (Thermo Scientific). Briefly, all searches were performed with a precursor mass tolerance of 10 ppm, a fragment mass tolerance of 5 ppm, no tryptic cleavage, and a maximum of one uncleaved fragment. The modifications required were ssed cleavage, fixed modification of cysteine ​​alkylation, oxidation of methionine / tryptophan, deamidation of asparagine / glutamine, phosphorylation, methylation, and variable modification of amidation. [Table 6-1] [Table 6-2]

[0168] In the case of the AAVhu68 capsid protein, four residues (N57, N329, N452, N512) routinely exhibited deamidation levels of greater than 70% across various lots, In most cases, it is greater than 90%. Additional asparagine residues (N94, N253, N270, N304, N409, N477, and Q599) also show deamidation levels of up to about 20% across various lots. Deamidation levels were initially identified using trypsin digestion and verified with chymotrypsin digestion.

[0169] Thus, an AAV comprising an AAVhu68 capsid protein can comprise a heterogeneous population of capsid proteins, since an AAV can contain AAVhu68 capsid proteins that exhibit different levels of deamidation. The heterogeneous population of AAVhu68 vp1 proteins having varying levels of deamidation can be vp1 proteins produced by expression from a nucleic acid sequence encoding the predicted amino acid sequence of 1-736 of SEQ ID NO:2, vp1 proteins produced from SEQ ID NO:1, or vp1 proteins produced from a nucleic acid sequence at least 70% identical to SEQ ID NO:1 that encodes the predicted amino acid sequence of 1-736 of SEQ ID NO:2. A heterogeneous population of AAVhu68 vp2 proteins having varying levels of deamidation can be vp2 proteins produced by expression from a nucleic acid sequence encoding the predicted amino acid sequence of at least about amino acids 138-736 of SEQ ID NO:2, vp2 proteins produced from a sequence including at least nucleotides 412-2211 of SEQ ID NO:1, or vp2 proteins produced from a nucleic acid sequence at least 70% identical to at least nucleotides 412-2211 of SEQ ID NO:1 that encodes the predicted amino acid sequence of at least about amino acids 138-736 of SEQ ID NO:2. A heterogeneous population of AAVhu68 vp3 proteins having varying levels of deamidation can be vp3 proteins produced by expression from a nucleic acid sequence encoding the predicted amino acid sequence of at least about amino acids 203-736 of SEQ ID NO:2, vp3 proteins produced from a sequence including at least nucleotides 607-2211 of SEQ ID NO:1, or vp3 proteins produced from a nucleic acid sequence at least 70% identical to at least nucleotides 607-2211 of SEQ ID NO:1 that encodes the predicted amino acid sequence of at least about amino acids 203-736 of SEQ ID NO:2.

[0170] Adult rhesus monkeys were transfected with AAVhu68.CB7.CI.eGFP.WPRE.rBG (3.00x10 13Mice were administered AAVhu68 in the ICM and autopsied 28 days later to assess vector transduction. Transduction of AAVhu68 was observed in widespread areas of the brain (data not shown). Thus, AAVhu68 capsids offer the potential for cross-correction in the CNS.

[0171] Example 2: Preparation - Ingredients and Materials The vectors are constructed from cis-plasmids containing the coding sequence of human GLB1 expressed from a chicken β-actin promoter with a cytomegalovirus enhancer (CB7) [SEQ ID NO: 10], human elongation initiation factor 1 alpha promoter (EF1a) [SEQ ID NO: 11], or human ubiquitin C promoter (UbC) [SEQ ID NO: 9] (1229 bp, GenBank #D63791.1)] flanked by AAV2 inverted terminal repeats. Various coding sequences of human GLB1 [aa sequence of SEQ ID NO: 4] are constructed. The wild type sequence is reproduced in SEQ ID NO: 5. Various engineered GLB1 coding sequences are generated and are provided in SEQ ID NO: 6, 7, or 8.

[0172] The vectors were packaged into AAV serotype hu68 capsids by triple transfection of adherent HEK293 cells and then transfected with 100% avian pheromone (AVV) in a 20-well plate. Lock, M., et al. Rapid, Simple, and Versatile Manufacturing of Recombinant Adeno-Associated Viral Vectors The AAV serotype Hu68 capsid is purified by iodixanol gradient centrifugation as previously described in J. Immunol. 2010, 14:1311-1315 (2012). ... (which is incorporated herein in its entirety by reference).

[0173] More specifically, AAVhu68.GLB1 is produced by triple transfection of human HEK293 WCB cells with 1) an AAV cis vector genome plasmid, 2) an AAV trans plasmid designated pAAV2 / hu68.KanR, which encodes the AAV2 replicase (rep) and the AAVhu68 capsid (cap), and 3) a helper adenovirus plasmid designated pAdΔF6.KanR.

[0174] Description of sequence elements of AAV cis vector genome plasmids: Inverted Terminal Repeats (ITRs): ITRs are identical reverse-complementary sequences derived from AAV2 (130 bp, GenBank# NC001401) that flank all components of the vector genome. The ITR sequences function as both origins of vector DNA replication and packaging signals for the vector genome when AAV and adenovirus helper functions are provided in trans. Thus, the ITR sequences represent the only cis sequences required for vector genome replication and packaging. · Promoter: Regulatory elements derived from the human Ubiquitin C (UbC) promoter: This ubiquitous promoter (1229 bp, GenBank# D63791.1) was selected to drive transgene expression in any CNS cell type. Coding sequence: The GLB1 gene encodes β-galactosidase and is based on maximized human codon usage. The GLB1 enzyme catalyzes the hydrolysis of β-linked galactose from gangliosides (2034 bp, 677 aa, Genbank# AAA51819.1, EC3.2.1.23). Chimeric intron (CI) - a hybrid intron consisting of a human β-globin splice donor and an immunoglobulin G (IgG) splice acceptor element · SV40 polyadenylation signal (239 bp, Genbank# KP659662.1): The SV40 polyadenylation signal promotes efficient polyadenylation of the gene's mRNA in cis. This element functions as a signal for transcription termination, a specific cleavage event at the 3' end of the nascent transcript, and the addition of a long polyadenylation tail.

[0175] AAVhu68 transplasmid: pAAV2 / hu68.KanR The AAV2 / hu68 transplasmid, pAAV2 / hu68.KanR, was constructed in the laboratory of Dr. James M. Wilson at the University of Pennsylvania. The AAV2 / hu68 transplasmid encodes four wild-type (WT) AAV2 replicase (Rep) proteins required for replication and packaging of the AAV vector genome. The AAV2 / hu68 transplasmid also encodes three WT AAVhu68 virion protein capsid (Cap) proteins that assemble into the virion shell of AAV serotype hu68 to accommodate the AAV vector genome. The AAVhu68 sequence was obtained from human heart tissue DNA.

[0176] To generate the AAV2 / hu68 transplasmid, the AAV9cap gene from plasmid pAAV2 / 9n, encoding the wild-type AAV2 rep and AAV9 cap genes on a plasmid backbone derived from the pBluescript KS vector, was removed and replaced with the AAVhu68 cap gene. The ampicillin resistance (AmpR) gene was replaced with the kanamycin resistance (KanR) gene, resulting in pAAV2 / hu68.KanR. The AAV p5 promoter that normally drives rep expression was moved from the 5' end of rep to the 3' end of the cap, leaving a truncated p5 promoter upstream of rep. This truncated promoter serves to downregulate expression of rep and, as a result, maximize vector production (Figure 1C). All component parts of the plasmid have been verified by direct sequencing.

[0177] pAdDeltaF6(KanR) adenovirus helper plasmid Plasmid pAdDeltaF6(KanR) is 15,774 bp in size. This plasmid contains regions of the adenoviral genome important for AAV replication, namely E2A, E4, and VA RNAs (adenoviral E1 function is provided by HEK293 cells), but no other adenoviral replicative or structural genes. The plasmid does not contain cis elements important for replication, such as adenoviral inverted terminal repeats, and therefore is not expected to generate infectious adenovirus. The plasmid was derived from an E1, E3 deleted molecular clone of Ad5 (pBHG10, a pBR322-based plasmid). Deletions were introduced into Ad5 DNA to eliminate expression of unnecessary adenoviral genes and to reduce the amount of adenoviral DNA from 32 kb to 12 kb. Finally, the ampicillin resistance gene was replaced by a kanamycin resistance gene to generate pAdeltaF6(KanR). The adenoviral genes E2, E4, and VAI remaining on this plasmid, as well as E1 present in HEK293 cells, are necessary for AAV vector production.

[0178] AAVhu68.GM1 is produced by transient transfection of HEK293 cells followed by downstream purification. A flow diagram of the manufacturing process is shown in Figures 12A-12B. The key reagents that go into the preparation of the product are shown on the left side of the diagram, and the in-process quality assessments are shown on the right side of the diagram. A description of each production and purification step is also provided.

[0179] Cell culture and harvest: The cell culture and harvest manufacturing process involves four major manufacturing steps: cell seeding and growth, transient transfection, vector recovery, and vector clarification (Figure 12A).

[0180] Cell seeding and growth: A fully characterized HEK293 cell line is used for the production process.

[0181] Transient transfection: After approximately 4 days of growth (DMEM medium + 10% FBS), the cell culture medium is replaced with fresh serum-free DMEM medium and the cells are transfected with the three production plasmids using a polyethylenimine (PEI)-based transfection method. First, a DNA / PEI mixture containing the cis (vector genome) plasmid, the trans (rep and cap genes) plasmid, and the helper plasmid is prepared in a ratio with GMP-grade PEI (PEIPro HQ, PolyPlus Transfection SA). This plasmid ratio was determined to be optimal for AAV production in small-scale optimization studies. After mixing well, the solution is left at room temperature for up to 25 minutes, then added to serum-free medium to quench the reaction, and finally added to the iCELLis bioreactor. The reactor is adjusted for temperature and dissolved oxygen (DO), and the cells are incubated for 5 days.

[0182] Vector recovery: Transformed cells and media are harvested from the PALL iCELLis bioreactor using a disposable bioprocess bag by aseptically pumping the media from the bioreactor. After harvest, detergent, endonuclease, and MgCl2 (a cofactor for the endonuclease) are added to liberate the vector and digest unpackaged DNA. The product (in the disposable bioprocess bag) is incubated in a temperature-controlled single-use mixer at 37°C for 2 hours to provide sufficient time for enzymatic digestion of residual cell and plasmid DNA present in the harvest (obtained in the transfection procedure). This step is performed to minimize the amount of residual DNA in the final vector formulation (drug product, DP). After incubation, NaCl is added to a final concentration of 500 mM and the product is purified by filtration and downstream tangential flow filtration. Aids in recovery of product during TFF.

[0183] Vector clarification: Cells and cell debris are removed from the product using prefilters and depth filter capsules (1.2 / 0.22 μm) connected in series as a sterile closed tubing and bag set driven by a peristaltic pump. Clarification ensures that downstream filters and chromatography columns are protected from fouling, and bioburden reducing filtration ensures that at the end of the filter train, any bioburden that may have been introduced during the upstream production process is removed prior to downstream purification.

[0184] Purification process: The purification process includes four major manufacturing steps: concentration and buffer exchange by TFF, affinity chromatography, anion exchange chromatography, and concentration and buffer exchange by TFF. These process steps are shown in the overview process diagram (Figure 12B). A general description of each of these processes is provided below.

[0185] Large-scale tangential flow filtration: Volume reduction (20-fold) of clarified product is achieved by TFF using custom sterile closed bioprocessing tubing, bags, and membrane sets. The principle of TFF is to flow a solution under pressure parallel to a membrane of suitable porosity (100 kDa). The pressure difference effectively drives smaller sized molecules through the membrane to waste while retaining molecules larger than the membrane pores. By recirculating the solution, the parallel flow sweeps over the membrane surface, preventing membrane pore fouling and product loss due to membrane binding. By selecting the appropriate membrane pore size and surface area, a liquid sample can be rapidly reduced in volume while retaining and concentrating the desired molecules. Diafiltration in TFF applications involves adding fresh buffer to the recirculating sample at the same rate as the liquid passes through the membrane to waste. With increasing volumes of diafiltration, increasing amounts of small molecules are removed from the recirculating sample. This diafiltration results in moderate purification of the clarified product, but also achieves a buffer exchange compatible with the subsequent affinity column chromatography step. Therefore, we utilize a 100 kDa PES membrane for concentration and diafilter with a minimum of 4 diafiltration volumes of a buffer consisting of 20 mM Tris, pH 7.5 and 400 mM NaCl. The diafiltered product is then further clarified with a 1.2 / 0.22 μm depth filter capsule to remove any precipitated material.

[0186] Affinity Chromatography: The diafiltered product is applied to Poros™ Capture-Select™ AAV affinity resin (Life Technologies), which efficiently captures the AAVhu68 serotype. Under these ionic conditions, a significant percentage of residual cellular DNA and proteins flow through the column, and AAV particles are efficiently captured. After application, the column is treated with 5 volumes of low-salt endonuclease solution (250 U / mL endonuclease, 20 mM Tris (pH 7.5) and 40 mM NaCl, 1.5 mM MgCl2) to remove any remaining host cell and plasmid nucleic acid. The column is washed to remove additional feed impurities, followed by washing with low pH step eluate (400 mM NaCl, 20 mM sodium citrate, pH 2.5), which is immediately neutralized by recovery in 1 / 10 volume neutralization buffer (200 mM Bis Tris Propane, pH 10.2).

[0187] Anion exchange chromatography: To achieve further reduction of in-process impurities including empty AAV particles, the Poros AAV elution pool was diluted 50-fold (20 mM Bis-Tris-propane, 0.001% Pluronic F68, pH 10.2) to reduce ionic strength and allow binding to a CIMultus™ QA monolith matrix (BIA Separations). After a low-salt wash, the vector product was eluted over 60 column volumes (c Elute using a NaCl linear salt gradient (10 to 180 mM NaCl) of 100 cubic centimeters (volume, CV). This shallow salt gradient effectively separates capsid particles that do not contain vector genomes (empty particles) from those that do contain vector genomes (full particles), resulting in a preparation enriched for full particles. Collect the full particle peak eluate, neutralize, and dilute 20-fold in 20 mM Bis-Tris-propane, 0.001% Pluronic F68 (pH 10.2), and reapply to the same column that was cleaned in situ. Reapply a 10 to 180 mM NaCl salt gradient and collect the appropriate full particle peak. Evaluate the peak area and compare to previous data to determine approximate vector yield.

[0188] Concentration and buffer exchange by hollow fiber tangential flow filtration: The pooled anion exchange intermediate is concentrated and buffer exchanged using TFF. In this step, a 100 kDa membrane hollow fiber TFF membrane is used. During this step, the product is brought to a target concentration and then buffer exchanged into intrathecal final formulation buffer (ITFFB, i.e., artificial CSF with 0.001% Pluronic® F68). The product is sterile filtered (0.22 μm), stored in a sterile container, and frozen at -60°C or below in a quarantine location until released for final filling.

[0189] Final Fill: Frozen product is thawed, pooled, and adjusted to target concentration using final formulation buffer (dilution or concentration step via TFF). The product is finally filtered through a 0.22 μm filter and filled into sterile West Pharmaceutical's Crystal Zenith (cyclic olefin polymer) vials and crimp-sealed stoppers where the fill volume is determined. Vials are individually labeled. Labeled vials are stored at or below 60°C.

[0190] Example 3: We developed an optimized AAV vector expressing human β-gal and used a mouse disease model to evaluate the effects of administration of the vector into the CSF on brain enzyme activity, lysosomal storage pathology, and neurological signs.

[0191] A. Materials and Methods Animal procedures: All animal procedures were approved by the University of Pennsylvania's Institutional Animal Care and Use Committee. GLB1 knockout mice were obtained from the RIKEN BioResource Research Center. Mice were maintained as heterozygous carriers on a C57BL / 6J background. For ICV injections, vectors were diluted to a volume of 5 μL in sterile phosphate-buffered saline (Gibco) and injected freehand into isoflurane-anesthetized mice using a custom gas-tight syringe (Hamilton) and a cemented 10 mm 27-gauge needle with a plastic tube attached to the base of the needle to limit penetration to a depth of 3 mm. Submandibular blood collection was performed in isoflurane-anesthetized mice. Blood was collected in serum separator tubes, allowed to clot, and separated by centrifugation before being aliquoted and frozen at -60°C or below. At necropsy, mice were sedated with ketamine and xylazine, and CSF was collected by suboccipital puncture using a 32-gauge needle connected to a polyethylene tube. Euthanasia was performed by cervical dislocation. CSF, heart, lungs, liver, and spleen were immediately frozen on dry ice and stored at -60°C or below. Brains were removed and coronal sections of the frontal lobes were collected and frozen for biochemical studies. The remaining brains were used for histological analysis.

[0192] The vector was generated as described in Examples 1 and 2. Empty:Full Particle Ratio:Vector samples are loaded into cells with a two-channel charcoal-epon centerpiece with a 12 mm path length. The supplied dilution buffer is loaded into the reference channel of each cell. The loaded cells are then placed into an AN-60Ti analysis rotor and analyzed using a Beckman-Coulter P Load into a roteomeLab XL-I analytical ultracentrifuge. After full temperature equilibration to 20°C, bring the rotor to a final running speed of 12,000 rpm. Absorbance at 280 nm scans are recorded approximately every 3 minutes for approximately 5.5 hours (110 total scans for each sample). Raw data are analyzed using the c(s) method and implemented in the analytical program SEDFIT. The resulting size distributions are graphed and peaks are integrated. The percentage values ​​associated with each peak represent the peak area fraction of the total area under all peaks and are based on the raw data generated at 280 nm. Many laboratories use these values ​​to calculate the empty:full particle ratio. However, empty and full particles have different extinction coefficients at this wavelength, so the raw data can be adjusted accordingly. The ratio of the empty and full monomer peak values, both before and after the extinction coefficient adjustment, is used to determine the empty:full particle ratio.

[0193] Assay for replication-competent AAV: Samples are analyzed for the presence of replication-competent AAV2 / hu68 (rcAAV) that may arise during the production process. The cell-based component consists of inoculating a monolayer of HEK293 cells (P1) with dilutions of test sample and wild-type (WT) human adenovirus type 5 (Ad5). The maximum amount of product tested was 1.0 × 10 10AAVhu68 cap sequence is a vector product of GC. Due to the presence of adenovirus, rcAAV amplifies in cell culture. After 2 days, cell lysates are generated and Ad5 is heat inactivated. The clarified lysate is then passaged to second round cells (P2) to enhance sensitivity (again in the presence of Ad5). After 2 days, cell lysates are generated and Ad5 is heat inactivated. The clarified lysate is then passaged to third round cells (P3) to enhance sensitivity (again in the presence of Ad5). After 2 days, cells are lysed to release DNA, which is then subjected to qPCR to detect AAVhu68 cap sequence. Amplification of AAVhu68 cap sequence in an Ad5-dependent manner indicates the presence of rcAAV. The use of AAV2 / hu68 surrogate positive control containing AAV2 rep and AAVhu68 cap genes allows the detection limit of the assay to be determined (0.1, 1, 10, and 100 IU). rAAV (1.0 × 10 10 , 1.0×10 9 , 1.0×10 8 , and 1.0×10 7 Serial dilutions of GC can be used to quantitate the approximate amount of rcAAV present in a test sample.

[0194] In Vitro Efficacy: To relate DdPCR GC titers to gene expression, an in vitro relative potency bioassay is performed. Briefly, cells are seeded into 96-well plates and incubated overnight at 37°C / 5% CO2. The next day, cells are infected with serially diluted AAV vectors and incubated at 37°C / 5% CO2 for up to 3 days. Cell supernatants are harvested and analyzed for β-gal activity based on cleavage of a fluorogenic substrate.

[0195] Total protein, capsid protein, protein purity, and capsid protein ratio: Vector samples are first quantified for total protein using the bicinchoninic acid (BCA) assay against a standard curve of bovine serum albumin (BSA) protein. The determination is performed by mixing an equal amount of sample with the Micro-BCA reagent provided in the kit. Dilutions of the BSA standard also apply the same procedure. The mixture is incubated at 60°C and the absorbance is measured at 562 nm. A standard curve is generated from the absorbance of standards of known concentration using a four-parameter fit. Unknown samples are quantified according to the four-parameter regression. To provide a semi-quantitative determination of the purity of the rAAV, samples are normalized for genome titer, 5.0x10 9 GCs are separated by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) under reducing conditions. SDS-PAGE gels are then stained with SYPRO Ruby dye. All impurity bands are quantified by densitometry. Stained bands that appear in addition to the three AAV-specific proteins (VP1, VP2, and VP3) are considered protein impurities. The impurity mass percent and approximate molecular weight of the contaminant bands are reported. SDS-PAGE gels are also used to quantify VP1, VP2, and VP3 proteins and determine their ratios.

[0196] Enzyme activity assay: Tissues were homogenized in 0.9% NaCl (pH 4.0) using a steel bead homogenizer (TissueLyzer, Qiagen). After three freeze-thaw cycles, samples were clarified by centrifugation and protein content was quantified by BCA assay. Serum samples were used directly for enzyme assays. For β-gal activity assays, 1 μL of sample was combined with 99 μL of 0.5 mM 4-methylumbelliferyl β-D-galactopyranoside (Sigma M1633) in 0.15 M NaCl, 0.05% Triton-X100, 0.1 M sodium acetate (pH 3.58). Reactions were incubated at 37°C for 30 min and then stopped by adding 150 μL of 290 mM glycine, 180 mM sodium citrate (pH 10.9). Fluorescence was compared to a standard dilution of 4 MU. β-gal activity is expressed as nmol of 4MU released per hour per mg of protein (tissue) or per ml of serum or CSF. HEX assays were performed in the same manner as the β-gal activity assays, using 1 mM 4-methylumbelliferyl N-acetyl-β-D-glucosaminide (Sigma M2133) as substrate and a sample volume of 1 μL for tissue lysates and 2 μL for serum.

[0197] Histology: Brains were fixed overnight in 4% paraformaldehyde, equilibrated in 15% and 30% sucrose, and then frozen in OCT embedding medium. Frozen sections were stained with filipin (Sigma, 10 μg / mL) or antibodies against GFAP or LAMP1.

[0198] Anti-β-gal antibody ELISA: High-binding polystyrene ELISA plates were coated overnight with 100 μL per well of recombinant human β-gal (R&D Systems) at a concentration of 1 μg / mL in PBS. Plates were washed and blocked with 2% bovine serum albumin in PBS for 2 h at room temperature. Duplicate wells were incubated with serum samples diluted 1:1,000 in PBS for 1 h at room temperature. Plates were washed and incubated with horseradish peroxidase-conjugated anti-mouse IgG polyclonal antibody diluted 1:5,000 in blocking solution for 1 h and developed using TMB substrate.

[0199] Gait analysis: Gait analysis was performed using the CatWalk XT system (Noldus) according to the manufacturer's instructions. Mice were tested on two consecutive days. At least three complete trials were performed for each animal on each testing day. Trials longer than 5 seconds or where the animal stopped or turned around without traversing the entire length of the apparatus were excluded from the analysis.

[0200] B. Results Transgene cassettes were designed consisting of human GLB1 cDNA driven by the chicken β-actin promoter together with the cytomegalovirus enhancer (CB7), human elongation initiation factor 1α promoter (EF1a) or human ubiquitin C promoter (UbC). Each cassette was packaged into AAVhu68 capsids and delivered for 10 min. 11 A single dose of genome copies (GC) was administered to wild-type mice by intracerebroventricular (ICV) injection. Two weeks after injection, β-gal activity was measured in the brain and CSF (Figures 2A-2B). The vector carrying the UbC promoter resulted in a statistically significant increase in β-gal activity in both brain and CSF, with enzyme activity nearly two-fold greater in brain and 10-fold greater in CSF than that in untreated wild-type mice. Therefore, the AAVhu68.UbC.hGLB1 vector was selected for further studies.

[0201] Efficacy of the optimized vector was evaluated using GLB1 - / -The mouse model of GM1 gangliosidosis was evaluated by cloning the 6th and / or 15th exons of the GLB1 gene. Hahn, CN, et al. Generalized CNS disease and massive GM1-ganglioside accumulation in See, e.g., Matsuda, J., et al. Beta-galactosidase-deficient mouse as an animal model for GM1-gangliosidosis. Glycoconjugate journal 14, 729-736 (1997). Like infantile GM1 gangliosidosis patients, these mice do not express functional β-gal and show rapid accumulation of GM1 ganglioside in the brain. Brain GM1 accumulation is already evident at 1 week of age, and by 3 months of age, GLB1 - / - Mice have brain accumulation of GM1 comparable to that of 8-month-old infants with GM1 (Hahn 1997, cited above). - / - The clinical phenotype of the mice most closely models that of infantile GM1 gangliosidosis, with motor abnormalities present by 4 months of age and neurological symptoms severe enough (e.g., ataxia or paralysis) to require euthanasia by 10 months of age (Hahn et al., 2013). 1997, Matsuda 1997, cited above). GLB1 - / - The mouse model does not show any peripheral organ involvement and differs from infantile GM1 patients who often develop bone deformities and hepatosplenomegaly (Hahn 1997; Matsuda 1997, cited above). - / - The mouse represents a representative model of the neurological features of infantile GM1 gangliosidosis, but not the systemic disease symptoms.

[0202] GLB1 - / - Mice were treated at 1 month of age and observed until 4 months of age, a time when they would typically develop significant gait abnormalities associated with brain GM1 levels similar to those seen in infantile GM1 gangliosidosis patients with progressive disease (Matsuda 1997, cited above). - / - Mouse, 1.0x10 11 15 mice were treated with a single ICV injection of genomic copy (GC) AAVhu68.UbC.hGLB1 (n=15) or vehicle (n=15). Heterozygous (GLB1 + / - A group of 100% naive mice (n = 10) and 100% naive mice (n = 10) served as normal controls. Serum was collected on the day of injection (day 0), and days 10, 28, 60, and 90. After 90 days of treatment, motor function was assessed using a CatWalk XT gait analysis system (Noldus), after which animals were euthanized and tissues were collected for histological and biochemical analysis.

[0203] One AAV-treated mouse died during the ICV injection procedure. All other mice survived to the 90-day study endpoint. AAV delivery to the CSF has been shown to result in vector distribution in the peripheral blood and significant liver transduction (Hinderer, C., et al. Intrathecal gene therapy corrects CNS pathology in a feline model of mucopolysaccharidosis I. Molecular therapy: the journal of the American Society of Gene Therapy 22,2018 - 2027 (2014), Gray, S.J., Nagabhushan Kalburgi, S., McCown, T.J. & Jude Samulski, R. Global CNS gene delivery and evasion of anti - AAV - neutralizing antibodies by intrathecal AAV administration in non - human primates. Gene therapy 20,450 - 459 (2013), Haurigot, V., et al. Whole body correction of mucopolysaccharidosis IIIA by intracerebrospinal fluid gene therapy. The Journal of clinical in vestigation (2013), Hinderer, C., et al. Widespread gene transfer in the central nervous system of cynomolgus macaques following delivery of AAV9 into the cisterna magna. Molecular therapy. Methods & clinical development 1,14051(2014), Hordeaux, J., et al. Toxicology Study of Intra - Cisterna Magna Adeno - Associated Virus 9 Expressing Human Alpha - L - Iduronidase in Rhesus Macaques. Molecular therapy. Methods & clinical development 10,79 - 88(2018)). AAVhu68.UbC.hGLB1 - treated GLB1 - / - mice showed, 10 days after vector administration, heterozygous (GLB1 + / -) showed higher serum β-gal activity than controls (Figure 3A). Serum antibodies to human β-gal were detectable in 5 / 15 mice treated with AAVhu68.UbC.hGLB1 by day 90. Elevated serum β-gal activity persisted throughout the study for all but two mice, both of which expressed antibodies to human β-gal (Figure 6). Peripheral organs, including heart, lung, liver, and spleen, also showed elevated β-gal activity (Figures 3B-3E). Some animals that expressed antibodies to the human transgene product had lower β-gal activity in peripheral organs.

[0204] CSF collected at necropsy showed that AAVhu68.UbC.hGLB1-treated GLB1 - / - The β-gal activity in the brains of vector-treated mice exceeded that of heterozygous controls (Figure 4B). β-gal activity in the brains of vector-treated mice was similar to that of heterozygous controls (Figure 4A). Anti-β-gal antibodies do not appear to affect brain or CSF β-gal levels.

[0205] Correction of brain abnormalities was assessed using biochemical and histological assays. Lysosomal enzymes are frequently upregulated in the context of lysosomal storage, an observation that has been confirmed in patients with GM1 gangliosidosis (Van Hoof, F. & Hers, HG The abnormalities of lysosomal enzymes in mucopolysaccharidoses. European journal of biochemistry 7, 34-44 (1968)). Therefore, activity of the lysosomal enzyme hexosaminidase (HEX) was measured in brain lysates. Vehicle-treated GLB1 - / - HEX activity was elevated in brain samples from mice and was normalized in vector-treated animals (Fig. 5).

[0206] Lysosomal storage pathology was assessed by staining brain sections with filipin, a fluorescent molecule that binds to GM1 ganglioside, as well as by immunostaining for lysosome-associated membrane protein 1 (LAMP1). Although filipin also binds non-esterified cholesterol, previous studies have shown that filipin staining primarily binds to GLB1. - / - (Arthur, JR, Heinecke, KA & Seyfried, TNFilipin recognizes both GM1 and cholesterol in GM1 gangliosidosis mouse brain. Journal of lipid research 52, 1345-1351 (2011)). Filipin staining was not observed in vehicle-treated GLB1 mice. - / - LAMP1 immunohistochemistry revealed prominent GM1 accumulation in neurons of the mouse cortex, hippocampus, and thalamus, which was normalized in mice treated with AAVhu68.UbC.hGLB1 (data not shown). - / - We showed increased lysosomal membrane staining in the cortex and thalamus of mice, which was reduced in vector-treated mice (data not shown). Gliosis was associated with increased expression of the astrocyte marker, glial fibrillary acidic protein (GFAP). Vector-treated GLB1 - / - Mice showed a significant reduction in astrogliosis in the thalamus compared to vehicle-treated controls (data not shown).

[0207] Vector treatment GLB1 - / - To evaluate neurological function in mice, gait analysis was performed at 4 months of age (3 months after vector or vehicle administration). - / - It has previously been noted that mice develop clinically evident gait abnormalities by 3–4 months of age. - / -Quantitative gait assessment, performed using the CatWalk system on a cohort of mice and normal controls, revealed a variety of abnormalities, including slower spontaneous walking speed, differences in stride length, and duration of some phases of the step cycle (Figures 7C and 7D). - / - Because the walking speed of mice was significantly slower, the interpretation of many of these apparent differences was complicated by the speed-dependence of most gait parameters (Figures 8A and 8B) (Batka, RJ, et al. The need for speed in rodent locomotion analyses. Anatomical record (Hoboken, NJ: 2007) 297, 1839-1864 (2014)). - / - Mice also showed consistent abnormalities in hindlimb placement, measured as increased hindlimb footprint length (Figure 7D). This abnormality was found to be independent of walking speed, consistent with a previous report (Batka, et al., cited above). GLB1 - / - This gait signature was useful for assessing speed-independent gait dysfunction in mice (Figures 8A and 8B). In studies performed on two consecutive days using the same cohort of mice, slower spontaneous walking speed and increased hindlimb footprint length were observed in untreated GLB1 mice. - / - This was a reproducible observation in mice (Figures 7A and 7B). - / - Mice exhibited gait abnormalities similar to those previously identified in untreated animals (Figures 7A-7G). Walking speed and footprint length were significantly increased in the vector-treated GLB1 mice. - / - The results were normalized in mice (Figures 7A-7G).

[0208] C. Consideration This study aimed to determine whether GLB1 mice treated with AAV vectors at 4 weeks of age - / -We demonstrated a reduction in neuronal storage lesions in mice, one week after prominent brain storage lesions appeared in this model (Hahn 1997, cited herein). These results suggest that administration of AAVhu68.hGLB1 into the CSF increases brain β-gal activity, reduces neuronal lysosomal storage lesions, and prevents neurological decline, suggesting that gene transfer can prevent and reverse GM1 accumulation in the brain.

[0209] Example 4: Animal Model A.GLB1 - / - Identifying the minimal effective dose (MED) of AAVhu68.UbC.GLB1 in a mouse model The effects of different doses of rAAVhu68.UbC.GLB1 were examined using GLB1 - / - Mouse models were evaluated for CNS lesions and neurological signs. Efficacy was assessed by serum enzyme activity, reduction of brain lesions, neurological signs measured by automated gait analysis (e.g., via the CatWalk system), and standardized neurological examinations performed by blinded reviewers (e.g., a 9-point rating of posture, motor function, sensation, and reflexes), as well as survival. Safety analyses (including blood sampling and analysis) were also performed. Four-week-old GLB1 mice were randomly assigned to receive the treatment. - / - Mice were inoculated with rAAVhu68.UbC.GLB1 (1.3 × 10 11 GC, 4.4×10 10 GC, 1.3×10 10 GC or 4.4 x 10 9 They received one of four doses of GC or vehicle (n=24 per group). Heterozygous littermates treated with vehicle (n=24) served as normal controls.

[0210] Serum β-gal enzyme activity, gait analysis, and neurological examinations were performed every 60 days on half of the animals in each group, while body weights were measured at least every 30 days over a 120-day observation period. The results are plotted as Figures 9A-9F and are briefly described below.

[0211] All treated mice appeared healthy and showed normal weight gain, and no significant differences in body weight were detected between groups during the observation period (Figure 9B).

[0212] Serum enzyme expression was consistent with the study described in Example 3. As shown in FIG. 9A, vehicle-treated GLB1 - / - The β-gal enzyme activity in mice (which served as the negative control) remained around 10 nmol / mL / hr, whereas the positive control group (vehicle-treated GLB1 + / - The enzyme activity of the mouse was approximately 100 nmol / mL / h. 10 Treatment with rAAVhu68.UbC.GLB1 at a dose of GC significantly increased β-gal enzyme activity compared to the negative control at both days 60 and 120. 11 rAAVhu68.UbC.GLB1 with a higher dose of GC resulted in greater β-gal enzyme activity than the positive control at day 60, with a further increase at day 120.

[0213] The gait phenotype of GM1 mice was also consistent with previous results shown in Example 3. Neurological examination scores hind paw print length, hind paw swing time, and hind paw stride length were obtained. The results are plotted in Figures 9C-9F. There were significant statistical differences between the negative and positive controls for all four plotted parameters, indicating that these parameters can serve as good indicators for evaluating efficacy. Vehicle-treated GLB1 - / - Compared to mice, 4.4 x 10 10 Mice treated with GC rAAVhu68.UbC.GLB1 showed significant improvements in hindlimb footprint length, hindlimb swing time, and hindlimb stride length. 11 Higher doses of GC provided increased hindlimb swing time and longer stride length, indicating successful correction. Neurological examination is more sensitive compared to gait analysis. As shown in Figure 9C, a dose-dependent improvement was observed, indicated by a decreased neurological score with increasing dose, but at 1.3 × 10 10Treatment of GCs with rAAVhu68.UbC.GLB1 demonstrated statistical significance in total score compared to that of the negative control. Evidence of phenotypic correction was seen at only 1.3 × 10 per mouse. 10 was observed at GC doses.

[0214] If all untreated animals are expected to remain alive, the same set of parameters will continue to be collected within this cohort of animals for at least another 150 days. - / - Changes in survival rate compared to mice are assessed.

[0215] Half of the animals discussed in the previous section will be euthanized after 270 days of treatment. The remaining half of the animals will be euthanized after 150 days of treatment. Another 24 mice will serve as baseline necropsy controls. For all euthanized animals, histological and biochemical comparisons will be performed between treated and untreated animals. After necropsy, brains will be sectioned and stained for LAMP1 to evaluate lysosomal storage pathology, which will be quantified using an automated imaging system. β-gal activity will be measured in brain, serum, and peripheral organs. For safety analyses, blood will be collected at necropsy for complete blood count and serum chemistry panel, and brain, spinal cord, heart, lungs, liver, spleen, kidneys, and gonads will be harvested for evaluation of histopathology by a board-certified veterinary pathologist. Vehicle-treated GLB1 - / - The lowest dose of rAAVhu68.UbC.GLB1 that achieves a significant reduction in brain accumulation lesions compared to mice is selected as the minimal effective dose (MED).

[0216] B. Toxicity studies in nonhuman primates (NHPs) Rhesus monkeys are a representative sample of the patient population (infants aged 4–18 months). They were selected for toxicity studies because they best recapitulate size and CNS anatomy and can be treated using clinical routes of administration (ROA). Juvenile animals were selected to represent the pediatric trial population. In one embodiment, juvenile rhesus macaques are 15-20 months of age. The similarity in size, anatomy, and ROA results in representative vector distribution and transduction profiles, allowing for accurate assessment of toxicity. In addition, more rigorous neurological evaluations are performed in NHPs than in rodent models, allowing for more sensitive detection of CNS toxicity.

[0217] A 120-day GLP-compliant safety study will be conducted in juvenile rhesus macaques to investigate the toxicity of AAVhu68.UbC.GLB1 following ICM administration. The 120-day evaluation period was selected to allow sufficient time for the secreted transgene product to reach stable steady-state levels following AAV administration of the ICM. The study design is outlined in the table below. Rhesus macaques will receive one of three dose levels: a total of 3.0 x 10 12 GC, total 1.0×10 13 GC, or a total of 3.0 x 10 13 GC (n=6 / dose) or vehicle (n=4). Dose levels were selected to be equivalent to those assessed in minimal effective dose (MED) studies when scaled by brain mass (assuming 0.4 g in mice and 90 g in rhesus monkeys). Baseline neurological examinations, clinical pathology (cell counts with differential, clinical chemistry, and coagulation panel), CSF chemistry, and CSF cytology are performed. Following AAVhu68.UbC.GLB1 or vehicle administration, animals are monitored daily for signs of distress and abnormal behavior.

[0218] Blood and CSF clinical pathology evaluations and neurological examinations are performed for 30 days after rAAVhu68.UbC.GLB1 or vehicle administration and every 30 days thereafter. Neutralizing antibodies to AAVhu68 and cytotoxic T lymphocyte (CTL) responses to the AAVhu68 and AAVhu68.UbC.GLB1 transgene products are assessed by enzyme-linked immunospot (ELISpot) assays for interferon gamma (IFN-γ) at baseline and each 30-day time point thereafter. [Table 7]

[0219] Following administration of either rAAVhu68.UbC.GLB1 or vehicle, half of the animals are euthanized on day 60 and half are euthanized on day 120. Tissues are harvested for comprehensive microscopic histopathological examination. Histopathological examination focuses on central nervous system tissues (brain, spinal cord, and dorsal root ganglia) and liver, as these are the most heavily transduced tissues following ICM administration of AAVhu68 vectors. Additionally, lymphocytes are harvested from the spleen and bone marrow to assess the presence of T cells reactive to both the capsid and transgene product within these organs at necropsy.

[0220] The biodistribution of the vector will be assessed by quantitative PCR in tissue samples. Serum and C Vector genomes are quantified in SF samples.

[0221] C. Sensory Neuron Toxicity in Preclinical AAV Studies Preclinical studies evaluating systemic and intrathecal (IT) administration of AAV have consistently demonstrated efficient transduction of sensory neurons within the dorsal root ganglion (DRG) and, in some cases, evidence of toxicity with these cells. Intrathecal administration may allow for sensory neuron transduction because their central axons are exposed to CSF, or rAAV may reach the cell bodies directly because DRG are exposed to spinal CSF.

[0222] Minimal to mild subclinical degeneration of DRG sensory neurons is expected to appear in the AAVhu68.UbC.GLB1 GLP NHP toxicity study at all doses evaluated. Based on existing nonclinical and clinical data for other AAV programs, sensory neuron findings are expected not to explain adverse events in humans, and therefore subclinical sensory neuron lesions will not be used to determine the maximum tolerated dose (MTD) in nonclinical studies. However, the true risk of sensory neuron toxicity in humans is unknown. The current study is designed to further improve the safety profile of previous AAV clinical trials by requiring lower doses of AAVhu68.UbC.GLB1 than those typically administered systemically and by using an ICM route of administration that appears to result in a lower degree of sensory neuron toxicity. The study will use detailed monitoring of sensory changes as well as nerve conduction studies to detect even subclinical DRG toxicity. Given the severity of infantile GM1 gangliosidosis, it is anticipated that the risk-benefit profile for ICM administration of AAVhu68.UbC.GLB1 remains favorable, despite the unknown risk of sensory neuron toxicity.

[0223] Example 5: A Phase 1 / 2, Open-Label, Multicenter, Dose-Escalation Study to Evaluate the Safety and Tolerability of a Single Dose of rAAVhu68.GLB1 Delivered to the Cisterna Magna (ICM) in Pediatric Subjects with Infantile GM1 Gangliosidosis Pediatric subjects aged 1 to 18 months with infantile forms of GM1 gangliosidoses will be selected for Phase 1 / 2 trials because they represent a population with the greatest unmet need and the most devastating disease course, characterized by a rapid and predictable decline in both motor and cognitive impairments (Jarnes Utz et al., 2017, Infantile gangliosidoses: Mapping (2011, GM1 gangliosidosis and Morquio B disease: an update on genetic alterations and clinical findings. Biochimica et Biophysica Acta (BBA)-Molecular Basis of Disease. 1812(7):782-790). Patients with infantile GM1 gangliosidosis typically have an onset of symptoms with neurological symptoms before 6 months of age, and some patients present at birth with hypotonia, psychomotor retardation, or other disease symptoms (Caciotti et al., 2011, GM1 gangliosidosis and Morquio B disease: an update on genetic alterations and clinical findings. Biochimica et Biophysica Acta (BBA)-Molecular Basis of Disease. 1812(7):782-790). The majority of patients with infantile GM1 die within the first few years of life (median survival 19-46 months, depending on the level of research and supportive care) (Regier et al., 2016, MRI / MRS as a surrogate marker for clinical progression in GM1 gangliosidosis. American Journal of Medical Genetics Part A. 170(3):634-644, Regier et al. al.,2016,The GM1 and GM2 Gangliosidoses: Natural History and Progress toward Th erapy.Pediatric endocrinology reviews: PER.13 Suppl 1:663-673, and Jarnes Utz et al.,2017). These patients therefore represent the population with the potentially most favorable risk / benefit profile. Moreover, the predictable and rapid decline in these patients supports robust study design and allows for the assessment of functional outcomes within reasonable follow-up periods. In this group, treatment is expected to stabilize the underlying pathology, thereby stabilizing disease progression, prolonging survival, preventing loss of skills (such as acquired developmental milestones, neurocognitive and / or motor skills), and slowing the progression of neurocognitive and behavioral decline.

[0224] Nonclinical safety testing of the administration procedure performed in adult nonhuman primates best represents the size and cisternal anatomy of infants aged 4 months or older. However, given the rapid course of disease after the onset of symptoms and the young age at the onset of symptoms, treatment should be administered as early as possible to maximize the potential benefits of gene therapy. The lower age limit used here is 1 month of age at enrollment so that treatment, specifically the ICM procedure, can be safely performed. After careful review of imaging scans from infants as young as 1 or 2 weeks of age, expert interventional radiologists at the University of Pennsylvania indicated that there are no specific anatomical concerns with performing CT-guided ICM administration in infants as young as 1 month of age, as long as the rationale for treatment is supported. As mentioned above, patients with infantile (type 1) GM1 have a rapid disease course with a typical age of onset of seizures and other signs of progressive disease by 18 months of age (Jarnes Utz et al., 2017). Due to the progressive neurological disease, the upper age limit of 18 months was chosen to prevent enrollment of subjects with limited potential to benefit from AAVhu68.GLB1 beyond disease stabilization at low levels of clinical function. Natural history studies have shown that infantile GM1 gangliosidosis patients have lost most developmental milestones by age 2 years.

[0225] As mentioned above, given the rapid and destructive disease course after the onset of symptoms, treatment should be administered as early as possible to maximize the potential benefits of gene therapy. Sibling concordance data suggest that the clinical course of siblings with infantile GM1 is similar in terms of time to onset and general disease symptoms (Gururaj et al., 2005. Magnetic Resonance Imaging Findings and Novel Mutations in GM1 Gangliosidosis. Journal of Child Neurology. 20(1):57-60). Thus, presymptomatic infants with a confirmed genetic and biochemical diagnosis of GM1 gangliosidosis can be included in the study if they have an affected older sibling with documented symptom onset (with short stature) at or before the age of 6 months.

[0226] This study is a Phase 1 / 2 open-label, dose-escalation study of AAVhu68.GLB1 to evaluate safety, tolerability, and exploratory efficacy endpoints following a single dose of AAVhu68.GLB1 delivered into the cisterna magna (ICM) in pediatric subjects with infantile forms of GM1. The study will enroll up to 12 pediatric subjects with infantile forms of GM1 gangliosidosis (type 1) and subjects will receive a single dose of ICM-administered AAVhu68.GLB1. Subjects will be followed for 2 years to evaluate safety, tolerability, pharmacokinetics, and clinical outcomes, with additional long term follow up (LTFU) for a total of 5 years post-treatment to evaluate long-term outcomes and durability of transgene expression and clinical responses. The period from LTFU to 5 years post-treatment will allow for assessment of the durability of transgene expression, as well as whether the treatment is effective in prolonging survival and stabilizing subjects at a level of function superior to untreated patients, in accordance with the following draft FDA Guidance for Industry: Long Term Follow-Up After Administration of a Human Gene Therapy Product. Administration of Human Gene Therapy Products, July 2018), Europe, Brazil and other local regulations. Upon completion of the study, subjects may be invited to enroll in patients to continue monitoring for long-term outcomes, including safety (monitoring for tumor events), survival, and clinical outcomes. Subsequent developments of AAVhu68.GLB1 include expansion to the treatment of patients with milder late-onset forms of the disease.

[0227] Two doses of rAAVhu68.GLB1 are evaluated in staggered sequential dosing of subjects. rAAVhu68.GLB1 dose levels are determined based on data from mouse MED studies and GLP NHP toxicity studies and consist of a low dose (administered to cohort 1) and a high dose (administered to cohort 2). The high dose is based on the maximum tolerated dose (MTD) in the NHP toxicity study scaled to the equivalent human dose. A safety margin is applied so that the high dose selected for human subjects is one-third to one-half of the equivalent human dose. The low dose is typically 2-3 times lower than the selected high dose, as long as it is a dose that exceeds the equivalent scaled MED in the animal study. This ensures that both dose levels have the potential to confer therapeutic benefit, with the understanding that if tolerated, the higher dose is expected to be advantageous. Sequential evaluation of the low dose followed by the high dose allows for identification of the maximum tolerated dose (MTD) of the two doses tested. Finally, an expansion cohort (Cohort 3) will receive the MTD of rAAVhu68.GLB1. Six subjects in Cohort 3 (MTD) will be enrolled simultaneously without staggered dosing. Cohort 3 may receive hematopoietic stem cell transplantation (HSCT) and combination therapy with rAAVhu68.GLB1. If tolerated, it is expected that a higher dose will be beneficial.

[0228] The primary focus of this study is to evaluate the safety and tolerability of rAAVhu68.GLB1. Because NHP studies of ICM AAVhu68 delivery have demonstrated minimal to mild subclinical degeneration of DRG sensory neurons in some animals, detailed testing will be performed to assess sensory neurotoxicity and sensory nerve conduction studies will be utilized in this trial to monitor for subclinical sensory neuron pathology. Of note, sensory neuron functional loss (due to potential dorsal root ganglion toxicity) will be assessed by sensory nerve conduction studies performed at 30 days, 3 months, 6 months, 12 months, 18 months, 24 months, and at annual intervals thereafter. Given that sensory neuron pathology appears within 2-4 weeks after AAV administration in nonclinical NHP studies, more frequent evaluations throughout the 3 months posttreatment will allow for evaluation of similar events in humans and allow for evaluation of potential variability in toxicokinetics. Follow-up observations throughout the study will allow for evaluation of delayed effects if different time courses in humans or if clinical sequelae are observed, and assess how long they last and whether they improve, remain stable, or worsen over time.

[0229] Pharmacokinetic and efficacy endpoints were also evaluated in this study and were selected for their potential to demonstrate meaningful functional and clinical outcomes in this population. Endpoints, except those requiring sedation and / or LP, will be measured at 30 days, 90 days, 6 months, 12 months, 18 months, 24 months, and annually thereafter for a maximum follow-up period of 5 years. In the long-term follow-up phase, the frequency of measurements will be reduced to once every 12 months. These time points were selected to facilitate a full evaluation of the safety and tolerability of rAAVhu68.GLB1. The early time points and 6-month intervals were also selected given the rapid rate of disease progression in untreated infant GM1 patients. This approach allows for a full evaluation of pharmacokinetic and clinical efficacy measures in treated subjects over a follow-up period where untreated comparative data exist and where untreated patients are expected to show significant declines.

[0230] Secondary and exploratory efficacy endpoints included survival, feeding tube independence, seizure incidence and frequency, quality of life as measured by PedsQL, and neurocognitive and and behavioral development. The Bayley and Vineland Scales of Infant Development will be used to quantify the impact of rAAVhu68.GLB1 on development and changes in adaptive behavior, cognition, language, motor function, and health-related quality of life. Each measure will be used in either GM1 disease or related populations and will be further refined based on input from parents and families to select the measures that are most meaningful and impactful to them. To standardize the assessments, clinical trial sites will be trained in the administration of the various scales by experienced neuropsychologists.

[0231] Given the severity of the disease in the target population, subjects may have achieved motor skills by enrollment, developed other motor milestones and subsequently lost them, or may not yet show signs of motor milestone development. Assessments will track ages achieved and lost for all milestones. Motor milestone achievement is defined based on WHO criteria into six gross milestones.

[0232] Considering that subjects with infantile GM1 gangliosidosis may develop symptoms within the first few months of life and acquisition of the first WHO motor milestone (sitting unsupported) typically does not occur before 4 months of age (median age: 5.9 months), this endpoint may lack sensitivity for assessing the extent of therapeutic benefit, especially in subjects who had more obvious symptoms at the time of treatment. For this reason, evaluation of age-appropriate developmental milestones that may be applicable to infants is also included (Scharf et al., 2016, Developmental Milestones. Pediatr Rev. 37(1):25-37; quiz 38,47.). These data may be informative to summarize the retention, gain, or loss of developmental milestones over time compared to typical acquisition times in untreated or typically developing children with infantile GM1 disease.

[0233] As the disease progresses, children may develop seizures. The onset of seizure activity will allow for the determination of whether treatment with rAAVhu68.GLB1 will prevent or delay the onset of seizures or reduce the frequency of seizure events in this population. Parents will be asked to keep a seizure diary, tracking the onset, frequency, duration, and type of seizures. These entries will be discussed and interpreted with a clinician at each visit.

[0234] To assess the effect of rAAVhu68.GLB1 on CNS symptoms, disease volumetric changes will be measured with MRI over time. All gangliosidosis infantile phenotypes have been shown to have a consistent pattern with macrocephaly and rapid increases in intracranial MRI volumes, both in brain tissue volume (cerebral cortex and other smaller structures) and ventricular volume. In addition, various small brain substructures, including the corpus callosum, caudate, and putamen, as well as the cerebellar cortex, commonly decrease in size with disease progression (Regier et al., 2016, and Nestrasil et al., 2018, cited herein). Treatment with rAAVhu68.GLB1 is expected to slow or halt the progression of CNS disease symptoms, with evidence of stabilization in atrophy and volumetric changes. Exploratory endpoints evaluating T1 / T2 signal intensity changes (normal / abnormal) in the thalamus and basal ganglia were based on reported evidence of alterations in thalamic structure in patients with GM1 and GM2 gangliosidosis (Kobayashi and Takashima, 1994, Thalamic hyperdensity on CT in infantile GM1-gangliosidosis. Brain and Development. 16(6):472-474).

[0235] Biomarkers for clinical trials include β-gal enzyme (GLB1) activity, which can be measured in CSF and serum, and the rapid and consistent β-gal activity in infantile GM1 gangliosidosis. Clinical findings include brain MRI showing significant atrophy (Regier et al., 2016b, cited herein). Additional biomarkers will be investigated in CSF and serum from collected samples.

[0236] A. Main purpose: To evaluate the safety and tolerability of rAAVhu68.GLB1 over a 2-year period following a single administration into the cisternal cavity magna (ICM).

[0237] B. Secondary objectives: To evaluate the pharmacokinetics and biological activity of rAAVhu68.GLB1 over a 24-month period following a single ICM dose based on GLB1 activity in CSF and serum. This evaluation may further include CSF GM1 concentrations, as well as serum and urinary keratan sulfate levels and hexosaminidase activity. To evaluate the effect of rAAVhu68.GLB1 on survival To evaluate the effect of rAAVhu68.GLB1 on the probability of tube-dependence at 24 months of age To assess disease progression by assessing age at achievement, age at loss, and the proportion of children who maintain or gain age-appropriate developmental and motor milestones (as defined by World Health Organization [WHO] criteria) To evaluate the effect of rAAVhu68.GLB1 on neurocognitive development based on: Changes in age-equivalent cognitive, gross motor, fine motor, receptive and expressive communication scores on the Bayley Scales of Infant and Toddler Development Change in standard scores for each domain of the Vineland Adaptive Behavior Scales

[0238] C. Exploratory purpose: To further evaluate the efficacy of rAAVhu68.GLB1 for 24 months following a single ICM dose by: Age at onset and frequency of seizures assessed by seizure diary To assess the impact of rAAVhu68.GLB1 on children's quality of life as measured by change in total score on the Pediatric Quality of Life Inventory (PedsQL) and Pediatric Quality of Life Inventory Infant Scale (PedsQL-IS) To further evaluate the pharmacodynamic effects of rAAVhu68.GLB1 over a 24-month period following a single ICM dose, as measured by: Changes in total brain volume, brain substructure volume, and lateral ventricle volume measured by oMRI o Changes in T1 / T2 signal intensity in the thalamus and basal ganglia activity To evaluate the effect of rAAVhu68.GLB1 on liver and spleen volumes To evaluate the effects of rAAVhu68.GLB1 on EEG, Echo, and Visual Evoked Potentials (VEPs)

[0239] D. Research design: A multicenter, open-label, single-arm, dose-escalation study of rAAVhu68.GLB1 (table below). A total of 12 pediatric subjects with infantile GM1 gangliosidosis will be enrolled in two dosing cohorts and will receive a single dose of rAAVhu68.GLB1 administered by ICM infusion. Safety and tolerability will be assessed over a two-year period, and all subjects will be followed for five years after dosing with rAAVhu68.GLB1 to assess safety and tolerability, pharmacokinetics (transgene expression), and pharmacokinetics. The long-term evaluation will include the durability of clinical outcomes as well as the durability of expression. [Table 8]

[0240] Potential subjects will be screened on Day 35 to Day 1 pre-dose to determine eligibility for the study. Subjects who meet the inclusion / exclusion criteria will be admitted on the morning of Day 1 or according to facility practice. Subjects will receive a single ICM dose of rAAVhu68.GLB1 on Day 1 and will remain in the hospital for at least 24 hours after dosing for observation. Subsequent evaluations will be performed 7, 14, and 30 days after dosing, then every 60 days for the first year, and every 90 days for the second year. Safety and tolerability of rAAVhu68.GLB1 will be monitored through evaluation of adverse events (AEs) and serious adverse events (SAEs), vital signs, physical examination, sensory nerve conduction studies, and laboratory tests (chemistry, hematology, coagulation studies, CSF analysis). Immunogenicity of the AAV and transgene products will also be evaluated. Efficacy assessments will include survival rates, measures of cognitive, motor and social development, changes in visual function and electroencephalogram (EEG), changes in liver and spleen volumes, and biomarkers in CSF, serum, and urine.

[0241] The study consisted of three cohorts that received rAAVhu68.GLB1 as a single ICM infusion: Cohort 1 (low dose): Enroll 3 eligible subjects (subjects #1-#3) and receive a low dose of rAAVhu68.GLB1 with a 4-week safety observation period between the first and second subjects. If no safety review triggers (SRTs) are observed, all available safety data will be evaluated by an independent safety board 4 weeks after the third subject in cohort 1 receives rAAVhu68.GLB1. Cohort 2 (high dose): If progression is determined, 3 eligible subjects (subjects #4-#6) will be enrolled and administered high dose rAAVhu68.GLB1 with a 4-week safety observation period between the 4th and 5th subject. If SRT is not observed, an independent safety committee will evaluate all available safety data, including safety data from subjects in Cohort 1, 4 weeks after the 3rd subject in Cohort 2 receives rAAVhu68.GLB1. Cohort 3 (MTD): Pending a positive recommendation by the Safety Committee, up to 6 additional subjects will be enrolled and dosed with a single ICM dose of rAAVhu68.GLB1 at the MTD. Dosing for subjects in this cohort will be subject to Safety Committee review following dosing of the first 3 subjects in this cohort, without staggering the 4-week safety observation period between subjects.

[0242] E. Eligibility Criteria: 1. At the time of registration, the dog must be over 1 month old and under 18 months old. 2.Documented biochemical and molecular diagnosis of GM1 gangliosidosis based on identification of homozygous or compound heterozygous mutations or deletions in the GLB1 gene and β-galactosidase enzyme activity below the lower limit of normal. 3. Onset of symptoms by 6 months of age, hypotonia on examination, or medical history elicited from parent / caregiver documented. or Having a sibling with a confirmed diagnosis of infantile GM1 gangliosidosis who was presymptomatic and had onset of symptoms by age 6 months.

[0243] F. Exclusion criteria: 1. Clinically significant neurocognitive impairment not attributable to GM1 gangliosidosis or secondary causes that, in the investigator's opinion, may confound interpretation of the study results.

[0244] 2. Any condition (e.g., history of disease, evidence of current disease, findings on physical examination, or laboratory abnormalities) that, in the opinion of the investigator, may place the subject at undue risk or interfere with the evaluation of the investigational product or interfere with the subject's safety or interpretation of the study results.

[0245] 3. Having an acute illness requiring hospitalization within 30 days of enrollment.

[0246] 4. Having respiratory problems requiring medical treatment or hospitalization within 30 days of enrollment.

[0247] 5. Have any contraindications to the ICM administration procedure, including contraindications to fluoroscopic imaging.

[0248] 6.Contraindication to MRI or lumbar puncture.

[0249] 7. Enrollment in another clinical trial with an investigational drug within 4 weeks prior to screening or within 5 half-lives of the investigational drug used in that clinical trial, whichever is longer (patients who received miglustat off-label are eligible).

[0250] G. Routes of Administration and Treatments rAAVhu68.GLB1 will be administered to subjects as a single dose on Day 1 via CT-guided suboccipital injection into the cisterna magna.

[0251] On Day 1, rAAVhu68.GLB1 at the appropriate concentration will be prepared by the investigational pharmacy associated with the study. A syringe containing 5.6 mL of rAAVhu68.GLB1 at the appropriate concentration will be delivered to the procedure room. The following personnel will be present for investigational drug administration: the interventionalist performing the procedure, the anesthesiologist and respiratory technician(s), nurses and physician assistants, CT (or operating room) technicians, and the site research coordinator.

[0252] Prior to administration of the investigational agent, a lumbar puncture is performed to remove a predetermined volume of CSF, and then iodinated contrast is injected intrathecally (IT) to aid in visualization of the relevant anatomical structures of the cisterna magna. Intravenous (IV) contrast may be administered before or during needle puncture as an alternative to intrathecal contrast. The decision to use IV or IT contrast is left to the discretion of the interventionalist. The subject is anesthetized, intubated, and positioned on the procedure table. Using sterile technique, the injection site is prepared and draped. Under fluoroscopic guidance, a spinal needle (22-25G) is advanced into the cisterna magna. A larger introducer needle may be used to aid in needle placement. After needle placement is confirmed, an extension set is attached to the spinal needle and filled with CSF. The interventionalist's At discretion, a syringe containing contrast may be connected to the extension set and a small volume injected to confirm needle placement within the cisterna magna. After needle placement is confirmed with CT guidance + / - contrast injection, a syringe containing 5.6 mL of rAAVhu68.GLB1 is connected to the extension set. The contents of the syringe are slowly injected over 1-2 minutes to deliver a volume of 5.0 mL. The needle is slowly removed from the subject.

[0253] A single intracisternal (ICM) dose of rAAVhu68.GLB1 was safe and tolerable up to 2 years after administration.

[0254] A single administration of rAAVhu68.GLB1 into the cisterna magna (ICM) improves survival, reduces the odds of tube-feeding dependence at 24 months of age, and / or reduces disease progression as assessed by age at achievement, age at loss, and the proportion of children who maintain or achieve age-appropriate developmental and motor milestones.

[0255] Treatment slows the loss of neurocognitive function.

[0256] All documents cited herein are incorporated by reference, as are U.S. Provisional Patent Application No. 62 / 739,811, filed October 1, 2018, and U.S. Provisional Patent Application No. 62 / 835,178, filed April 17, 2019. Similarly, the sequence listing attached hereto, labeled "18-8537PCT_SequenceListing_ST25.txt," and the sequences and text therein, are incorporated by reference. The present invention has been described with reference to certain embodiments, but it will be understood that modifications can be made without departing from the spirit of the invention. Such modifications are intended to be within the scope of the appended claims.

[0257] (Sequence Listing Free Text) The following information is identified by <223> Below we provide an array containing free text. [Table 9-1] [Table 9-2] [Table 9-3] [Table 9-4] [Table 9-5] [Table 9-6] [Table 9-7] [Table 9-8] [Table 9-9] [Table 9-10]

Table 9-11

Table 9-12

Table 9-13

Table 9-14

Table 9-15

Table 9-16

Table 9-17

Table 9-18

Table 9-19

Table 9-20

Table 9-21

Table 9-22

Table 9-23

Table 9-24

Table 9-25

Table 9-26

Table 9-27

Table 9-28

Table 9-29

Table 9-30

Table 9-31

Table 9-32

Table 9-33

Table 9-34

Table 9-35

Table 9-36

Claims

1. An adeno-associated virus (AAV) having an AAVhu68 capsid and a vector genome comprising the GLB1 gene encoding human β-galactosidase under the control of regulatory sequences that direct the expression of human β-galactosidase in target human cells.

2. The AAV of claim 1, wherein the human β-galactosidase comprises a signal peptide and a mature β-galactosidase having an amino acid sequence of amino acids 24 to 677 of SEQ ID NO:

4.

3. The AAV of claim 2, wherein the signal peptide has the amino acid sequence of amino acids 1 to 23 of SEQ ID NO:

4.

4. The AAV of any one of claims 1 to 3, wherein the GLB1 gene has a sequence selected from SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7 or SEQ ID NO:8, which encodes the mature β-galactosidase from amino acids 24 to 677 of SEQ ID NO:4, or a sequence that is at least 95% to 99.9% identical to any one of SEQ ID NOs:5 to 8.

5. The AAV of any one of claims 1 to 4, wherein the regulatory sequence comprises a human ubiquitin C (UbC) promoter.

6. The AAV of any one of claims 1 to 5, wherein the vector genome has a sequence selected from SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, or SEQ ID NO:

16.

7. The AAVhu68 capsid is produced from a sequence encoding the nucleic acid sequence of SEQ ID NO:1 or the predicted amino acid sequence of SEQ ID NO:2, or the AAVhu68 is a heterogeneous population of AAVhu68 vp1 proteins selected from vp1 proteins produced by expression from a nucleic acid sequence encoding the predicted amino acid sequence of 1-736 of SEQ ID NO:2, vp1 proteins produced from SEQ ID NO:1, or vp1 proteins produced from a nucleic acid sequence that is at least 70% identical to SEQ ID NO:1 and that encodes the predicted amino acid sequence of 1-736 of SEQ ID NO:2; a heterologous population of AAVhu68 vp2 proteins selected from vp2 proteins produced by expression from a nucleic acid sequence encoding the predicted amino acid sequence of at least about amino acids 138-736 of SEQ ID NO:2, vp2 proteins produced from a sequence including at least nucleotides 412-2211 of SEQ ID NO:1, or vp2 proteins produced from a nucleic acid sequence that is at least 70% identical to at least nucleotides 412-2211 of SEQ ID NO:1 and that encodes the predicted amino acid sequence of at least about amino acids 138-736 of SEQ ID NO:2; 7. The AAV of any one of claims 1-6, comprising a heterogeneous population of AAVhu68 vp3 proteins selected from vp3 proteins produced by expression from a nucleic acid sequence encoding the predicted amino acid sequence of at least about amino acids 203-736 of SEQ ID NO:2, vp3 proteins produced from a sequence comprising at least nucleotides 607-2211 of SEQ ID NO:1, or vp3 proteins produced from a nucleic acid sequence that is at least 70% identical to at least nucleotides 607-2211 of SEQ ID NO:1 which encodes the predicted amino acid sequence of at least about amino acids 203-736 of SEQ ID NO:

2.

8. 8. An aqueous pharmaceutical composition comprising a formulation buffer and an AAV according to any one of claims 1 to 7.

9. The formulation buffer comprises an artificial cerebrospinal fluid comprising a buffered saline solution and one or more of sodium, calcium, magnesium, potassium, or mixtures thereof; A pharmaceutical composition according to claim 8, comprising a surfactant.

10. 10. The pharmaceutical composition of claim 9, wherein the surfactant is present at 0.0005% w / w to about 0.001% w / w of the pharmaceutical composition.

11. The pharmaceutical composition according to any one of claims 8 to 10, wherein the composition has a pH in the range of 7.5 to 7.8, or 6.2 to 7.7, or about 7.

12. 12. An AAV according to any one of claims 1 to 7 or a pharmaceutical composition according to any one of claims 8 to 11 for use in the treatment of GM1 gangliosidosis, suitable for administration to a patient via intracisternal injection (ICM).

13. An AAV according to any one of claims 1 to 7 and 12, or a composition according to any one of claims 8 to 12, for use in the treatment of GM1 gangliosidosis, suitable for administration to patients with GM1 gangliosidosis or to patients with infantile gangliosidosis of 18 months of age or less.

14. An AAV according to any one of claims 1 to 7 and 12 to 13, or a composition according to any one of claims 8 to 13, for use in the treatment of GM1 gangliosidosis, suitable for administration to a patient in need of such treatment to ameliorate a symptom of GM1 gangliosidosis or to ameliorate a neurological symptom of GM1 gangliosidosis.

15. The AAV or composition of claim 14 for use in treating GM1 gangliosidosis, wherein the improvement of GM1 gangliosidosis comprises increased life expectancy, reduced need for feeding tubes, reduced incidence and frequency of seizures, reduced progression to neurocognitive decline, and / or improved neurocognitive development.

16. 16. The AAV of any one of claims 1 to 7 and 12 to 15, or the composition of any one of claims 8 to 15, for use in the treatment of GM1 gangliosidosis, wherein the AAV or composition is administered via CT-guided suboccipital injection into the cisterna magna.

17. 17. The AAV of any one of claims 1 to 7 and 12 to 16, or the composition of any one of claims 8 to 16, for use in the treatment of GM1 gangliosidosis, wherein the AAV or composition is administered in a single dose.

18. The AAV is administered at a concentration of 2×10 per patient. 12 GC ~ 3 × 10 per patient 14 Dose of GC, or 8 × 10 per patient 12 Genome copies (GC) ~ 3 x 10 per patient 14 Dose of GC, optionally 2×10 per patient 13 GC ~ 3 × 10 per patient 14 Dose of GC, 8 × 10 per patient 13 GC ~ 3 × 10 per patient 14 GC, or approximately 9 × 10 per patient 13 An AAV according to any one of claims 1 to 7 and 12 to 17, or a composition according to any one of claims 8 to 17, for use in the treatment of GM1 gangliosidosis, administered in a dose of GC.

19. The administration is 1x10 10 GC / g brain mass ~3.4x10 11 Dose of GC / g brain mass, optionally 3.4×10 10 GC / g brain mass ~3.4x10 11 GC / g brain mass, 1 .0x10 11 GC / g brain mass ~ approx. 3.4x10 11 GC / g brain mass, or approximately 1.1 x 10 11 An AAV according to any one of claims 1 to 7 and 12 to 18, or a composition according to any one of claims 8 to 18, for use in the treatment of GM1 gangliosidosis comprising delivering said AAV at a dose of GC / g brain mass.

20. Use of an AAV according to any one of claims 1 to 7 and 12 to 19 or a composition according to any one of claims 8 to 19 in the manufacture of a medicament for the treatment of GM1 gangliosidosis.

21. A method for treating a patient with GM1 gangliosidosis, comprising administering to said patient an effective amount of an AAV according to any one of claims 1 to 7 or a pharmaceutical composition according to any one of claims 8 to 11.

22. 22. The method of claim 21, wherein the AAV or pharmaceutical composition is administered via intracisternal injection (ICM), optionally via CT-guided suboccipital injection into the cisterna magna.

23. 23. The method of claim 21 or 22, wherein the method involves delivering the AAV or pharmaceutical composition in a single dose.

24. The method of any one of claims 21 to 23, wherein the patient has infantile gangliosidosis and is 18 months of age or younger.

25. The method of any one of claims 20-24, wherein said administration of said AAV or composition ameliorates a symptom of GM1 gangliosidosis or ameliorates a neurological symptom of GM1 gangliosidosis, and optionally said patient has one or more of increased life expectancy, reduced need for feeding tubes, reduced incidence and frequency of seizures, reduced progression to neurocognitive decline, and / or improved neurocognitive development after treatment.

26. The AAV is administered at a concentration of 2 x 10 per patient. 12 GC ~ 3 x 10 per patient 14 GC, or 8x10 per patient 12 Genome copies (GC) ~ 3 x 10 per patient 14 GC, optionally 2x10 per patient 13 GC ~ 3 x 10 per patient 14 GC, 8 x 10 per patient 13 GC ~ 3 x 10 per patient 14 GC, or approximately 9 x 10 per patient 13 The method according to any one of claims 20 to 25, administered in a dose of GC.

27. The AAV is 1x10 10 GC / g brain mass ~3.4x10 11 Dose of GC / g brain mass, optionally 3.4×10 10 GC / g brain mass ~3.4x10 11 GC / g brain mass, 1.0x10 11 GC / g brain mass ~ approx. 3.4x10 11 GC / g brain mass, or approximately 1.1 x 10 11 The method of any of claims 20 to 26, wherein the dose is administered in a dose of GC / g brain mass.

Citation Information

Patent Citations

  • Modified polynucleotides for the production of proteins associated with human diseases

    JP2015516143A

  • Modulation of AAV vector transgene expression

    WO2016172155A1

  • Adeno-associated virus (AAV) clade f vector and uses therefor

    WO2018160582A1